日本臨牀　別冊　内分泌症候群（第3版）IV

出版社： 日本臨牀社
発行日： 2019-03-31
分野： 臨床医学：一般  >  雑誌
ISSN： 00471852
雑誌名：
特集： 内分泌症候群（第3版）IV―その他の内分泌疾患を含めて―
電子書籍版： 2019-03-31 （第3版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

18,700 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

18,700 円(税込)

購入する

目次

  • VIII．糖代謝
    　１．耐糖能異常
    　２．1型糖尿病
    　３．緩徐進行1型糖尿病
    　４．劇症1型糖尿病
    　５．2型糖尿病
    　６．妊娠糖尿病
    　７．若年発症糖尿病 (MODY) の遺伝素因と臨床病態について
    　８．ミトコンドリア糖尿病
    　９．インスリン受容体異常症(A型，B型)
    　10．膵外分泌疾患に伴う糖尿病
    　11．内分泌疾患に伴う糖尿病
    　12．肝疾患に伴う糖尿病
    　13．薬物・化学物質による糖尿病
    　14．ウイルス感染と糖尿病
    　15．清涼飲料水ケトーシス
    　16．インスリン抵抗性・耐糖能異常を伴う遺伝性(先天性)症候群
    　17．糖尿病性合併症
    　18．低血糖症

    IX．ホルモン異常による先天性肥満症
    　１．レプチン遺伝子異常
    　２．レプチン受容体遺伝子異常症
    　３．プロホルモン変換酵素1(PC1)遺伝子異常症
    　４．プロオピオメラノコルチン(POMC)遺伝子異常症
    　５．メラノコルチン4型（MC4）受容体遺伝子異常症
    　６．アディポネクチン遺伝子異常症

    X．腫瘍とホルモン
    　１．異所性ホルモン産生腫瘍
    　２．多腺性腫瘍
    　３．消化管神経内分泌腫瘍
    　４．ホルモン依存性癌

    XI．低身長を伴う遺伝性(先天性)症候群
    　1．Aarskog-Scott症候群
    　2．Bloom症候群
    　3．Börjeson-Forssman-Lehmann症候群
    　4．Cockayne症候群
    　5．Crouzon症候群
    　6．Fanconi貧血
    　7．Goltz症候群
    　8．SHOX異常症（SHOX半量不全）
    　9．多発性翼状片症候群
    　10．Prader-Willi症候群
    　11．Silver-Russell症候群
    　12．Noonan症候群
    　13．Williams症候群
    　14．家族性低身長
    　15．胎児性アルコール症候群

    XII．性機能低下を伴う遺伝性(先天性)症候群
    　1．CHARGE症候群
    　2．Denys-Drash症候群
    　3．LEOPARD症候群（多発性黒子を伴うNoonan症候群）
    　4．Lowe症候群
    　5．Martsolf症候群
    　6．Rothmund-Thomson症候群
    　7．Rud症候群
    　8．Smith-Lemli-Opitz症候群
    　9．Sohval-Soffer症候群
    　10．ステロイドサルファターゼ欠損症
    　11．MIRAGE症候群

    XIII．内分泌性高血圧
    　１．高血圧を伴う内分泌疾患
    　２．エストロゲン誘発性高血圧
    　３．妊娠高血圧症候群
    　４．エリスロポエチン誘発性高血圧
    　５．レニン産生腫瘍
    　６．低レニン性高血圧

    XIV．電解質異常を伴う内分泌疾患
    　１．低カリウム・高カリウム血症を伴う内分泌疾患
    　２．低ナトリウム血症・高ナトリウム血症を伴う内分泌疾患
    　３．低カルシウム・高カルシウム血症を伴う内分泌疾患
    　４．低リン・高リン血症を伴う内分泌疾患
    　５．低マグネシウム血症を伴う内分泌疾患

    XV．その他　　
    　１．LOH症候群（加齢男性性腺機能低下症候群）
    　２．腎不全による内分泌機能不全
    　３．放射線による内分泌機能不全
    　４．ライソゾーム病に伴う内分泌異常
    　５．家族性・体質性高身長
    　６．Beckwith-Wiedemann症候群
    　７．Hall症候群(Pallister-Hall症候群)
    　８．重篤な遺伝性早老症：ハッチンソン・ギルフォード・プロジェリア症候群
    　９．Kearns-Sayre症候群
    　10．POEMS症候群(Crow-Fukase症候群)
    　11．11p13欠失症候群（WAGR症候群）

    XVI．トピックス
    　1．免疫チェックポイント阻害薬と劇症1型糖尿病
    　2．免疫チェックポイント阻害薬と内分泌異常

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

VIII 糖代謝

P.10 掲載の参考文献
1) Varghese RT, et al : Mechanisms Underlying the Pathogenesis of Isolated Impaired Glucose Tolerance in Humans. J Clin Endocrinol Metab 101 : 4816-4824, 2016.
PubMed
2) Basu A, et al : Prediabetes : evaluation of β-cell function. Diabetes 61 : 270-271, 2012.
 
3) Borel AL, et al : Visceral, subcutaneous abdominal adiposity and liver fat content distribution in normal glucose tolerance, impaired fasting glucose and/or impaired glucose tolerance. Int J Obes (Lond) 39 : 495-501, 2015.
PubMed
4) Kalyani RR, et al : Glucose and insulin measurements from the oral glucose tolerance test and relationship to muscle mass. J Gerontol A Biol Sci Med Sci 67 : 74-81, 2012.
 
5) Kwankaew J, et al : Lean mass inversely predicts plasma glucose levels after oral glucose load independent of insulin secretion or insulin sensitivity in glucose intolerance subjects. Endocr J 61 : 77-83, 2014.
PubMed
6) Someya Y, et al : Characteristics of Glucose Metabolism in Underweight Japanese Women. J Endocr Soc 2 : 279-289, 2018.
PubMed
7) IDF DIABETES ATLAS, 8th ed, 2017. [https://www.idf.org/component/attachments/attachments.html?id=1405&task=download] (2019年2月閲覧)
 
8) 伊藤千賀子 : 耐糖能異常 (IGT) ・境界型の自然史. 日本臨牀 63 (増刊 : 耐糖能障害) : 63-66, 2005.
 
9) DECODE Study Group, the European Diabetes Epidemiology Group : Glucose tolerance and cardiovascular mortality : comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 161 : 397-405, 2001.
 
10) Nakagami T ; DECODE Study Group : Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin. Diabetologia 47 : 385-394, 2004.
 
11) Oizumi T, et al : Impaired glucose tolerance is a risk factor for stroke in a Japanese sample-the Funagata study. Metab Clin Exp 57 : 333-338, 2008.
 
12) Doi Y, et al : Impact of glucose tolerance status on development of ischemic stroke and coronary heart disease in a general Japanese population : the Hisayama study. Stroke 41 : 203-209, 2010.
 
13) Ohara T, et al : Glucose tolerance status and risk of dementia in the community : the Hisayama study. Neurology 77 : 1126-1134, 2011.
PubMed
14) Knowler WC, et al : Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346 : 393-403, 2002.
 
15) Sakane N, et al : Prevention of type 2 diabetes in a primary healthcare setting : three-year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health 11 : 40, 2011.
 
16) Kawamori R, et al : Voglibose for prevention of type 2 diabetes mellitus : a randomised, doubleblind trial in Japanese individuals with impaired glucose tolerance. Lancet 373 : 1607-1614, 2009.
PubMed
17) Chiasson JL, et al : Acarbose for prevention of type 2 diabetes mellitus : the STOP-NIDDM randomised trial. Lancet 359 : 2072-2077, 2002.
PubMed
18) Torgerson JS, et al : XENical in the prevention of diabetes in obese subjects (XENDOS) study : a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 27 : 155-161, 2004.
PubMed
19) Heymsfield SB, et al : Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med 160 : 1321-1326, 2000.
PubMed
P.16 掲載の参考文献
1) Oizumi T, et al : Impaired glucose tolerance is a risk factor for stroke in a Japanese sample-the Funagata study. Metab Clin Exp 57 : 333-338, 2008.
 
2) Qiao Q, et al : Age- and sex-specific prevalence of diabetes and impaired glucose regulation in 11 Asian cohorts. Diabetes Care 26 : 1770-1780, 2003.
PubMed
3) Oizumi T, et al : Assessment of plasma glucose cutoff values to predict the development of type 2 diabetes in a Japanese sample : the Funagata Study. Diabetol Int 2 : 26-31, 2011.
 
4) Knowler WC, et al : Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346 : 393-403, 2002.
 
5) Chiasson JL, et al : Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance : the STOP-NIDDM trial. JAMA 290 : 486-494, 2003.
PubMed
P.20 掲載の参考文献
1) Diabetes Control and Complications Trial Research Group, et al : The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 : 977-986, 1993.
 
2) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352 : 837-853, 1998.
 
3) International Diabetes Federation. [https://www.idf.org/e-library/guidelines/82-management-of-postmeal-glucose.html] (2019年2月閲覧)
 
4) 日本糖尿病学会 (編) : 糖尿病治療ガイド 2018-2019, 文光堂, 2018.
 
5) Nauck MA, et al : Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 63 : 492-498, 1986.
 
6) Tominaga M, et al : Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 22 : 920-924, 1999.
 
7) DECODE Study Group, the European Diabetes Epidemiology Group : Glucose tolerance and cardiovascular mortality : comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 161 : 397-405, 2001.
 
8) Chiasson JL, et al ; STOP-NIDDM Trial Research Group : Acarbose for prevention of type 2 diabetes mellitus : the STOP-NIDDM randomised trial. Lancet 359 : 2072-2077, 2002.
 
9) 今井佐恵子, ほか : 糖尿病患者における食品の摂取順序による食後血糖上昇抑制効果. 糖尿病 53 : 112-115, 2010.
 
10) Kuwata H, et al : Meal sequence and glucose excursion, gastric emptying and incretin secretion in type 2 diabetes : a randomised, controlled crossover, exploratory trial. Diabetologia 59 : 453-461, 2016.
PubMed
11) Schulze MB, et al : Fiber and magnesium intake and incidence of type 2 diabetes : a prospective study and meta-analysis. Arch Intern Med 167 : 956-965, 2007.
PubMed
12) Henson J, et al : Associations of objectively measured sedentary behaviour and physical activity with markers of cardiometabolic health. Diabetologia 56 : 1012-1020, 2013.
PubMed
13) Terada T, et al : Exploring the variability in acute glycemic responses to exercise in type 2 diabetes. J Diabetes Res 2013 : 591574, 2013.
PubMed
14) Hatamoto Y, et al : Effect of exercise timing on elevated postprandial glucose levels. J Appl Physiol 123 : 278-284, 2017.
 
15) Jimenez A, et al : GLP-1 action and glucose tolerance in subjects with remission of type 2 diabetes after gastric bypass surgery. Diabetes Care 36 : 2062-2069, 2013.
PubMed
16) American Diabetes Association : 1. Improving Care and Promoting Health in Populations : Standards of Medical Care in Diabetes-2019. Diabetes Care 42 (Suppl 1) : S7-S12, 2019.
 
P.26 掲載の参考文献
1) 日本糖尿病学会 (編・著) : 1型糖尿病の成因と分類. 糖尿病専門医研修ガイドブック [改訂第7版] (日本糖尿病学会), p65-69, 診断と治療社, 2017.
 
2) Onda Y, et al : Incidence and prevalence of childhood-onset Type 1 diabetes in Japan : the T1D study. Diabet Med 34 : 909-915, 2017.
PubMed
3) Thomas NJ, et al : Frequency and phenotype of type 1 diabetes in the first six decades of life : a cross-sectional, genetically stratified survival analysis from UK Biobank. Lancet Diabetes Endocrinol 6 : 122-129, 2018.
PubMed
4) Pugliese A : Autoreactive T cells in type 1 diabetes. J Clin Invest 127 : 2881-2891, 2017.
PubMed
5) Kent SC, et al : Expanded T cells from pancreatic lymph nodes of type 1 diabetic subjects recognize an insulin epitope. Nature 435 : 224-228, 2005.
PubMed
6) Nakayama M, et al : Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature 435 : 220-223, 2005.
PubMed
7) Baker RL, et al : Cutting Edge : Nonobese Diabetic Mice Deficient in Chromogranin A Are Protected from Autoimmune Diabetes. J Immunol 196 : 39-43, 2016.
PubMed
8) Stadinski BD, et al : Chromogranin A is an autoantigen in type 1 diabetes. Nat Immunol 11 : 225-231, 2010.
PubMed
9) Abreu JR, et al : CD8 T cell autoreactivity to preproinsulin epitopes with very low human leucocyte antigen class I binding affinity. Clin Exp Immunol 170 : 57-65, 2012.
 
10) Delong T, et al : Pathogenic CD4 T cells in type 1 diabetes recognize epitopes formed by peptide fusion. Science 351 : 711-714, 2016.
PubMed
11) Kracht MJ, et al : Autoimmunity against a defective ribosomal insulin gene product in type 1 diabetes. Nat Med 23 : 501-507, 2017.
PubMed
12) Luo X, et al : Immunotherapy of type 1 diabetes : where are we and where should we be going? Immunity 32 : 488-499, 2010.
PubMed
13) Ikegami H, et al : Genetics and pathogenesis of type 1 diabetes : prospects for prevention and intervention. J Diabetes Investig 2 : 415-420, 2011.
PubMed
14) 急性発症1型糖尿病の診断基準 (2012) の策定-1型糖尿病調査研究委員会 (劇症および急性発症1型糖尿病分科会) 報告-. 糖尿病 56 : 584-589, 2013.
 
15) Kawabata Y, et al : Differential association of HLA with three subtypes of type 1 diabetes : fulminant, slowly progressive and acute-onset. Diabetologia 52 : 2513-2521, 2009.
PubMed
16) Rewers MJ, et al : ISPAD Clinical Practice Consensus Guidelines 2014. Assessment and monitoring of glycemic control in children and adolescents with diabetes. Pediatr Diabetes 15 (Suppl 20) : 102-114, 2014.
 
17) 日本糖尿病学会・日本老年医学会 (編・著) : 高齢者糖尿病の治療方針. 高齢者糖尿病治療ガイド 2018, p26-31, 文光堂, 2018.
 
18) Pickup JC : Are insulin pumps underutilized in type 1 diabetes? Yes. Diabetes Care 29 : 1449-1452, 2006.
PubMed
19) Choudhary P, et al : Insulin pump therapy with automated insulin suspension in response to hypoglycemia : reduction in nocturnal hypoglycemia in those at greatest risk. Diabetes Care 34 : 2023-2025, 2011.
PubMed
20) Buckingham BA, et al : Outpatient safety assessment of an in-home predictive low-glucose suspend system with type 1 diabetes subjects at elevated risk of nocturnal hypoglycemia. Diabetes Technol Ther 15 : 622-627, 2013.
 
21) 日本糖尿病学会 (編・著) : [医療者のための] カーボカウント指導テキスト, p36-44, 文光堂, 2017.
 
22) Livingstone SJ, et al : Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008-2010. JAMA 313 : 37-44, 2015.
 
P.31 掲載の参考文献
1) Irvine WJ, et al : Clinical and pathogenic significance of pancreatic-islet-cell antibodies in diabetics treated with oral hypoglycaemic agents. Lancet 1 : 1025-1027, 1977.
PubMed
2) Kobayashi T, et al : Islet-cell antibodies in insulin-dependent and non-insulin dependent diabetics in Japan, their prevalence and clinical significance. In : Clinico-Genetic Genesis of Diabetes Mellitus (ed by Mimura G, et al), p150-160, Excerpta Medica, Amsterdam, 1982.
 
3) 北川照男, ほか : 小児のインスリン依存性糖尿病の自然経過. Diabetes Journal 10 : 10-16, 1982.
 
4) Tuomi T, et al : Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes 42 : 359-362, 1993.
PubMed
5) Urakami T, et al : Incidence of children with slowly progressive form of type 1 diabetes detected by the urine glucose screening at schools in the Tokyo Metropolitan Area. Diabetes Res Clin Pract 80 : 473-476, 2008.
PubMed
6) Kawasaki E, et al : Type 1 diabetes in Japan. Diabetologia 49 : 828-836, 2006.
PubMed
7) 緩徐進行1型糖尿病 (slowly progressive insulin-dependent diabetes mellitus : SPIDDM) の臨床的特徴-日本糖尿病学会1型糖尿病調査研究委員会緩徐進行1型糖尿病分科会報告 (第一報) -. 糖尿病 54 : 65-75, 2011.
 
8) Takino H, et al : Antibodies to GAD in Japanese patients classified as Type 2 diabetes at diagnosis. High titre of GAD Ab is a predictive marker for early insulin treatment-report of west Japan (Kyushu, Yamaguchi, Osaka) study for GAD Ab (+) diabetes. Diabet Med 19 : 730-734, 2002.
 
9) Kawabata Y, et al : Differential association of HLA with three subtypes of type 1 diabetes : fulminant, slowly progressive and acute-onset. Diabetologia 52 : 2513-2521, 2009.
PubMed
10) Yasui J, et al : Clinical and Genetic Characteristics of Non-Insulin-Requiring Glutamic Acid Decarboxylase (GAD) Autoantibody-Positive Diabetes : A Nationwide Survey in Japan. PLoS ONE 11 : e0155643, 2016.
PubMed
11) Kawasaki E, et al : Autoantibodies to insulin, insulinoma-associated antigen-2, and zinc transporter 8 improve the prediction of early insulin requirement in adult-onset autoimmune diabetes. J Clin Endocrinol Metab 95 : 707-713, 2010.
PubMed
12) 田中昌一郎, ほか : 緩徐進行1型糖尿病 (SPIDDM) の診断基準 (2012) -1型糖尿病調査研究委員会 (緩徐進行1型糖尿病分科会) 報告-. 糖尿病 56 : 590-597, 2013.
 
13) Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group. Ann Intern Med 128 : 517-523, 1998.
 
14) Pozzilli P, Pieralice S : Latent Autoimmune Diabetes in Adults : Current Status and New Horizons. Endocrinol Metab (Seoul) 33 : 147-159, 2018.
PubMed
15) Pozzilli P, et al : Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA) : A post-hoc analysis of the AWARD-2, -4 and -5 Trials. Diabetes Obes Metab 20 : 1490-1498, 2018.
 
P.36 掲載の参考文献
1) Imagawa A, et al : A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. Osaka IDDM Study Group. N Engl J Med 342 : 301-307, 2000.
 
2) 清野裕, ほか : 糖尿病の分類と診断基準に関する委員会報告. 糖尿病 53 : 450-467, 2010.
 
3) 花房俊昭, ほか : 劇症1型糖尿病調査研究委員会報告-疫学調査の解析と診断基準の策定-. 糖尿病 48 (Suppl 1) : A1-A13, 2005.
 
4) Imagawa A, et al : Fulminant type 1 diabetes : a nationwide survey in Japan. Diabetes Care 26 : 2345-2352, 2003.
PubMed
5) Hughes J, et al : Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy. Diabetes Care 38 : e55-57, 2015.
PubMed
6) Baden MY, et al : Characteristics and clinical course of type 1 diabetes mellitus related to anti-programmed cell death-1 therapy. Diabetol Int 10 : 58-66, 2019.
PubMed
7) Tsutsumi C, et al : Class II HLA genotype in fulminant type 1 diabetes : A nationwide survey with reference to glutamic acid decarboxylase antibodies. J Diabetes Investig 3 : 62-69, 2012.
PubMed
8) Shimizu I, et al : Clinical and immunogenetic characteristics of fulminant type 1 diabetes associated with pregnancy. J Clin Endocrinol Metab 91 : 471-476, 2006.
PubMed
9) Kawabata Y, et al : Genome-Wide Association Study Confirming a Strong Effect of HLA and Identifying Variants in CSAZ) /lnc-ITGB7-1 on Chromosome 12q13.13 Associated with Susceptibility to Fulminant Type 1 Diabetes. 68 : 665-675, 2019.
 
10) Imagawa A, et al : High titres of IgA antibodies to enterovirus in fulminant type-1 diabetes. Diabetologia 48 : 290-293, 2005.
PubMed
11) Sano H, et al : A case of fulminant type 1 diabetes mellitus after influenza B infection. Diabetes Res Clin Pract 79 : e8-9, 2008.
PubMed
12) Akatsuka H, et al : A case of fulminant type 1 diabetes with coxsackie B4 virus infection diagnosed by elevated serum levels of neutralizing antibody. Diabetes Res Clin Pract 84 : e50-52, 2009.
PubMed
13) Chiou CC, et al : Fulminant type 1 diabetes mellitus caused by drug hypersensitivity syndrome with human herpesvirus 6 infection. J Am Acad Dermatol 54 : S14-17, 2006.
PubMed
14) Shibasaki S, et al : Expression of toll-like receptors in the pancreas of recent-onset fulminant type 1 diabetes. Endocr J 57 : 211-219, 2010.
PubMed
15) 1型糖尿病調査研究委員会報告-劇症1型糖尿病の新しい診断基準 (2012). 糖尿病 55 : 815-820, 2012.
 
P.42 掲載の参考文献
1) 清野裕, ほか : 糖尿病の分類と診断基準に関する委員会報告 (国際標準化対応版). 糖尿病 55 : 485-504, 2012.
 
2) International Diabetes Federation : IDF Diabetes Atlas, 8th ed, 2017. [http://www.diabetesatlas.org/] (2018年11月閲覧)
 
3) World Health Organization : Global report on diabetes, 2016. [http://www.who.int/diabetes/global-report/en/] (2018年11月閲覧)
 
4) 厚生労働省 : 平成28年国民健康・栄養調査報告, 2017. [https://www.mhlw.go.jp/bunya/kenkou/eiyou/h28-houkoku.html] (2018年11月閲覧)
 
5) Dabelea D, et al : Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009. JAMA 311 : 1778-1786, 2014.
PubMed
6) Urakami T, et al : Screening and treatment of childhood type 1 and type 2 diabetes mellitus in Japan. Pediatr Endocrinol Rev 10 Suppl 1 : 51-61, 2012.
 
7) Jin T, et al : The Wnt signaling pathway effector TCF7L2 and type 2 diabetes mellitus. Mol Endocrinol 22 : 2383-2392, 2008.
PubMed
8) Asahara S, et al : Paternal allelic mutation at the Kcnq1 locus reduces pancreatic β-cell mass by epigenetic modification of Cdkn1c. Proc Natl Acad Sci USA 112 : 8332-8337, 2015.
 
9) Shai I, et al : Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. N Engl J Med 359 : 229-241, 2008.
 
10) Kurotani K, et al : Red meat consumption is associated with the risk of type 2 diabetes in men but not in women : a Japan Public Health Center-based Prospective Study. Br J Nutr 110 : 1910-1918, 2013.
 
11) 藤本新平 : 2型糖尿病-インスリン分泌障害. 糖尿病学 (門脇孝, ほか編), p228-238, 西村書店, 2015.
 
12) Lean ME, et al : Primary care-led weight management for remission of type 2 diabetes (DiRECT) : an open-label, cluster-randomised trial. Lancet 391 : 541-551, 2018.
PubMed
13) Boule NG, et al : Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus : a meta-analysis of controlled clinical trials. JAMA 286 : 1218-1227, 2001.
PubMed
14) Ueki K, et al : Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3) : an open-label, randomised controlled trial. Lancet Diabetes Endocrinol 5 : 951-964, 2017.
PubMed
15) Nakamura J, et al : Causes of death in Japanese patients with diabetes based on the results of a survey of 45,708 cases during 2001-2010 : Report of the Committee on Causes of Death in Diabetes Mellitus. J Diabetes Investig 8 : 397-410, 2017.
 
P.45 掲載の参考文献
1) 日本糖尿病・妊娠学会と日本糖尿病学会との合同委員会 : 妊娠中の糖代謝異常と診断基準の統一について. 糖尿病と妊娠 15 : 127-129, 2015.
 
2) 平松祐司 : 妊娠糖尿病とは? 妊婦の糖代謝異常 診療・管理マニュアル [改訂第2版] (日本糖尿病・妊娠学会編), p56-58, メジカルビュー社, 2018.
 
3) Omori Y, Jovanovic L : Proposal for the reconsideration of the definition of gestational diabetes. Diabetes Care 28 : 2592-2593, 2005.
PubMed
4) 菱田明, 佐々木敏 (監修) : 参考資料 1 対象特性 1. 妊婦・授乳婦. 日本人の食事摂取基準 [2015年版], p345-353, 第一出版, 2015.
 
5) Bhattacharyya A, et al : Insulin lispro and regular insulin in pregnancy. QJM 94 : 255-260, 2001.
PubMed
6) Wyatt JW, et al : Congenital anomaly rate in offspring of mothers with diabetes treated with insulin lispro during pregnancy. Diabet Med 22 : 803-807, 2005.
PubMed
7) Mathiesen ER, et al : Maternal glycemic control and hypoglycemia in type 1 diabetic pregnancy : a randomized trial of insulin aspart versus human insulin in 322 pregnant women. Diabetes Care 30 : 771-776, 2007.
PubMed
8) Hod M, et al : Fetal and perinatal outcomes in type 1 diabetes pregnancy : a randomized study comparing insulin aspart with human insulin in 322 subjects. Am J Obstet Gynecol 198 : 186. e1-7, 2008.
 
9) Mathiesen ER, et al : Maternal efficacy and safety outcomes in a randomized, controlled trial comparing insulin detemir with NPH insulin in 310 pregnant women with type 1 diabetes. Diabetes Care 35 : 2012-2017, 2012.
 
10) Hod M, et al : A randomized trial comparing perinatal outcomes using insulin detemir or neutral protamine Hagedorn in type 1 diabetes. J Matern Fetal Neonatal Med 27 : 7-13, 2014.
 
11) Bellamy L, et al : Type 2 diabetes mellitus after gestational diabetes : asystematic review and meta-analysis. Lancet 373 : 1773-1779, 2009.
 
P.51 掲載の参考文献
1) Vionnet N, et al : Nonsense mutation in the glucokinase gene causes early-onset non-insulin-dependent diabetes mellitus. Nature 356 : 721-722, 1992.
PubMed
2) Horikawa Y : Maturity-onset diabetes of the young as a model for elucidating the multifactorial origin of type 2 diabetes mellitus. J Diabetes Investig 9 : 704-712, 2018.
 
3) Pearson ER, et al : Genetic cause of hyperglycaemia and response to treatment in diabetes. Lancet 362 : 1275-1281, 2003.
PubMed
4) Bacon S, et al : Successful maintenance on sulphonylurea therapy and low diabetes complication rates in a HNF1A-MODY cohort. Diabet Med 33 : 976-984, 2016.
 
5) Najmi LA, et al : Functional Investigations of HNF1A Identify Rare Variants as Risk Factors for Type 2 Diabetes in the General Population. Diabetes 66 : 335-346, 2017.
PubMed
6) SIGMA Type 2 Diabetes Consortium, et al : Association of a low-frequency variant in HNF1A with type 2 diabetes in a Latino population. JAMA 311 : 2305-2314, 2014.
 
7) Triggs-Raine BL, et al : HNF-1alpha G319S, a transactivation-deficient mutant, is associated with altered dynamics of diabetes onset in an Oji-Cree community. Proc Natl Acad Sci USA 99 : 4614-4619, 2002.
 
8) Locke JM, et al : The Common HNF1A Variant I27 L Is a Modifier of Age at Diabetes Diagnosis in Individuals With HNF1A-MODY. Diabetes 67 : 1903-1907, 2018.
 
9) Steele AM, et al : Use of HbA1c in the identification of patients with hyperglycaemia caused by a glucokinase mutation : observational case control studies. PLoS ONE 8 : e65326, 2013.
PubMed
10) Bacon S, et al : The clinical management of hyperglycemia in pregnancy complicated by maturity-onset diabetes of the young. Am J Obstet Gynecol 213 : 236.e1-7, 2015.
 
11) Horikawa Y, et al : Mutation in hepatocyte nuclear factor-1 beta gene (TCF2) associated with MODY. Nat Genet 17 : 384-385, 1997.
 
12) Verhave JC, et al : Hepatocyte Nuclear Factor 1β-Associated Kidney Disease : More than Renal Cysts and Diabetes. J Am Soc Nephrol 27 : 345-353, 2016.
 
13) Bellanne-Chantelot C, et al : Large genomic rearrangements in the hepatocyte nuclear factor-1beta (TCF2) gene are the most frequent cause of maturity-onset diabetes of the young type 5. Diabetes 54 : 3126-3132, 2005.
PubMed
14) Clissold RL, et al : Chromosome 17q12 microdeletions but not intragenic HNF1B mutations link developmental kidney disease and psychiatric disorder. Kidney Int 90 : 203-211, 2016.
PubMed
15) Horikawa Y, et al : Screening of diabetes of youth for hepatocyte nuclear factor 1 mutations : clinical phenotype of HNF1β-related maturity-onset diabetes of the young and HNF1α-related maturity-onset diabetes of the young in Japanese. Diabet Med 31 : 721-727, 2014.
 
16) Dubois-Laforgue D, et al : Diabetes, Associated Clinical Spectrum, Long-term Prognosis, and Genotype/Phenotype Correlations in 201 Adult Patients With Hepatocyte Nuclear Factor 1B (HNF1B) Molecular Defects. Diabetes Care 40 : 1436-1443, 2017.
 
17) Tanaka T, et al : Dysregulated expression of P1 and P2 promoter-driven hepatocyte nuclear factor-4alpha in the pathogenesis of human cancer. J Pathol 208 : 662-672, 2006.
 
18) Lau HH, et al : The molecular functions of hepatocyte nuclear factors-In and beyond the liver. J Hepatol 68 : 1033-1048, 2018.
 
19) Shepherd MH, et al : A UK nationwide prospective study of treatment change in MODY : genetic subtype and clinical characteristics predict optimal glycaemic control after discontinuing insulin and metformin. Diabetologia 61 : 2520-2527, 2018.
PubMed
20) Tung JY, et al : Clinical heterogeneity of hyperinsulinism due to HNF1A and HNF4A mutations. Pediatr Diabetes 19 : 910-916, 2018.
 
21) Walsh SB, et al : Fainting Fanconi syndrome clarified by proxy : a case report. BMC Nephrol 18 : 230, 2017.
PubMed
22) Odom DT, et al : Control of pancreas and liver gene expression by HNF transcription factors. Science 303 : 1378-1381, 2004.
PubMed
23) Horikawa Y, Enya M : Genetic dissection and clinical features of MODY6 (NEUROD1-MODY). Curr Diab Rep 19 : 12, 2019.
 
24) Horikawa Y, et al : NEURODI-deficient diabetes (MODY6) : Identification of the first cases in Japanese and the clinical features. Pediatr Diabetes 19 : 236-242, 2018.
 
25) Stoy J, et al : In vivo measurement and biological characterisation of the diabetes-associated mutant insulin p. R46Q (GlnB22-insulin). Diabetologia 60 : 1423-1431, 2017.
PubMed
26) Gjesing AP, et al : High Prevalence of Diabetes-Predisposing Variants in MODY Genes Among Danish Women With Gestational Diabetes Mellitus. J Endocr Soc 1 : 681-690, 2017.
PubMed
27) Rudland VL, et al : Identifying Glucokinase Monogenic Diabetes in a Multiethnic Gestational Diabetes Mellitus Cohort : New Pregnancy Screening Criteria and Utility of HbA1c. Diabetes Care 39 : 50-52, 2016.
 
P.57 掲載の参考文献
1) 鈴木進, 鈴木道子 : 単一遺伝子異常による糖尿病 ミトコンドリアDNA異常. 日本臨牀 70 (増刊 : 最新臨床糖尿病学 (下)) : 193-198, 2012.
 
2) Kadowaki T, et al : A subtype of diabetes mellitus associated with a mutation of mitochondrial DNA. N Engl J Med 330 : 962-968, 1994.
PubMed
3) Nomiyama T, et al : Accumulation of somatic mutation in mitochondrial DNA extracted from peripheral blood cells in diabetic patients. Diabetologia 45 : 1577-1583, 2002.
PubMed
4) Kakimoto M, et al : Accumulation of 8-hydroxy-2'-deoxyguanosine and mitochondrial DNA deletion in kidney of diabetic rats. Diabetes 51 : 1588-1595, 2002.
PubMed
5) Nomiyama T, et al : Accumulation of somatic mutation in mitochondrial DNA and atherosclerosis in diabetic patients. Ann N Y Acad Sci 1011 : 193-204, 2004.
PubMed
6) Ninomiya H, et al : Treatment of Mitochondrial Diabetes with a Peroxisome Proliferator-activated Receptor (PPAR) -gamma Agonist. Intern Med 55 : 1143-1147, 2016.
PubMed
7) 鈴木吉彦, ほか : 3271番位tRNALeu (UUR) 変異を有するミトコンドリア糖尿病の15年を超えた追跡経過観察. 糖尿病 56 : 173-178, 2013.
 
8) Vial G, et al : Imeglimin normalizes glucose tolerance and insulin sensitivity and improves mitochondrial function in liver of a high-fat, high-sucrose diet mice model. Diabetes 64 : 2254-2264, 2015.
PubMed
9) Pirags V, et al : Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients. Diabetes Obes Metab 14 : 852-858, 2012.
PubMed
P.63 掲載の参考文献
1) Kahn CR, et al : The syndromes of insulin resistance and acanthosis nigricans. Insulin-receptor disorders in man. N Engl J Med 294 : 739-745, 1976.
 
2) Kim H, et al : Detection of mutations in the insulin receptor gene in patients with insulin resistance by analysis of single-stranded conformational polymorphisms. Diabetologia 35 : 261-266, 1992.
PubMed
3) Fujita S, et al : Hyperinsulinemia and Insulin Receptor Gene Mutation in Nonobese Healthy Subjects in Japan. J Endocr Soc 1 : 1351-1361, 2017.
PubMed
4) 阪口雅司, ほか : インスリン-作用機構とインスリン製剤の特徴. 糖尿病治療薬のサイエンス-From Bench to Bedside-, p170, 南山堂, 2012.
 
5) Ullrich A, et al : Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes. Nature 313 : 756-761, 1985.
 
6) Ebina Y, et al : The human insulin receptor cDNA : the structural basis for hormone-activated transmembrane signalling. Cell 40 : 747-758, 1985.
PubMed
7) Flier JS, et al : Receptors, antireceptor antibodies and mechanisms of insulin resistance. N Engl J Med 300 : 413-419, 1979.
PubMed
8) Taylor SI : Lilly Lecture : molecular mechanisms of insulin resistance. Lessons from patients with mutations in the insulin-receptor gene. Diabetes 41 : 1473-1490, 1992.
PubMed
9) Emkey R, Kahn CR : Molecular aspects of insulin signaling. In : Supplement 21 : Handbook of Physiology, The Endocrine System, The Endocrine Pancreas and Regulation of Metabolism, John Wiley & Sons, Hoboken, 2001.
 
10) 厚生省特定疾患ホルモン受容機構異常調査研究班, 平成7年度総括研究事業報告書版, バージョン1.1 [更新日 : 2015年6月1日] 文責 : 日本小児内分泌学会
 
11) Ben Harouch S, et al : INSR-related severe syndromic insulin resistance. GeneReviews(R) [Internet], University of Washington, Seattle, 2018. [https://www.ncbi.nlm.nih.gov/books/NBK476444/] (2019年2月閲覧)
 
12) Musso C, et al : Clinical course of genetic diseases of the insulin receptor (type A and Rabson-Mendenhall syndromes) : a 30-year prospective. Medicine (Baltimore) 83 : 209-222, 2004.
PubMed
13) Willard DL, et al : Type B insulin resistance syndrome. Curr Opin Endocrinol Diabetes Obes 23 : 318-323, 2016.
PubMed
14) Imai J, et al : Eradication of insulin resistance. Lancet 374 : 264, 2009.
PubMed
15) Coll AP, et al : Rituximab therapy for the type B syndrome of severe insulin resistance. N Engl J Med 350 : 310-311, 2004.
PubMed
P.68 掲載の参考文献
1) 五十嵐久人, ほか : ライフステージ・タイプ別糖尿病の病態と治療 二次性糖尿病 膵性糖尿病. 日本臨牀 70 (増刊 : 最新臨床糖尿病学 (下)) : 161-164, 2012.
 
2) 葛谷健, ほか : 糖尿病の分類と診断基準に関する委員会報告. 糖尿病 42 : 385-404, 1999.
 
3) 伊藤鉄英, 五十嵐久人 : 膵性糖尿病の特徴と診断. スマートな糖尿病診断と治療の進め方 (荒木栄一編), p88-93 中山書店, 2011.
 
4) Woodmansey C, et al : Incidence, Demographics, and Clinical Characteristics of Diabetes of the Exocrine Pancreas (Type 3c) : A Retrospective Cohort Study. Diabetes Care 40 : 1486-1493, 2017.
PubMed
5) Ito T, et al : Epidemiological study of pancreatic diabetes in Japan in 2005 : a nationwide study. Pancreas 39 : 829-835, 2010.
PubMed
6) 木原康之, 原田大 : 膵性糖尿病の病態に基づいた最適治療-超速効型インスリン治療の有用性-. 胆と膵 30 : 161-165, 2009.
Medical*Online
7) 中村光男, ほか : 膵内外分泌不全に対する膵消化酵素及びインスリン補充療法. 膵臓 22 : 454-461, 2007.
Medical*Online
8) Nishimori I, et al : Influence of steroid therapy on the course of diabetes mellitus in patients with autoimmune pancreatitis : findings from a nationwide survey in Japan. Pancreas 32 : 244-248, 2006.
 
9) 中村光男, 丹藤雄介 : 膵性糖尿病患者への対応-診断. 膵臓 25 : 658-659, 2010.
Medical*Online
10) 伊藤鉄英, ほか : 慢性膵炎-治療. 日本内科学会雑誌 99 : 56-61, 2010.
 
11) 中村光男 (編) : 膵外分泌不全診療マニュアル, 診断と治療社, 2017.
 
12) Kawabe K, et al : The current managements of pancreatic diabetes in Japan. Clin J Gastroenterol 2 : 1-8, 2009.
PubMed
13) 中村光男, 丹藤雄介 : 膵性糖尿病患者への対応-食事指導. 膵臓 25 : 660-661, 2010.
Medical*Online
14) 五十嵐久人 : 膵性糖尿病患者への対応-インスリン療法の留意点. 膵臓 25 : 662-664, 2010.
Medical*Online
15) 日本消化器病学会 (編) : 慢性膵炎診療ガイドライン 2015 [改訂第2版], 南江堂, 2015.
 
P.73 掲載の参考文献
1) 野見山崇, 柳瀬敏彦 : 二次性糖尿病. 日本臨牀 73 : 2008-2012, 2015.
Medical*Online
2) Suda K, et al : The prevalence of acromegaly in hospitalized patients with type 2 diabetes. Endocr J 62 : 53-59, 2015.
PubMed
3) Colao A, et al : Pasireotide versus octreotide in acromegaly : a head-to-head superiority study. J Clin Endocrinol Metab 99 : 791-799, 2014.
PubMed
4) 松本俊一, 山田正信 : 甲状腺. 日本臨牀 74 (増刊 : 新時代の臨床糖尿病学 (上)) : 267-271, 2016.
 
5) 後藤広昌 : 甲状腺疾患と糖代謝異常. 月刊糖尿病 9 : 31-36, 2017.
 
6) Krarup T, et al : Do patients with type 2 diabetes mellitus have an increased prevalence of Cushing's syndrome? Diabetes Metab Res Rev 28 : 219-227, 2012.
PubMed
7) Kawate H, et al : Long-term study of subclinical Cushing's syndrome shows high prevalence of extra-adrenal malignancy in patients with functioning bilateral adrenal tumors. Endocr J 61 : 1205-1212, 2014.
PubMed
8) Iacobone M, et al : Systematic review of surgical treatment of subclinical Cushing's syndrome. Br J Surg 102 : 318-330, 2015.
PubMed
9) 日本内分泌学会, ほか : 日本内分泌学会臨床重要課題 : 潜在性クッシング症候群 (下垂体性と副腎) の診断基準の作成. 副腎性サブクリニカルクッシング症候群 新診断基準の作成と解説. 日本内分泌学会雑誌 93 (Suppl) : 1-18, 2017.
 
10) Akehi Y, et al : High prevalence of diabetes in patients with primary aldosteronism (PA) associated with subclinical hypercortisolism and prediabetes more prevalent in bilateral than unilateral PA : A large multicenter cohort study in Japan. Diabetes Care, 2019. [Epub ahead of print]
 
11) Murase K, et al : Prevalence and clinical characteristics of primary aldosteronism in Japanese patients with type 2 diabetes mellitus and hypertension. Endocr J 60 : 967-976, 2013.
PubMed
12) 宗友厚 : 内分泌疾患に伴う糖尿病. Diabetes Frontier 27 : 41-44, 2016.
Medical*Online
13) 田辺晶代 : 代謝異常と心血管系障害. 褐色細胞腫診療マニュアル改訂第3版 (成瀬光栄ほか編), p52-53, 診断と治療社, 2017.
 
14) Tanabe M, et al : Total testosterone is the most valuable indicator of metabolic syndrome among various testosterone values in middle-aged Japanese men. Endocr J 62 : 123-132, 2015.
PubMed
15) 高松潔, 小川真理子 : ホルモン補充療法のパラダイムシフト～HRTガイドライン 2017年度版改訂の要点と最近の考え方. 診断と治療 106 : 1141-1149, 2018.
 
P.78 掲載の参考文献
1) Nakamura J, et al : Causes of death in Japanese patients with diabetes based on the results of a survey of 45, 708 cases during 2001-2010 : Report of the Committee on Causes of Death in Diabetes Mellitus. J Diabetes Investig 8 : 397-410, 2017.
 
2) 國府島庸之, 加藤正樹 : C型肝炎ウイルス排除は糖質代謝, 脂質代謝にどう影響するか. 日本内科学会雑誌 107 : 50-56, 2018.
 
3) Fujino T, et al : Expression profile of lipid metabolism-associated genes in hepatitis C virusinfected human liver. Hepatol Res 40 : 923-929, 2010.
PubMed
4) Tazawa J, et al : Diabetes mellitus may be associated with hepatocarcinogenesis in patients with chronic hepatitis C. Dig Dis Sci 47 : 710-715, 2002.
PubMed
5) Eguchi Y, et al : Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan : a multicenter large retrospective study. J Gastroenterol 47 : 586-595, 2012.
PubMed
6) Ratziu V, et al : Current efforts and trends in the treatment of NASH. J Hepatol 62 : S65-75, 2015.
 
7) Seike N, et al : Alcohol consumption and risk of type 2 diabetes mellitus in Japanese : a systematic review. Asia Pac J Clin Nutr 17 : 545-551, 2008.
PubMed
8) He J, et al : Acute ethanol exposure inhibits insulin signaling in the liver. Hepatology 46 : 1791-1800, 2007.
PubMed
9) Lindtner C, et al : Binge drinking induces whole-body insulin resistance by impairing hypothalamic insulin action. Sci Transl Med 5 : 170ra14, 2013.
PubMed
10) Angulo P, et al : Liver Fibrosis, but No Other Histologic Features, Is Associated With Longterm Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology 149 : 389-397. e10, 2015.
 
11) Kawamura Y, et al : Large-scale long-term follow-up study of Japanese patients with nonalcoholic Fatty liver disease for the onset of hepatocellular carcinoma. Am J Gastroenterol 107 : 253-261, 2012.
PubMed
12) Hamaguchi E, et al : Histological course of nonalcoholic fatty liver disease in Japanese patients : tight glycemic control, rather than weight reduction, ameliorates liver fibrosis. Diabetes Care 33 : 284-286, 2010.
PubMed
13) NAFLD/NASH診療ガイドライン 2014 (日本消化器病学会編), p89-99, 南江堂, 2014.
 
14) Sumida Y, Yoneda M : Current and future pharmacological therapies for NAFLD/NASH. J Gastroenterol 53 : 362-376, 2018.
 
15) Funayama T, et al : Effects of alcohol abstinence on glucose metabolism in Japanese men with elevated fasting glucose : A pilot study. Sci Rep 7 : 40277, 2017.
PubMed
P.83 掲載の参考文献
1) Ganda OP : Secondary forms of diabetes. In : Joslin's Diabetes Mellitus, 14th ed (ed by Kahn RC, et al), p485, Lippincott Williams & Wilkins, Philadelphia, 2004.
 
2) 山形敞一, ほか : Steroid糖尿病臨牀統計を中心として. ホルモンと臨床 11 : 249-258, 1963.
 
3) Imano E, et al : Interferon induces insulin resistance in patients with chronic active hepatitis C. J Hepatol 28 : 189-193, 1998.
 
4) McGillicuddy FC, et al : Interferon gamma attenuates insulin signaling, lipid storage, and differentiation in human adipocytes via activation of the JAK/STAT pathway. J Biol Chem 284 : 31936-31944, 2009.
PubMed
5) Nakamura K, et al : Type 1 diabetes and interferon therapy : a nationwide survey in Japan. Diabetes Care 34 : 2084-2089, 2011.
PubMed
6) American Diabetes Association, et al : Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27 : 596-601, 2004.
PubMed
7) Ozasa R, et al : The antipsychotic olanzapine induces apoptosis in insulin-secreting pancreatic β cells by blocking PERK-mediated translational attenuation. Cell Struct Funct 38 : 183-195, 2013.
 
8) Pandit MK, et al : Drug-induced disorders of glucose tolerance. Ann Intern Med 118 : 529-539, 1993.
PubMed
9) Bengtsson C, et al : Do antihypertensive drugs precipitate diabetes? Br Med J (Clin Res Ed) 289 : 1495-1497, 1984.
PubMed
10) Margolis KL, et al : Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women : results from the Women's Health Initiative Hormone Trial. Diabetologia 47 : 1175-1187, 2004.
PubMed
11) Keating NL, et al : Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24 : 4448-4456, 2006.
PubMed
12) Ikegami H, et al : Immune checkpoint therapy and type 1 diabetes. Diabetol Int 7 : 221-227, 2016.
PubMed
13) Assan R, et al : Pentamidine-induced derangements of glucose homeostasis. Determinant roles of renal failure and drug accumulation. A study of 128 patients. Diabetes Care 18 : 47-55, 1995.
PubMed
P.87 掲載の参考文献
1) Diabetes and Viruses (ed by Taylor K, et al), Springer, New York, 2013.
 
2) IDF Diabetes Atlas, 7th ed, International Diabetes Federation, 2015.
 
3) Tanaka S, et al : Enterovirus infection, CXC chemokine ligand 10 (CXCL10), and CXCR3 circuit : amechanism of accelerated beta-cell failure in fulminant type 1 diabetes. Diabetes 58 : 2285-2291, 2009.
 
4) Hanafusa T, et al : Report of Japan Diabetes Society Committee on Fulminant Type 1 Diabetes Mellitus Research : Epidemiological and clinical analylsis and proposal of diagnostic criteria. Journal of the Japan Diabetes Society 48 : A1-A13, 2005.
 
5) Gastaldi G, et al : Current level of evidence on causal association between hepatitis C virus and type 2 diabetes : A review. J Adv Res 8 : 149-159, 2017.
PubMed
6) Blackard JT, et al : A preliminary analysis of hepatitis C virus in pancreatic islet cells. Virol J 14 : 237, 2017.
PubMed
7) American Diabetes Association : Diagnosis and classification of diabetes mellitus. Diabetes Care 37 (Suppl 1) : S81-90, 2014.
 
8) Imagawa A, et al : Fulminant type 1 diabetes : a nationwide survey in Japan. Diabetes Care 26 : 2345-2352, 2003.
PubMed
9) 田嶼尚子 (研究代表者) : 厚生労働科学研究費補助金 疾病・障害対策研究分野 循環器疾患・糖尿病等生活習慣病対策総合研究 1型糖尿病の実態調査, 客観的診断基準, 日常生活・社会生活に着目した重症度評価の作成に関する研究, 2017.
 
10) Arao M, et al : Prevalence of diabetes mellitus in Japanese patients infected chronically with hepatitis C virus. J Gastroenterol 38 : 355-360, 2003.
PubMed
11) Hodik M, et al : Coxsackie-adenovirus receptor expression is enhanced in pancreas from patients with type 1 diabetes. BMJ Open Diabetes Res Care 4 : e000219, 2016.
PubMed
12) Barrett JC, et al : Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat Genet 41 : 703-707, 2009.
PubMed
13) Jun HS, Yoon JW : The role of viruses in type I diabetes : two distinct cellular and molecular pathogenic mechanisms of virus-induced diabetes in animals. Diabetologia 44 : 271-285, 2001.
PubMed
14) Nagafuchi S, Toniolo A : Viral Diabetes : Virus Diabetogenicity and Host Susceptibility. Immunoendocrinology 2 : e1026, 2015.
 
15) Oshima M, et al : Virus-like infection induces human β cell dedifferentiation. JCI Insight 3. pii : 97732, 2018.
 
16) Op de Beeck A, Eizirik DL : Viral infections in type 1 diabetes mellitus-why the β cells? Nat Rev Endocrinol 12 : 263-273, 2016.
 
17) Flodstrom M, et al : Target cell defense prevents the development of diabetes after viral infection. Nat Immunol 3 : 373-382, 2002.
PubMed
18) Izumi K, et al : Reduced Tyk2 gene expression in β-cells due to natural mutation determines susceptibility to virus-induced diabetes. Nat Commun 6 : 6748, 2015.
 
19) Hosokawa Y, et al : Insulin-producing cells derived from 'induced pluripotent stem cells' of patients with fulminant type 1 diabetes : Vulnerability to cytokine insults and increased expression of apoptosis-related genes. J Diabetes Investig 9 : 481-493, 2018.
 
20) Mine K, et al : Subtyping of Type 1 Diabetes as Classified by Anti-GAD Antibody, IgE Levels, and Tyrosine kinase 2 (TYK2) Promoter Variant in the Japanese. EBioMedicine 23 : 46-51, 2017.
PubMed
21) Azar ST, et al : Type I (insulin-dependent) diabetes is a Th1- and Th2-mediated autoimmune disease. Clin Diagn Lab Immunol 6 : 306-310, 1999.
PubMed
22) Nagafuchi S, et al : TYK2 Promoter Variant and Diabetes Mellitus in the Japanese. EBioMedicine 2 : 744-749, 2015.
PubMed
23) 河崎さつき, ほか : 原田病既往から25年, エンテロウイルス感染を契機に発症したと考えられた劇症1型糖尿病の1例. 糖尿病 59 : 768-774, 2016.
 
24) Hum J, et al : Improvement in Glycemic Control of Type 2 Diabetes After Successful Treatment of Hepatitis C Virus. Diabetes Care 40 : 1173-1180, 2017.
PubMed
25) Kounoue E, et al : The significance of T cells, B cells, antibodies and macrophages against encephalomyocarditis (EMC) -D virus-induced diabetes in mice. Arch Virol 153 : 1223-1231, 2008.
PubMed
26) Stone VM, et al : A Coxsackievirus B vaccine protects against virus-induced diabetes in an experimental mouse model of type 1 diabetes. Diabetologia 61 : 476-481, 2018.
 
27) Mine K, et al : Model Animal Mimicking Human Virus-induced Diabetes. EBioMedicine 32 : 8, 2018.
PubMed
P.91 掲載の参考文献
1) 山田研太郎, ほか : ケトーシスを伴って急性発症する肥満NIDDM症例-清涼飲料水ケトーシス-. 糖尿病 36 : 469-473, 1993.
 
2) 加藤智子, 山田研太郎 : 清涼飲料水ケトーシスの病態と治療糖尿病学の進歩 [第45集] (日本糖尿病学会編), p197-200, 診断と治療社, 2011.
 
3) Yamada K, et al : Diabetic ketoacidosis in young obese Japanese men : atypical diabetes induced by sugar-containing soft drinks. Diabetes Care 19 : 671, 1996.
 
4) 松本一成, ほか : 清涼飲料水ケトーシスにおけるインスリン分泌とインスリン感受性の治療による変化. 糖尿病 41 : 891-896, 1998.
 
5) 二田哲博, ほか : 治療によりインスリン初期分泌正常化を認めた再発性清涼飲料水ケトーシスの1例. 糖尿病 43 : 393-396, 2000.
 
6) Nakayama H, et al : Age-related changes in the diurnal variation of ketogenesis in patients with type 2 diabetes and relevance to hypoglycemic medications. Endocr J 62 : 235-241, 2015.
PubMed
7) 煙崎久子, ほか : ペットボトル症候群を呈した緊張型分裂病の一症例. 精神科治療学 16 : 283-287, 2001.
 
8) 藤井康男 : Olanzapine投与中の糖尿病性昏睡に伴う死亡例から我々はなにを学ぶべきか? 臨床精神薬理 5 : 1093-1113, 2002.
 
9) 杉山摩利子, ほか : 清涼飲料水多飲により著明な脱水をきたしケトアシドーシスに至った中枢性尿崩症合併2型糖尿病の1例. 糖尿病 58 : 835-841, 2015.
 
10) 神野和彦, ほか : 横紋筋融解症を発症した清涼飲料水ケトーシスの1例. 日本小児科学会雑誌 109 : 1457-1461, 2005.
 
11) 澤田雅彦, ほか : 肺梗塞を合併して死亡した "ペットボトル症候群" の1剖検例. 糖尿病 39 : 431-437, 1996.
 
12) 山本直, ほか : ソフトドリンクケトアシドーシスに高トリグリセライド血症と重症急性膵炎を合併した1例. 糖尿病 54 : 34-39, 2011.
 
13) 竹内康雄, ほか : 清涼飲料水ケトーシスによる糖尿病性昏睡に脳浮腫と重症膵炎を合併した若年肥満者の1例. 糖尿病 48 : 115-121, 2005.
 
14) 岩瀬孝志, ほか : 学童期に発症したHamman症候群の1例. 日本小児科学会雑誌 108 : 1495-1500, 2004.
 
15) 大石泰史, ほか : 糖尿病 (いわゆるペットボトル症候群) に伴った色素性痒疹の1例. アレルギーの臨床 26 : 1144-1146, 2006.
 
P.98 掲載の参考文献
1) Donohue WL, Fremes IA : Maternal isoimmunization without evidence of clinical erythroblastosis fetalis in the newborn. J Lab Clin Med 33 : 526-531, 1948.
 
2) Donohue WL, Uchida I : Leprechaunism : a euphemism for a rare familial disorder. J Pediatr 45 : 505-519, 1954.
PubMed
3) Taylor SI : Lilly Lecture : molecular mechanisms of insulin resistance. Lessons from patients with mutations in the insulin-receptor gene. Diabetes 41 : 1473-1490, 1992.
PubMed
4) Kadowaki T, et al : Two mutant alleles of the insulin receptor gene in a patient with extreme insulin resistance. Science 240 : 787-790, 1988.
 
5) Kadowaki H, et al : Mutagenesis of lysine 460 in the human insulin receptor. Effects upon receptor recycling and cooperative interactions among binding sites. J Biol Chem 265 : 21285-21296, 1990.
PubMed
6) Kadowaki T, et al : Substitution of Iysine for asparagine at position 15 in the alpha-subunit of the human insulin receptor. A mutation that impairs transport of receptors to the cell surface and decreases the affinity of insulin binding. J Biol Chem 265 : 19143-19150, 1990.
 
7) Nakae J, et al : Replacements of leucine 87 in human insulin receptor alter affinity for insulin. J Biol Chem 270 : 22017-22022, 1995.
PubMed
8) Garrett TP, et al : Crystal structure of the first three domains of the type-1 insulin-like growth factor receptor. Nature 394 : 395-399, 1998.
PubMed
9) McKern NM, et al : Structure of the insulin receptor ectodomain reveals a folded-over conformation. Nature 443 : 218-221, 2006.
PubMed
10) Menting JG, et al : How insulin engages its primary binding site on the insulin receptor. Nature 493 : 241-245, 2013.
PubMed
11) Hosoe J, et al : Structural Basis and Genotype-Phenotype Correlations of INSR Mutations Causing Severe Insulin Resistance. Diabetes 66 : 2713-2723, 2017.
PubMed
12) Accili D, et al : Early neonatal death in mice homozygous for a null allele of the insulin receptor gene. Nat Genet 12 : 106-109, 1996.
 
13) Nakae J, et al : Distinct and overlapping functions of insulin and IGF-I receptors. Endocr Rev 22 : 818-835, 2001.
PubMed
14) Ogilvy-Stuart AL, et al : Hypoglycemia and resistance to ketoacidosis in a subject without functional insulin receptors. J Clin Endocrinol Metab 86 : 3319-3326, 2001.
 
15) Nakae J, et al : Long-term effect of recombinant human insulin-like growth factor I on metabolic and growth control in a patient with leprechaunism. J Clin Endocrinol Metab 83 : 542-549, 1998.
 
16) Di Cola G, et al : Hypoglycemic effect of insulin-like growth factor-1 in mice lacking insulin receptors. J Clin Invest 99 : 2538-2544, 1997.
PubMed
P.105 掲載の参考文献
1) Miyajima H, et al : Familial apoceruloplasmin deficiency associated with blepharospasm and retinal degeneration. Neurology 37 : 761-767, 1987.
PubMed
2) Vroegindeweij LH, et al : Aceruloplasminemia presents as Type 1 diabetes in non-obese adults : a detailed case series. Diabet Med 32 : 993-1000, 2015.
PubMed
3) Piperno A, Alessio M : Aceruloplasminemia : Waiting for an Efficient Therapy. Front Neurosci 12 : 903, 2018.
PubMed
4) 日本神経学会 : 無セルロプラスミン血症の診断基準. [https://www.neurology-jp.org/guidelinem/pdf/syounin_05.pdf] (2019年2月閲覧)
 
5) Miyajima H, et al : Estimation of the gene frequency of aceruloplasminemia in Japan. Neurology 53 : 617-619, 1999.
PubMed
6) 大門真 : セルロプラスミン遺伝子異常との関係 1. 糖尿病. 日本内科学会雑誌 93 : 1573-1578, 2004.
 
7) Miyajima H : Aceruloplasminemia. Neuropathology 35 : 83-90, 2015.
PubMed
8) Morita H, et al : Hereditary ceruloplasmin deficiency with hemosiderosis : aclinicopathological study of a Japanese family. Ann Neurol 37 : 646-656, 1995.
 
9) Kato T, et al : Islet changes in hereditary ceruloplasmin deficiency. Hum Pathol 28 : 499-502, 1997.
PubMed
10) Miyajima H, et al : Cerebellar ataxia associated with heteroallelic ceruloplasmin gene mutation. Neurology 57 : 2205-2210, 2001.
PubMed
11) Patel BN, et al : Alternative RNA splicing generates a glycosylphosphatidylinositol-anchored form of ceruloplasmin in mammalian brain. J Biol Chem 275 : 4305-4310, 2000.
 
12) Pelucchi S, et al : Phenotypic heterogeneity in seven Italian cases of aceruloplasminemia, Parkinsonism Relat Disord 51 : 36-42, 2018.
PubMed
13) Miyajima H, Hosoi Y : Aceruloplasminemia. GeneReviews(R) [Internet] , University of Washington, Seattle, 1993-2019. 2003 Aug 12 [updated 2018 Sep 27].
 
14) Miyajima H, et al : Increased lipid peroxidation and mitochondrial dysfunction in aceruloplasminemia brains. Blood Cells Mol Dis 29 : 433-438, 2002.
PubMed
15) 加藤丈夫 : 糖尿病に伴う脳障害. 日本内科学会雑誌 94 : 490-496, 2005.
 
16) 宮嶋裕明, ほか : セルロプラスミンと銅, 鉄代謝. 神経内科 61 : 130-139, 2004.
 
17) Miyajima H, et al : Use of desferrioxamine in the treatment of aceruloplasminemia. Ann Neurol 41 : 404-407, 1997.
PubMed
18) Bethlehem C, et al : Central nervous system involvement in a rare genetic iron overload disorder. Neth J Med 68 : 316-318, 2010.
 
19) 岩下愛, ほか : GAD抗体陽性の糖尿病を合併した無セルロプラスミン血症の一例. 日本糖尿病学会関東甲信越地方会プログラム・抄録集, p76, 2019.
 
P.110 掲載の参考文献
1) Nakayama T, et al : Clinical and genetic analysis of the first known Asian family with myotonic dystrophy type 2. J Hum Genet 59 : 129-133, 2014.
PubMed
2) Harper PS : Myotonic Dystrophy, 3rd ed, Harcourt Publishers, London, 2001.
 
3) Nakamura T, et al : Splicing of human chloride channel 1. Biochem Biophys Rep 5 : 63-69, 2016.
PubMed
4) Ayhan F, et al : SCA8 RAN polySer protein preferentially accumulates in white matter regions and is regulated by eIF3F. EMBO J 37. pii : e99023, 2018.
 
5) Ashizawa T, et al : Consensus-based care recommendations for adults with myotonic dystrophy type 1. Neurol Clin Pract 8 : 507-520, 2018.
PubMed
6) Matsumura T, et al : A cross-sectional study for glucose intolerance of myotonic dystrophy. J Neurol Sci 276 : 60-65, 2009.
PubMed
7) 高田博仁 : 筋強直性ジストロフィーの代謝・内分泌障害の医療管理. 神経内科 85 : 258-264, 2016.
 
8) Iwahashi H : Glucose intolerance in myotonic dystrophy. In : Myotonic Dystrophy-Disease Mechanism, Current Management and Therapeutic Development (ed by Takahashi M, Matsumura T), p149-159, Springer, Singapore, 2018.
 
9) 荒畑創, 梅本丈二 : 筋強直性ジストロフィーの食と代謝に関わる問題. 難病と在宅ケア 22 : 18-22, 2016.
Medical*Online
10) 三木哲郎 : 筋強直性ジストロフィー (筋緊張性ジストロフィー). 糖尿病 58 : 532-534, 2015.
 
P.114 掲載の参考文献
1) Brown RJ, et al : The Diagnosis and Management of Lipodystrophy Syndromes : A Multi-Society Practice Guideline. J Clin Endocrinol Metab 101 : 4500-4511, 2016.
PubMed
2) Hussain I, et al : A Novel Generalized Lipodystrophy-Associated Progeroid Syndrome Due to Recurrent Heterozygous LMNA p.T10I Mutation. J Clin Endocrinol Metab 103 : 1005-1014, 2018.
 
3) Hayashi YK, et al : Human PTRF mutations cause secondary deficiency of caveolins resulting in muscular dystrophy with generalized lipodystrophy. J Clin Invest 119 : 2623-2633, 2009.
PubMed
4) Brown RJ, et al : Lymphoma in acquired generalized lipodystrophy. Leuk Lymphoma 57 : 45-50, 2016.
PubMed
5) Misra A, et al : Clinical features and metabolic and autoimmune derangements in acquired partial lipodystrophy : report of 35 cases and review of the literature. Medicine (Baltimore) 83 : 18-34, 2004.
PubMed
6) Garg A : Acquired and inherited lipodystrophies. N Engl J Med 350 : 1220-1234, 2004.
PubMed
7) Adachi M, et al : Abnormal adipose tissue distribution with unfavorable metabolic profile in five children following hematopoietic stem cell transplantation : anew etiology for acquired partial lipodystrophy. Clin Pediatr Endocrinol 22 : 53-64, 2013.
 
8) 海老原健, ほか : 我が国における脂肪萎縮症の現況. 肥満研究 17 : 15-20, 2011.
Medical*Online
9) Ebihara K, et al : Transgenic overexpression of leptin rescues insulin resistance and diabetes in a mouse model of lipoatrophic diabetes. Diabetes 50 : 1440-1448, 2001.
 
10) Oral EA, et al : Leptin-replacement therapy for lipodystrophy. N Engl J Med 346 : 570-578, 2002.
PubMed
11) Musso C, et al : The long-term effect of recombinant methionyl human leptin therapy on hyperandrogenism and menstrual function in female and pituitary function in male and female hypoleptinemic lipodystrophic patients. Metab Clin Exp 54 : 255-263, 2005.
 
12) Kawana Y, et al : Sodium-Glucose Cotransporter 2 Inhibitor Improves Complications of Lipodystrophy : A Case Report. Ann Intern Med 166 : 450-451, 2017.
PubMed
P.120 掲載の参考文献
1) Louis-Bar D : Sur un syndrome progressif comprenant des telangiectasies capillaires cutanees et conjonctivales symetriques, a disposition naevoide et des troubles cerebelleux. Confinia Neurologica 4 : 32-42, 1941.
 
2) Boder E, Sedgwig RP : Ataxia-telangiectasia ; a familial syndrome of progressive cerebellar ataxia, oculocutaneous telangiectasia and frequent pulmonary infection. Pediatrics 21 : 526-554, 1958.
 
3) Savitsky K, et al : A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 268 : 1749-1753, 1995.
PubMed
4) Swift M, et al : The incidence and gene frequency of ataxia-telangiectasia in the United States. Am J Hum Genet 39 : 573-583, 1986.
PubMed
5) Lempiainen H, Halazonetis TD : Emerging common themes in regulation of PIKKs and PI3Ks. EMBO J 28 : 3067-3073, 2009.
PubMed
6) Gatti RA, et al : Ataxia-telangiectasia : an interdisciplinary approach to pathogenesis. Medicine (Baltimore) 70 : 99-117, 1991.
PubMed
7) Suarez F, et al : Incidence, presentation, and prognosis of malignancies in ataxia-telangiectasia : a report from the French national registry of primary immune deficiencies. J Clin Oncol 33 : 202-208, 2015.
 
8) Nissenkorn A, et al : Endocrine abnormalities in ataxia telangiectasia : findings from a national cohort. Pediatr Res 79 : 889-894, 2016.
PubMed
9) Marabelli M, et al : Penetrance of ATM Gene Mutations in Breast Cancer : A Meta-Analysis of Different Measures of Risk. Genet Epidemiol 40 : 425-431, 2016.
PubMed
10) Voss S, et al : Growth retardation and growth hormone deficiency in patients with Ataxia telangiectasia. Growth Factors 32 : 123-129, 2014.
PubMed
11) Schalch DS, et al : An unusual form of diabetes mellitus in ataxia telangiectasia. N Engl J Med 282 : 1396-1402, 1970.
PubMed
12) Rothblum-Oviatt C, et al : Ataxia telangiectasia : a review. Orphanet J Rare Dis 11 : 159, 2016.
PubMed
13) Stagni V, et al : Ataxia-Telangiectasia Mutated Kinase in the Control of Oxidative Stress, Mitochondria, and Autophagy in Cancer : A Maestro With a Large Orchestra. Front Oncol 8 : 73, 2018.
 
14) Takagi M, et al : ATM regulates adipocyte differentiation and contributes to glucose homeostasis. Cell Rep 10 : 957-967, 2015.
PubMed
15) Zannolli R, et al : A randomized trial of oral betamethasone to reduce ataxia symptoms in ataxia telangiectasia. Mov Disord 27 : 1312-1316, 2012.
PubMed
P.123 掲載の参考文献
1) Herrmann C Jr, et al : Hereditary Photomyoclonus Associated with Diabetes mellitus, Deafness, Nephropathy, and Cerebral Dysfunction. Neurology 14 : 212-221, 1964.
PubMed
2) van den Ouweland JM, et al : Functional and morphological abnormalities of mitochondria harbouring the tRNA (Leu) (UUR) mutation in mitochondrial DNA derived from patients with maternally inherited diabetes and deafness (MIDD) and progressive kidney disease. Diabetologia 42 : 485-492, 1999.
PubMed
3) Medlej R, et al : Diabetes mellitus and optic atrophy : a study of Wolfram syndrome in the Lebanese population. J Clin Endocrinol Metab 89 : 1656-1661, 2004.
PubMed
4) Jin H, et al : A novel X-linked gene, DDP, shows mutations in families with deafness (DFN-1), dystonia, mental deficiency and blindness. Nat Genet 14 : 177-180, 1996.
 
5) Feigenbaum A, et al : Premature diffuse atherosclerosis in two siblings with photomyoclonic epilepsy, diabetes mellitus, deafness, and nephropathy : a genetic syndrome distinct from Herrmann syndrome (Abst). Am J Hum Genet 47 (Suppl) : A55, 1990.
 
6) Feigenbaum A, et al : Premature atherosclerosis with photomyoclonic epilepsy, deafness, diabetes mellitus, nephropathy, and neurodegenerative disorder in two brothers : a new syndrome? Am J Med Genet 49 : 118-124, 1994.
 
P.128 掲載の参考文献
1) Klinefelter HF, et al : Syndrome characterized by gynecomastia, aspermatogenesis without a-Leydigism and increased secretion of follicle-stimulating hormone. J Clin Endocrinol 2 : 615-627, 1942.
 
2) Bojesen A, et al : Prenatal and postnatal prevalence of Klinefelter syndrome : a national registry study. J Clin Endocrinol Metab 88 : 622-626, 2003.
 
3) Morris JK, et al : Is the prevalence of Klinefelter syndrome increasing? Eur J Hum Genet 16 : 163-170, 2008.
PubMed
4) Forti G, et al : Klinefelter's syndrome : a clinical and therapeutical update. Sex Dev 4 : 249-258, 2010.
PubMed
5) Gravholt CH, et al : Klinefelter syndrome : integrating genetics, neuropsychology, and endocrinology. Endocr Rev 39 : 389-423, 2018.
PubMed
6) Lanfranco F, et al : Klinefelter's syndrome. Lancet 364 : 273-283, 2004.
PubMed
7) Samplaski MK, et al : Phenotypic differences in mosaic Klinefelter patients as compared with non-mosaic Klinefelter patients. Fertil Steril 101 : 950-955, 2014.
PubMed
8) Thomas NS, Hassold TJ : Aberrant recombination and the origin of Klinefelter syndrome. Hum Reprod Update 9 : 309-317, 2003.
PubMed
9) Sharma A, et al : DNA methylation signature in peripheral blood reveals distinct characteristics of human X chromosome numerical aberrations. Clin Epigenetics 7 : 76, 2015.
PubMed
10) Tournaye H, et al : Correlation between testicular histology and outcome after intracytoplasmic sperm injection using testicular spermatozoa. Hum Reprod 11 : 127-132, 1996.
PubMed
11) Koga M, et al : Clinical comparison of successful and failed microdissection testicular sperm extraction in patients with nonmosaic Klinefelter syndrome. Urology 70 : 341-345, 2007.
PubMed
12) Takada S, et al : Androgen decline in patients with nonobstructive azoospemia after micro-dissection testicular sperm extraction. Urology 72 : 114-118, 2008.
 
13) Van Saen D, et al : When does germ cell loss and fibrosis occur in patients with Klinefelter syndrome? Hum Reprod 33 : 1009-1022, 2018.
PubMed
14) Bojesen A, et al : Morbidity in Klinefelter syndrome : a Danish register study based on hospital discharge diagnoses. J Clin Endocrinol Metab 91 : 1254-1260, 2006.
PubMed
15) Salzano A, et al : Klinefelter syndrome, insulin resistance, metabolic syndrome, and diabetes : review of literature and clinical perspectives. Endocrine 61 : 194-203, 2018.
PubMed
16) Han SJ, et al : Obesity and Hyperglycemia in Korean Men with Klinefelter Syndrome : The Korean Endocrine Society Registry. Endocrinol Metab (Seoul) 31 : 598-603, 2016.
PubMed
17) Tahani N, et al : Long-term effect of testosterone replacement therapy on bone in hypogonadal men with Klinefelter Syndrome. Endocrine 61 : 327-335, 2018.
 
18) Bojesen A, et al : Socioeconomic trajectories affect mortality in Klinefelter syndrome. J Clin Endocrinol Metab 96 : 2098-2104, 2011.
PubMed
P.133 掲載の参考文献
1) Rabson SM, et al : Familial hypertrophy of pineal body, hyperplasia of adrenal cortex and diabetes mellitus ; report of 3 cases. Am J Clin Pathol 26 : 283-290, 1956.
PubMed
2) Kadowaki T, et al : Two mutant alleles of the insulin receptor gene in a patient with extreme insulin resistance. Science 240 : 787-790, 1988.
 
3) Kadowaki T, et al : Five mutant alleles of the insulin receptor gene in patients with genetic forms of insulin resistance. J Clin Invest 86 : 254-264, 1990.
PubMed
4) Longo N, et al : Genotype-phenotype correlation in inherited severe insulin resistance. Hum Mol Genet 11 : 1465-1475, 2002.
PubMed
5) Longo N, et al : Progressive decline in insulin levels in Rabson-Mendenhall syndrome. J Clin Endocrinol Metab 84 : 2623-2629, 1999.
PubMed
6) Leiter SM, Semple RK : Syndromes associated with mutations in the insulin signaling pathway. In : Diabetes Associated with Single Gene Defects and Chromosomal Abnormalities, Vol 25 (ed by Barbetti F, et al), p104-118, Karger, Basel, 2017.
 
7) Thiel CT, et al : Two novel mutations in the insulin binding subunit of the insulin receptor gene without insulin binding impairment in a patient with Rabson-Mendenhall syndrome. Mol Genet Metab 94 : 356-362, 2008.
 
8) Kim D, et al : Two novel insulin receptor gene mutations in a patient with Rabson-Mendenhall syndrome : the first Korean case confirmed by biochemical, and molecular evidence. J Korean Med Sci 27 : 565-568, 2012.
 
9) Mohanan S, et al : Rabson-Mendenhall syndrome with recurrent cerebral infarcts caused by a novel INSR mutation. Int J Dermatol 52 : 182-185, 2013.
PubMed
10) Abe Y, et al : A case of Rabson-Mendenhall syndrome with a novel mutation in the tyrosine kinase domain of the insulin receptor gene complicated by medullary sponge kidney. J Pediatr Endocrinol Metab 25 : 587-590. 2012.
PubMed
11) Grasso V, et al : Six cases with severe insulin resistance (SIR) associated with mutations of insulin receptor : Is a Bartter-like syndrome a feature of congenital SIR? Acta Diabetol 50 : 951-957, 2013.
PubMed
12) Murphy R, et al : Novel mutation in insulin receptor gene identified after muscle biopsy in a Niuean woman with severe insulin resistance. Diabet Med 32 : e24-28, 2015.
 
13) Hosoe J, et al : Structural Basis and Genotype-Phenotype Correlations of INSR Mutations Causing Severe Insulin Resistance. Diabetes 66 : 2713-2723, 2017.
PubMed
14) Brown RJ, et al : Metreleptin improves blood glucose in patients with insulin receptor mutations. J Clin Endocrinol Metab 98 : E1749-1756, 2013.
PubMed
15) Musso C, et al : Clinical course of genetic diseases of the insulin receptor (type A and Rabson-Mendenhall syndromes) : a 30-year prospective. Medicine (Baltimore) 83 : 209-222, 2004.
PubMed
P.139 掲載の参考文献
1) Cassidy SB : Prader-Willi syndrome. J Med Genet 34 : 917-923, 1997.
PubMed
2) Matsubara K, et al : Maternal age effect on the development of Prader-Willi syndrome resulting from upd (15) mat through meiosis 1 errors. J Hum Genet 56 : 566-571, 2011.
PubMed
3) Holm VA, et al : Prader-Willi syndrome : consensus diagnostic criteria. Pediatrics 91 : 398-402, 1993.
PubMed
4) Gunay-Aygun M, et al : The changing purpose of Prader-Willi syndrome clinical diagnostic criteria and proposed revised criteria. Pediatrics 108 : E92, 2001.
PubMed
5) Zipf WB : Glucose homeostasis in Prader-Willi syndrome and potential implications of growth hormone therapy. Acta Paediatr Suppl 88 : 115-117, 1999.
PubMed
6) Tsuchiya T, et al : Characterization of diabetes mellitus in Japanese prader-willi syndrome. Clin Pediatr Endocrinol 20 : 33-38, 2011.
PubMed
7) 綾部匡之, ほか : 小児期・思春期の成長ホルモン補充療法はプラダー・ウィリ症候群の糖尿病発症頻度を低下させる. 日本内分泌学会雑誌 91 : 55-57, 2015.
Medical*Online
8) Schuster DP, et al : Characterization of alterations in glucose and insulin metabolism in Prader-Willi subjects. Metabolism 45 : 1514-1520, 1996.
PubMed
9) Festen DA, et al : Adiponectin levels in prepubertal children with Prader-Willi syndrome before and during growth hormone therapy. J Clin Endocrinol Metab 92 : 1549-1554, 2007.
PubMed
10) Tanaka Y, et al : Characterization of fat distribution in Prader-Willi syndrome : relationships with adipocytokines and influence of growth hormone treatment. Am J Med Genet A 161A : 27-33, 2013.
PubMed
11) Bakker NE, et al : Eight years of growth hormone treatment in children with Prader-Willi syndrome : maintaining the positive effects. J Clin Endocrinol Metab 98 : 4013-4022, 2013.
PubMed
12) Salehi P, et al : Effects of exenatide on weight and appetite in overweight adolescents and young adults with Prader-Willi syndrome. Pediatr Obes 12 : 221-228, 2017.
 
13) Horikawa Y, et al : Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitor as an Add-on Drug to GLP-1 Receptor Agonists for Glycemic Control of a Patient with Prader-Willi Syndrome : A Case Report. Diabetes Ther 9 : 421-426, 2018.
PubMed
P.144 掲載の参考文献
1) Moersch FP, Woltman HW : Progressive fluctuating muscular rigidity and spasm ("stiff-man" syndrome) ; report of a case and some observation in 13 cases. Proc Staff Meet Mayo Clin 31 : 421-427, 1956.
PubMed
2) 石井亜紀子, 大越教夫 : Stiff-person症候群とIsaacs症候群. Clin Neurosci 30 : 580-581, 2012.
 
3) 石井亜紀子 : Stiff-person症候群 ; 自己免疫性疾患, 傍腫瘍性神経症候群. 別冊日本臨牀新領域別症候群シリーズ No. 27神経症候群 (第2版) II, p772-775, 日本臨牀社, 2014.
 
4) Ishii A : [Stiff-person syndrome and other myelopathies constitute paraneoplastic neurological syndromes]. Brain Nerve 62 : 377-385, 2010.
PubMed
5) Dalakas MC : Progress and stiff challenges in understanding the role of GAD-antibodies in stiffperson syndrome. Exp Neurol 247 : 303-307, 2013.
PubMed
6) Dalakas MC : Stiff person syndrome : advances in pathogenesis and therapeutic interventions. Curr Treat Options Neurol 11 : 102-110, 2009,
PubMed
7) Balint B, et al : Movement disorders with neuronal antibodies : syndromic approach, genetic parallels and pathophysiology. Brain 141 : 13-36, 2018.
PubMed
8) Raju R, et al : Autoimmunity to GABAA-receptor-associated protein in stiff-person syndrome. Brain 129 : 3270-3276, 2006.
PubMed
9) De Camilli P, et al : The synaptic vesicle-associated protein amphiphysin is the 128-kD autoantigen of Stiff-Man syndrome with breast cancer, J Exp Med 178 : 2219-2223, 1993.
PubMed
10) Butler MH, et al : Autoimmunity to gephyrin in Stiff-Man syndrome. Neuron 26 : 307-312, 2000.
PubMed
11) Wendt A, et al : Glucose inhibition of glucagon secretion from rat alpha-cells is mediated by GABA released from neighboring beta-cells. Diabetes 53 : 1038-1045, 2004.
PubMed
12) Tuomiiehto J, et al : Antibodies to glutamic acid decarboxylase as predictors of insulindependent diabetes mellitus before clinical onset of disease. Lancet 343 : 1383-1385, 1994.
 
13) Shiang R, et al : Mutations in the alpha 1 subunit of the inhibitory glycine receptor cause the dominant neurologic disorder, hyperekplexia. Nat Genet 5 : 351-358, 1993.
PubMed
14) Takagi M, et al : Cognitive dysfunction associated with anti-glutamic acid decarboxylase autoimmunity : a case-control study. BMC Neurol 13 : 76, 2013.
 
15) Rees MI, et al : Evidence for recessive as well as dominant forms of startle disease (hyperekplexia) caused by mutations in the alpha 1 subunit of the inhibitory glycine receptor. Hum Mol Genet 3 : 2175-2179, 1994.
PubMed
P.147 掲載の参考文献
1) Turner HH : A syndrome of infantilism, congenital webbed neck, and cubitus valgus. Endocrinology 23 : 566-574, 1938.
 
2) Ullrich O : Uber typische Kombinationsbilder multipler Abartungen. Zeitschrift fur Kinderheilk 49 : 271-276, 1930.
 
3) Ford CE, et al : A sex-chromosome anomaly in a case of gonadal dysgenesis (Turner's syndrome). Lancet 1 : 711-713, 1959.
 
4) Ferguson-Smith MA : Karyotype-phenotype correlations in gonadal dysgenesis and their bearing on the pathogenesis of malformations. J Med Genet 2 : 142-155, 1965.
PubMed
5) 黒木良和 : 新生児集団 (5,026例) の細胞遺伝学的検討. 米子医学雑誌 134 : 1-7, 1983.
 
6) Maeda T, et al : A cytogenetic survey of 14,835 consecutive liveborns. Jinrui Idengaku Zasshi 36 : 117-129, 1991.
 
7) Kajii T, et al : Anatomic and chromosomal anomalies in 639 spontaneous abortuses. Hum Genet 55 : 87-98, 1980.
PubMed
8) Chervenak FA, et al : Fetal cystic hygroma Cause and natural history. N Engl J Med 309 : 822-825, 1983.
PubMed
9) Suwa S : Standards for growth and growth velocity in Turner's syndrome. Acta Paediatr Jpn 34 : 206-220 ; discussion 221, 1992.
PubMed
10) Lippe BM : Physical and anatomical abnormalities in Turner syndrome. In : Turner Syndrome (ed by Rosenfeld by RG, Grumbach MM), p183-196, Marcel Dekker, New York, 1990.
 
11) Ferencz C, et al : Congenital cardiovascular malformations associated with chromosome abnormalities : an epidemiologic study. J Pediatr 114 : 79-86, 1989.
PubMed
12) Lippe B, et al : Renal malformations in patients with Turner syndrome : imaging in 141 patients. Pediatrics 82 : 852-856, 1988.
PubMed
13) Singh RP, Carr DH : The anatomy and histology of XO human embryos and fetuses. Anat Rec 155 : 369-383, 1966.
PubMed
14) Carr DH, et al : Germ cells in the ovaries of XO female infants. Am J Clin Pathol 49 : 521-526, 1968.
PubMed
15) Forbes AP, Engel E : The high incidence of diabetes mellitus in 41 patients with gonadal dysgenesis, and their close relatives. Metab Clin Exp 12 : 428-439, 1963.
PubMed
16) Tanaka T, et al : Glucose tolerance in Turner syndrome. In : Basic and Clinical Approach to Turner Syndrome (ed by Hibi I, Takano K), p197-201, Excerpta Medica, Amsterdam, 1993.
 
17) 田中敏章, ほか : Turner症候群における経口ブドウ糖負荷試験-第1報 年齢による耐糖能の変化-. 糖尿病 46 : 849-856, 2003.
 
18) Caprio S, et al : Insulin resistance : an early metabolic defect of Turner's syndrome. J Clin Endocrinol Metab 72 : 832-836, 1991.
PubMed
19) Williams ED, et al : Thyroiditis and gonadal dysgenesis. N Engl J Med 270 : 805-810, 1964.
PubMed
20) Hultcrantz M, et al : Ear and hearing problems in 44 middle-aged women with Turner's syndrome. Hear Res 76 : 127-132, 1994.
PubMed
P.153 掲載の参考文献
1) http://www.m.chiba-u.ac.jp/dept/clin-cellbiol/werner/#item5
 
2) Yokote K, et al : WRN Mutation Update : Mutation Spectrum, Patient Registries, and Translational Prospects. Hum Mutat 38 : 7-15, 2017.
PubMed
3) 千葉大学大学院医学研究院 : ウェルナー症候群の診断・診療ガイドライン 2012年版. [http://www.m.chiba-u.jp/dept/clin-cellbiol/files/5215/0752/8288/guideline.pdf]
 
4) Epstein CJ, et al : Werner's syndrome a review of its symptomatology, natural history, pathologic features, genetics and relationship to the natural aging process. Medicine (Baltimore) 45 : 177-221, 1966.
 
5) Goto M, Matsuura M : Secular trends towards delayed onsets of pathologies and prolonged longevities in Japanese patients with Werner syndrome. Biosci Trends 2 : 81-87, 2008.
PubMed
6) Goto M, et al : Werner syndrome : achanging Pattern of clinical manifestations in Japan (1917-2008). Biosci Trends 7 : 13-22, 2013.
 
7) Shima F, et al : Autophosphorylation of insulin receptor in a patient with Werner's syndrome associated with insulin resistant diabetes mellitus. Endocr J 42 : 107-113, 1995.
 
8) Mori S, et al : Enhanced intra-abdominal visceral fat accumulation in patients with Werner's syndrome. Int J Obes Relat Metab Disord 25 : 292-295, 2001.
PubMed
9) Yokote K, et al : Dysadipocytokinemia in werner syndrome and its recovery by treatment with pioglitazone. Diabetes Care 27 : 2562-2563, 2004.
PubMed
10) Yamada K, et al : All patients with Werner's syndrome are insulin resistant, but only those who also have impaired insulin secretion develop overt diabetes. Diabetes Care 22 : 2094-2095, 1999.
PubMed
11) Yokote K, et al : Metabolic improvement and abdominal fat redistribution in Werner syndrome by pioglitazone. J Am Geriatr Soc 52 : 1582-1583, 2004.
PubMed
12) Kahn SE, et al : Rosiglitazone-associated fractures in type 2 diabetes : an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 31 : 845-851, 2008.
PubMed
13) Kitamoto T, et al : Sitagliptin successfully ameliorates glycemic control in Werner syndrome with diabetes. Diabetes Care 35 : e83, 2012.
PubMed
14) Yamaga M, et al : Werner syndrome : a model for sarcopenia due to accelerated aging. Aging (Albany NY) 9 : 1738-1744, 2017.
 
P.157 掲載の参考文献
1) Wolfram DJ, Wagener HP : Diabetes mellitus and simple optic atrophy among siblings : report of four cases. Mayo Clin Proc 13 : 715-718, 1938.
 
2) Barrett TG, et al : Neurodegeneration and diabetes : UK nationwide study of Wolfram (DIDMOAD) syndrome. Lancet 346 : 1458-1463, 1995.
PubMed
3) Inoue H, et al : A gene encoding a transmembrane protein is mutated in patients with diabetes mellitus and optic atrophy (Wolfram syndrome). Nat Genet 20 : 143-148, 1998.
PubMed
4) Matsunaga K, et al : Wolfram syndrome in the Japanese population ; molecular analysis of WFS1 gene and characterization of clinical features. PLoS ONE 9 : e106906, 2014.
PubMed
5) Zatyka M, et al : Sodium-potassium ATPase 1 subunit is a molecular partner of Wolframin, an endoplasmic reticulum protein involved in ER stress. Hum Mol Genet 17 : 190-200, 2008.
PubMed
6) Hatanaka M, et al : Wolfram syndrome 1 gene (WFS1) product localizes to secretory granules and determines granule acidification in pancreatic beta-cells. Hum Mol Genet 20 : 1274-1284, 2011.
PubMed
7) Cano A, et al : Microvascular diabetes complications in Wolfram syndrome (diabetes insipidus, diabetes mellitus, optic atrophy, and deafness [DIDMOAD]) : an age-and duration-matched comparison with common type 1 diabetes. Diabetes Care 30 : 2327-2330, 2007.
PubMed
8) Bille M, et al : Two families with phenotypically different hereditary low frequency hearing impairment : longitudinal data and linkage analysis. Scand Audiol 30 : 246-254, 2001.
PubMed
9) Toth T, et al : Phenotypic characterization of a DFNA6 family showing progressive low-frequency sensorineural hearing impairment. Int J Pediatr Otorhinolaryngol 70 : 201-206, 2006.
PubMed
10) Lugar HM, et al : Neuroimaging evidence of deficient axon myelination in Wolfram syndrome. Sci Rep 6 : 21167, 2016.
PubMed
11) Bespalova IN, et al : Mutations in the Wolfram syndrome 1 gene (WFS1) are a common cause of low frequency sensorineural hearing loss. Hum Mol Genet 10 : 2501-2508, 2001.
PubMed
12) Eiberg H, et al : Autosomal dominant optic atrophy associated with hearing impairment and impaired glucose regulation caused by a missense mutation in the WFS1 gene. J Med Genet 43 : 435-440, 2006.
 
13) El-Shanti H, et al : Homozygosity mapping identifies an additional locus for Wolfram syndrome on chromosome 4q. Am J Hum Genet 66 : 1229-1236, 2000.
PubMed
14) al-Sheyyab M, et al : Bleeding tendency in Wolfram syndrome : anewly identified feature with phenotype genotype correlation. Eur J Pediatr 160 : 243-246, 2001.
PubMed
15) Rotig A, et al : Deletion of mitochondrial DNA in a case of early-onset diabetes mellitus, optic atrophy, and deafness (Wolfram syndrome, MIM 222300). J Clin Invest 91 : 1095-1098, 1993.
 
16) Hofmann S, et al : Wolfram (DIDMOAD) syndrome and Leber hereditary optic neuropathy (LHON) are associated with distinct mitochondrial DNA haplotypes. Genomics 39 : 8-18, 1997.
PubMed
17) Kondo M, et al : Activation of GLP-1 receptor signalling alleviates cellular stresses and improves beta cell function in a mouse model of Wolfram syndrome. Diabetologia 61 : 2189-2201. 2018.
 
P.160 掲載の参考文献
1) Chiasson JL, et al : Diagnosis and treatment of diabetic ketoacidosis and the hyperglycemic hyperosmolar state. CMAJ 168 : 859-866, 2003.
PubMed
2) Newton CA, Raskin P : Diabetic ketoacidosis in type 1 and type 2 diabetes mellitus : clinical and biochemical differences. Arch Intern Med 164 : 1925-1931, 2004.
PubMed
3) Wang ZH, et al : Ketoacidosis occurs in both Type 1 and Type 2 diabetes-a population-based study from Northern Sweden. Diabet Med 25 : 867-870, 2008.
PubMed
4) Kitabchi AE, et al : Hyperglycemic crises in adult patients with diabetes. Diabetes Care 32 : 1335-1343, 2009.
PubMed
5) Linfoot P, et al : Pathophysiology of ketoacidosis in Type 2 diabetes mellitus. Diabet Med 22 : 1414-1419, 2005,
PubMed
6) Nyenwe EA, Kitabchi AE : Evidence-based management of hyperglycemic emergencies in diabetes mellitus. Diabetes Res Clin Pract 94 : 340-351, 2011.
PubMed
7) Trachtenbarg DE : Diabetic ketoacidosis. Am Fam Physician 71 : 1705-1714, 2005.
PubMed
8) Morris LR, et al : Bicarbonate therapy in severe diabetic ketoacidosis. Ann Intern Med 105 : 836-840, 1986.
PubMed
9) Fisher JN, Kitabchi AE : A randomized study of phosphate therapy in the treatment of diabetic ketoacidosis. J Clin Endocrinol Metab 57 : 177-180, 1983.
PubMed
P.165 掲載の参考文献
1) Nyenwe EA, et al : Evidence-based management of hyperglycemic emergencies in diabetes mellitus. Diabetes Res Clin Pract 94 : 340-351, 2011.
PubMed
2) Gosmanov AR, et al : Hyperglycemic Crises : Diabetic Ketoacidosis (DKA), And Hyperglycemic Hyperosmolar State (HHS). Endotext [Internet] , Last Update : May 17, 2018. [https://www.ncbi.nlm.nih.gov/books/NBK279052/] (2019年2月閲覧)
 
3) 日本糖尿病学会 (編・著) : 糖尿病専門医研修ガイドブック [改訂第7版], p272-274, 診断と治療社, 2017.
 
4) Pasquel FJ, et al : Hyperosmolar hyperglycemic state : a historic review of the clinical presentation, diagnosis, and treatment. Diabetes Care 37 : 3124-3131, 2014.
PubMed
5) Kitabchi AE, et al : Hyperglycemic crises in adult patients with diabetes, Diabetes Care 32 : 1335-1343, 2009.
PubMed
6) Gerich J, et al : Effect of dehydration and hyperosmolarity on glucose, free fatty acid and ketone body metabolism in the rat. Diabetes 22 : 264-271, 1973.
PubMed
7) Kitabchi AE, et al : Hyperglycemic crises in diabetes mellitus : diabetic ketoacidosis and hyperglycemic hyperosmolar state. Endocrinol Metab Clin North Am 35 : 725-751, viii, 2006.
PubMed
8) Zeitler P, et al : Hyperglycemic hyperosmolar syndrome in children : pathophysiological considerations and suggested guidelines for treatment. J Pediatr 158 : 9-14, 14.e1-2, 2011.
 
9) Scott AR, et al : Management of hyperosmolar hyperglycaemic state in adults with diabetes. Diabet Med 32 : 714-724, 2015.
PubMed
10) Dhatariya KK, Vellanki P : Treatment of Diabetic Ketoacidosis (DKA) /Hyperglycemic Hyperosmolar State (HHS) : Novel Advances in the Management of Hyperglycemic Crises (UK Versus USA). Curr Diab Rep 17 : 33, 2017.
PubMed
P.170 掲載の参考文献
1) Ferguson BS, et al : Lactate metabolism : historical context, prior misinterpretations, and current understanding Eur J Appl Physiol 118 : 691-728, 2018.
PubMed
2) Brooks GA : The Science and Translation of Lactate Shuttle Theory. Cell Metab 27 : 757-785, 2018.
PubMed
3) Reaven GM, et al : Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 h in patients with NIDDM. Diabetes 37 : 1020-1024, 1988.
 
4) 河西浩一, ほか : 乳酸代謝と乳酸アシドーシス. 臨床病理 46 : 804-812, 1998.
Medical*Online
5) Davies MJ, et al : Management of Hyperglycemia in Type 2 Diabetes, 2018, A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 41 : 2669-2701, 2018.
 
6) Rena G, et al : The mechanisms of action of metformin. Diabetologia 60 : 1577-1585, 2017.
PubMed
7) DeFronzo R, et al : Metformin-associated lactic acidosis : Current perspectives on causes and risk. Metab Clin Exp 65 : 20-29, 2016.
 
8) Richy FF, et al : Incidence of lactic acidosis in patients with type 2 diabetes with and without renal impairment treated with metformin : aretrospective cohort study. Diabetes Care 37 : 2291-2295, 2014.
 
9) Chang CH, et al : Epidemiology of lactic acidosis in type 2 diabetes patients with metformin in Japan. Pharmacoepidemiol Drug Saf 25 : 1196-1203, 2016.
PubMed
10) Lazarus B, et al : Association of Metformin Use With Risk of Lactic Acidosis Across the Range of Kidney Function : A Community-Based Cohort Study. JAMA Intern Med 178 : 903-910, 2018.
PubMed
11) Kajbaf F, et al : Mortality rate in so-called "metformin-associated lactic acidosis" : a review of the data since the 1960s. Pharmacoepidemiol Drug Saf 23 : 1123-1127, 2014.
PubMed
12) Kraut JA, et al : Lactic acidosis. N Engl J Med 371 : 2309-2319, 2014.
PubMed
13) Yeh HC, et al : Serum lactate level and mortality in metformin-associated lactic acidosis requiring renal replacement therapy : asystematic review of case reports and case series. BMC Nephrol 18 : 229, 2017.
 
P.176 掲載の参考文献
1) Maser RE, et al : Epidemiological correlates of diabetic neuropathy. Report from Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes 38 : 1456-1461, 1989.
PubMed
2) Young MJ, et al : A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 36 : 150-154, 1993.
PubMed
3) 佐藤譲ほか : 糖尿病神経障害の発症頻度と臨床診断におけるアキレス腱反射の意義-東北地方15,000人の実態調査. 糖尿病 50 : 799-806, 2007.
 
4) 糖尿病性神経障害を考える会 : 糖尿病性多発神経障害 (distal symmetric polyneuropathy) の簡易診断基準の改訂について. 末梢神経 14 : 225-227, 2003.
 
5) Brownlee M : Biochemistry and molecular cell biology of diabetic complications. Nature 414 : 813-820, 2001.
PubMed
6) Toth C, et al : Rescue and regeneration of injured peripheral nerve axons by intrathecal insulin. Neuroscience 139 : 429-449, 2006.
PubMed
7) Callaghan BC, et al : Diabetic neuropathy : clinical manifestations and current treatments. Lancet Neurol 11 : 521-534, 2012.
PubMed
8) Tesfaye S, et al : Vascular risk factors and diabetic neuropathy. N Engl J Med 352 : 341-350, 2005.
PubMed
9) Carrington AL : The aldose reductase pathway and nonenzymatic glycation in the pathogenesis of diabetic neuropathy : a critical review for the end of the 20th century. Diabetes Rev 7 : 275-299, 1999.
 
10) Armstrong DG, et al : Diabetic Foot Ulcers and Their Recurrence. N Engl J Med 376 : 2367-2375, 2017.
PubMed
11) Pop-Busui R, et al : Diabetic Neuropathy : A Position Statement by the American Diabetes Association. Diabetes Care 40 : 136-154, 2017.
PubMed
12) Dyck PJ, et al : Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort. Neurology 49 : 229-239, 1997.
PubMed
13) 馬場正之, 鈴木千恵子 : 神経伝導検査による糖尿病性多発神経障害の重症度診断. 医学のあゆみ 244 : 146-150, 2013.
Medical*Online
14) 出口尚寿, 西尾善彦 : アキレス腱反射, 振動覚検査, 神経伝導検査 (大径線維障害). 日本臨牀 74 (増刊 : 新時代の臨床糖尿病学 (下)) : 244-248, 2016.
 
15) 出口尚寿, 西尾善彦 : 糖尿病神経障害の最近の進歩 対症療法. 糖尿病 57 : 602-605, 2014.
 
16) Soedamah-Muthu SS, et al : Relationship between risk factors and mortality in type 1 diabetic patients in Europe : the EURODIAB Prospective Complications Study (PCS). Diabetes Care 31 : 1360-1366, 2008.
PubMed
17) Graveling AJ, Frier BM : The risks of nocturnal hypoglycaemia in insulin-treated diabetes. Diabetes Res Clin Pract 133 : 30-39, 2017.
PubMed
P.180 掲載の参考文献
1) 清原裕, ほか : 糖尿病の分類と診断基準に関する委員会報告. 糖尿病 53 : 450-467, 2010.
 
2) 向井直子, 清原裕 : 糖尿病の疫学 : 久山町研究. 福岡医学雑誌 102 : 175-184, 2011.
Medical*Online
3) 佐藤さくら, ほか : 糖尿病網膜症-診断と治療の最新の知見- : 糖代謝. 糖尿病性合併症. 別冊日本臨牀新領域別症候群シリーズ No. 3 内分泌症候群 (第2版) III, p161-168, 目本臨牀社, 2006.
 
4) Miyazaki M, et al : Comparison of diagnostic methods for diabetes mellitus based on prevalence of retinopathy in a Japanese population : the Hisayama Study. Diabetologia 47 : 1411-1415, 2004.
 
5) Antonetti DA, et al : Diabetic retinopathy : seeing beyond glucose-induced microvascular disease. Diabetes 55 : 2401-2411, 2006.
PubMed
6) Noda K, Ishida S : Role of chronic inflammation in diabetic retinopathy. Inflamm Regen 33 : 230-237, 2013.
 
7) Adamis AP, et al : Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 118 : 445-450, 1994.
PubMed
8) Ishida S, et al : VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J Exp Med 198 : 483-489, 2003.
 
9) Enaida H, et al : Possible benefits of triamcinolone-assisted pars plana vitrectomy for retinal diseases. Retina (Philadelphia, Pa) 23 : 764-770, 2003.
 
10) Hisatomi T, et al : Staining ability and biocompatibility of brilliant blue G : preclinical study of brilliant blue G as an adjunct for capsular staining. Arch Ophthalmol 124 : 514-519, 2006.
PubMed
11) Enaida H, et al : Brilliant blue G selectively stains the internal limiting membrane/brilliant blue G-assisted membrane peeling. Retina (Philadelphia, Pa) 26 : 631-636, 2006.
 
12) Hisatomi T, et al : Brilliant Blue G double staining enhances successful internal limiting membrane peeling with minimal adverse effect by low cellular permeability into live cells. Retina (Philadelphia, Pa) 35 : 310-318, 2015.
 
P.186 掲載の参考文献
1) 羽田勝計, ほか : 糖尿病性腎症病期分類2014の策定 (糖尿病性腎症病期分類改訂) について. 糖尿病 57 : 529-534, 2014.
 
2) 日本腎臓学会 (編) : エビデンスに基づくCKD診療ガイドライン 2018, 東京医学社, 2018.
 
3) 新田孝作, ほか : わが国の慢性透析療法の現況 (2017年12月31日現在). 日本透析医学会雑誌 51 : 699-766, 2018.
 
4) Brownlee M : The pathobiology of diabetic complications : a unifying mechanism. Diabetes 54 : 1615-1625, 2005.
PubMed
5) 馬場園哲也, ほか : 糖尿病性腎症と網膜症との関連. 糖尿病合併症 28 : 173-176, 2014.
 
6) 馬場園哲也, 北野滋彦 : それぞれの糖尿病合併症から他の合併症を眺める糖尿病性腎症から網膜症, 神経障害および動脈硬化症をみる. 糖尿病合併症 32 : 41-44, 2018.
 
7) Bouchi R, et al : Association of albuminuria and reduced estimated glomerular filtration rate with incident stroke and coronary artery disease in patients with type 2 diabetes. Hypertens Res 33 : 1298-1304, 2010.
PubMed
8) 糖尿病性腎症と高血圧性腎硬化症の病理診断への手引き (和田隆志, ほか監佐藤博, ほか編), 東京医学社, 2015.
 
9) Groop PH, et al : Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. Diabetes Care 36 : 3460-3468, 2013.
 
10) Cornel JH, et al : Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes : Outcomes From TECOS. Diabetes Care 39 : 2304-2310, 2016.
PubMed
11) Rosenstock J, et al : Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk. The CARMELINA randomized clinical trial. JAMA, 321 : 69-79, 2019.
PubMed
12) Wanner C, et al : Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med 375 : 323-334, 2016.
PubMed
13) Neal B, et al : Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 377 : 644-657, 2017.
PubMed
14) Wiviott SD, et al : Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 380 : 347-357, 2019.
PubMed
15) Kadowaki T, et al : Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease : results from the EMPA-REG OUTCOME(R) trial. J Diabetes Investig, 2018. (doi : 10.1111/jdi.12971)
 
16) Marso SP, et al : Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 375 : 1834-1844, 2016.
PubMed
17) Mann JFE, et al : Liraglutide and Renal Outcomes in Type 2 Diabetes. N Engl J Med 377 : 839-848, 2017.
PubMed
18) Lewis EJ, et al : The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329 : 1456-1462, 1993.
 
19) Pergola PE, et al : Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 365 : 327-336, 2011.
PubMed
P.191 掲載の参考文献
1) Smellie WS : Hypertriglyceridaemia in diabetes. BMJ 333 : 1257-1260, 2006.
PubMed
2) Mullins TB, Bhimji SS : Reactive Perforating Collagenosis. StatPearls [Internet]. Treasure Island, StatPearls Publishing, 2018 Oct 27.
 
3) Muller SA, Winkelmann RK : Necrobiosis lipoidica diabeticorum. A clinical and pathological investigation of 171 cases. Arch Dermatol 93 : 272-281, 1966.
PubMed
4) Erfurt-Berge C, et al : Updated results of 100 patients on clinical features and therapeutic options in necrobiosis lipoidica in a retrospective multicentre study. Eur J Dermatol 25 : 595-601, 2015.
 
5) Muller SA, Winkelmann RK : Necrobiosis lipoidica diabeticorum histopathologic study of 98 cases. Arch Dermatol 94 : 1-10, 1966.
PubMed
6) O'Toole EA, et al : Necrobiosis lipoidica : only a minority of patients have diabetes mellitus. Br J Dermatol 140 : 283-286, 1999.
 
7) Erfurt-Berge C, et al : Update on clinical and laboratory features in necrobiosis lipoidica : a retrospective multicentre study of 52 patients. Eur J Dermatol 22 : 770-775, 2012.
PubMed
8) Hammer E, et al : Risk factors for necrobiosis lipoidica in Type 1 diabetes mellitus. Diabet Med 34 : 86-92, 2017.
PubMed
9) Roberts DT, et al : Guidelines for treatment of onychomycosis. Br J Dermatol 148 : 402-410, 2003.
PubMed
10) Mills JL, et al : The Society for Vascular Surgery Lower Extremity Threatened Limb Classification System : risk stratification based on wound, ischemia, and foot infection (WIfI). J Vasc Surg 59 : 220-234.e1-2, 2014.
 
P.195 掲載の参考文献
1) 河井昌彦 : 新生児医学, p367, 金芳堂, 2015.
 
2) Srinivasan G, et al : Plasma glucose values in normal neonates : a new look. J Pediatr 109 : 114-117, 1986.
 
3) Stanley CA, et al : Re-evaluating "Transitional Neonatal Hypoglycemia" : Mechanism and implications for management. J Pediatr 166 : 1520-1525, 2015.
PubMed
4) 日本小児内分泌学会, 日本小児外科学会 : 先天性高インスリン血症診療ガイドライン, 平成29年10月22日 Ver 1.1. [http://jspe.umin.jp/medical/files/guide171015.ver1.1.pdf] (2019年1月閲覧)
 
5) 依藤亨 : 低血糖. 小児科臨床ピクシス 23 見逃せない先天代謝異常 (五十嵐隆, 高柳正樹編), p5-7, 中山書店, 2010.
 
6) Stanley CA : Hypoglycemia in the neonate. Pediatr Endocrinol Rev 4 (Suppl 1) : 76-81, 2006.
 
7) Committee on fetus and newborn, Adamkin DH : Postnatal Glucose Homeostasis in Late-Preterm and Term Infants. Pediatrics 127 : 575-579, 2011.
PubMed
8) 河井昌彦 : 低血糖症と脳障害 ; 周産期障害. 別冊日本臨牀新領域別症候群シリーズ No. 30 神経症候群 (第2版) V, p31-34, 日本臨牀社, 2014.
 
9) Cryer PE : Hypoglycemia, functional brain failure, and brain death. J Clin Invest 117 : 868-870, 2007.
PubMed
10) Tin W, et al : 15-Year Follow-Up of Recurrent "Hypoglycemia" in Preterm Infants. Pediatrics 130 : e1497-e1503, 2012.
PubMed
11) Goode RH, et al : Developmental Outcomes of Preterm Infants With Neonatal Hypoglycemia. Pediatrics 138. pii : e20161424, 2016.
 
P.198 掲載の参考文献
1) 依藤 享 : 低血糖. ビギナーのための小児内分泌診療ガイド (有阪治編), p117-122, 中山書店, 2014.
 
2) 都研一 : ケトン性低血糖症. 小児内分泌学 [改訂第2版] (日本小児内分泌学会編), p543-545, 診断と治療社, 2016.
 
3) Michael SK : Carbohydrate metabolism and hypoglycemia. In : Wilkins the Diagnosis and Treatment of Endocrine Disorders in Childhood and Adolescence, 4th ed (ed by Kappy MS, et al), p919-959, Charles C Thomas, Springfield, 1994.
 
4) Brown LM, et al : Evaluation of glycogen storage disease as a cause of ketotic hypoglycemia in children. J Inherit Metab Dis 38 : 489-493, 2015.
 
5) Sperling MA : Ketotic hypoglycemia. In : Nelson Textbook of Pediatrics, 19th ed (ed by Robert MK, et al), p528, Elsevier/Saunders, Philadelphia, 2011.
 
P.203 掲載の参考文献
1) 川北理恵, ほか : 本邦における先天性高インスリン血症の実態調査. 日本小児科学会雑誌 115 : 563-569, 2011.
 
2) Snider KE, et al : Genotype and phenotype correlations in 417 children with congenital hyperinsulinism. J Clin Endocrinol Metab 98 : E355-363, 2013.
PubMed
3) Kapoor RR, et al : Clinical and molecular characterisation of 300 patients with congenital hyperinsulinism. Eur J Endocrinol 168 : 557-564, 2013.
PubMed
4) 依藤亨 : 遺伝性インスリン分泌異常症の診療最前線 : personalized medicineのモデルとして. 日本小児科学会雑誌 115 : 1727-1735, 2011.
 
5) 日本小児内分泌学会, 日本小児外科学会 : 先天性高インスリン血症診療ガイドライン, 2016. [http://minds4.jcqhc.or.jp/minds/congenital-hyperinsulinism/congenital-hyperinsulinism.pdf] (2019年2月閲覧)
 
6) Sakakibara A, et al : Diagnosis of congenital hyperinsulinism : Biochemical profiles during hypoglycemia. Pediatr Diabetes 19 : 259-264, 2018.
 
7) 依藤亨 : 低血糖. ビギナーのための小児内分泌診療ガイド (有阪治編), p117-122, 中山書店, 2014.
 
8) Jackson DA, et al : Prevention of Severe Hypoglycemia-Induced Brain Damage and Cognitive Impairment With Verapamil. Diabetes 67 : 2107-2112, 2018.
PubMed
9) Arya VB, et al : Pancreatic endocrine and exocrine function in children following near-total pancreatectomy for diffuse congenital hyperinsulinism. PLoS ONE 9 : e98054, 2014.
PubMed
10) 依藤亨 : 高インスリン性低血糖症 ; 内分泌疾患, 糖尿病. 内科疾患にみられる神経障害 (疾患). 別冊日本臨牀新領域別症候群シリーズ No. 30 神経症候群 (第2版) V, p289-293, 日本臨牀社, 2014.
 
11) Hershey T, et al : Frequency and timing of severe hypoglycemia affects spatial memory in children with type 1 diabetes. Diabetes Care 28 : 2372-2377, 2005.
PubMed
P.207 掲載の参考文献
1) Zammitt NN, Frier BM : Hypoglycemia in type 2 diabetes : pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care 28 : 2948-2961, 2005.
PubMed
2) Glaser B, Leibowitz G : Hypoglycemia. In : Joslin's Diabetes Mellitus, 14th ed (ed by Kahn CR, et al), p1147-1175, Lippincott Williams & Wilkins, Philadelphia, 2005.
 
3) Takada M, et al : The relationship between risk of hypoglycemia and use of cibenzoline and disopyramide. Eur J Clin Pharmacol 56 : 335-342, 2000.
PubMed
4) Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes : UKPDS 39. UK Prospective Diabetes Study Group. BMJ 317 : 713-720, 1998.
Medical*Online
5) Uchigata Y, et al : Insulin autoimmune syndrome (Hirata disease) : clinical features and epidemiology in Japan. Diabetes Res Clin Pract 22 : 89-94, 1994.
PubMed
6) Kim JK, et al : Prevention of fat-induced insulin resistance by salicylate. J Clin Invest 108 : 437-446, 2001.
PubMed
7) 糖尿病治療ガイド 2018-2019 (日本糖尿病学会編・著), p52-73, 文光堂, 2018.
 
P.212 掲載の参考文献
1) Wilder RM, et al : Carcinoma of the islands of the pancreas : hyperinsulinism and hypoglycemia. JAMA 89 : 348-355, 1927.
 
2) 角尾晋, 中村英夫 : インスリン分泌過多症に就て. グレンツゲビート 4 : 1089, 1930.
 
3) Ito T, et al : Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol 45 : 234-243, 2010.
PubMed
4) Sakurai A, et al : Clinical features of insulinoma in patients with multiple endocrine neoplasia type 1 : analysis of the database of the MEN Consortium of Japan. Endocr J 59 : 859-866, 2012.
PubMed
5) 中山雄介, ほか : インスリノーマとの鑑別が困難であった膵島細胞症の1例. 膵臓 26 : 613-618, 2011.
Medical*Online
6) Izumiyama H, et al : Glucose-responsive and Octreotide-sensitive Insulinoma. Intern Med 45 : 519-524, 2006.
PubMed
7) Sahani DV, et al : Gastroenteropancreatic neuroendocrine tumors : role of imaging in diagnosis and management. Radiology 266 : 38-61, 2013.
PubMed
8) Kulke MH, et al : NANETS treatment guidelines : well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas 39 : 735-752, 2010.
PubMed
9) Grant CS : Insulinoma. Best Pract Res Clin Gastroenterol 19 : 783-798, 2005.
 
10) 高野幸路 : 非切除膵神経内分泌腫瘍 (膵NET) の治療. 日本内分泌・甲状腺外科学会雑誌 31 : 298-302, 2014.
 
11) Niitsu Y, et al : Clinical outcomes of 20 Japanese patients with insulinoma treated with diazoxide. Endocr J, 2018. [Epub ahead of print]
 
12) 膵・消化管神経内分泌腫瘍 (NET) 診断・治療実践マニュアル (今村正之監修, 田中雅夫, 平田公一編集), p34, 総合医学社, 2011.
 
13) Cryer PE : Glucose homeostasis and hypoglycemia. In : Williams Textbook of Endocrinology, 11th ed (ed by Kronenberg HM, et al), p1503-1533, Elsevier Saunders, Philadelphia, 2008.
 
P.216 掲載の参考文献
1) 高山澄子, ほか : アンケート調査による低血糖症中に占めるインスリン自己免疫症候群の頻度について. 糖尿病 26 : 143-146, 1983.
 
2) Daughaday WH, et al : Synthesis and secretion of insulin-like growth factor II by a leiomyosarcoma with associated hypoglycemia. N Engl J Med 319 : 1434-1440, 1988.
PubMed
3) Hizuka N, et al : Serum insulin-like growth factor II in 44 patients with non-islet cell tumor hypoglycemia. Endocr J 45 (Supple 1) : S61-65, 1998.
 
4) Virally ML, Guillausseau PJ : Hypoglycemia in adults. Diabetes Metab 25 : 477-490, 1999.
PubMed
5) Chung J, Henry RR : Mechanisms of tumor-induced hypoglycemia with intraabdominal hemangiopericytoma. J Clin Endocrinol Metab 81 : 919-925, 1996.
PubMed
6) 福田いずみ, ほか : 低血糖を呈するIGF-II産生膵外腫瘍78例の臨床像の検討. 日本内分泌学会雑誌 81 : S5-6, 2005.
 
7) Phillips LS, Robertson DG : Insulin-like growth factors and non-islet cell tumor hypoglycemia. Metab Clin Exp 42 : 1093-1101, 1993.
PubMed
8) Seckl MJ, et al : Hypoglycemia due to an insulin-secreting small-cell carcinoma of the cervix. N Engl J Med 341 : 733-736, 1999.
 
9) Hizuka N, et al : Insulin-like growth factor II (IGF-II) and non-islet cell tumor hypoglycemia (NICTH). In : Insulin-Like Growth Factors (ed by LeRoith D, et al), p434-440, Eurekah com, New York, 2003.
 
10) Zapf J, et al : Can "big" insulin-like growth factor II in serum of tumor patients account for the development of extrapancreatic tumor hypoglycemia? J Clin Invest 90 : 2574-2584, 1992.
PubMed
11) Zapf J : Insulinlike growth factor binding proteins and tumor hypoglycemia. Trends Endocrinol Metab 6 : 37-42, 1995.
PubMed
P.219 掲載の参考文献
1) 内潟安子 : 厚生労働科学研究費補助金難治性疾患克服研究事業 自発性低血糖症の実態把握のための全国調査, 平成21年度総括研究報告書, p1-50, 2010.
 
2) 平田幸正, ほか : インスリン自己免疫を示した自発性低血糖症の1例. 糖尿病 13 : 312-320, 1970.
 
3) Uchigata Y, et al : Strong association of insulin autoimmune syndrome with HLA-DR4. Lancet 339 : 393-394, 1992.
PubMed
4) Hirata Y, Uchigata Y : Insulin autoimmune syndrome in Japan. Diabetes Res Clin Pract 24 (Suppl) : S153-S157, 1994.
 
5) 江口洋子 : インスリン自己免疫症候群におけるインスリン自己抗体のScatchard解析について. 東京女子医科大学雑誌 59 : 1296-1305, 1989.
 
6) 平田悠ほか : Scatchard解析にて抗体の性質を4年にわたり観察したインスリン抗体陽性2型糖尿病の1例. 糖尿病 58 : 842-849, 2015.
 
7) 村山寛, ほか : 血清中インスリン抗体測定キットの開発. 医学と薬学 60 : 289-297, 2008.
Medical*Online
8) Uchigata Y, et al : Worldwide differences in the incidence of insulin autoimmune syndrome (Hirata disease) with respect to the evolution of HLA-DR4 alleles. Hum Immunol 61 : 154-157, 2000.
 
9) Hirata Y : Methimazole and insulin autoimmune syndrome with hypoglycemia. Lancet 2 : 1037-1038, 1983.
PubMed
10) Uchigata Y, et al : Drug-induced insulin autoimmune syndrome. Diabetes Res Clin Pract 83 : e19-20, 2009.
PubMed
11) Ishida Y, et al : Alpha-lipoic acid and insulin autoimmune syndrome. Diabetes Care 30 : 2240-2241, 2007.
PubMed
P.223 掲載の参考文献
1) Unger RH : The riddle of tumor hypoglycemia. Am J Med 40 : 325-330, 1966.
PubMed
2) Fujita T : Present status of paraneuron concept. Arch Histol Cytol 52 (Suppl) : 1-8, 1989.
 
3) Kojima H, et al : Extrapancreatic insulin-producing cells in multiple organs in diabetes. Proc Natl Acad Sci USA 101 : 2458-2463, 2004.
PubMed
4) Werner H, et al : The role of the insulin-like growth factor system in human cancer. Adv Cancer Res 68 : 183-223, 1996.
PubMed
5) Havrankova J, et al : Identification of insu1in in rat brain, Proc Natl Acad Sci USA 75 : 5737-5741, 1978.
PubMed
6) Eng J, et al : Evidence against extrapancreatic insulin synthesis. Proc Nati Acad Sci USA 78 : 4576-4578, 1981.
 
7) Kojima H, et al : Concerted regulation of early enterocyte differentiation by insulin-like growth factor I, insulin, and transforming growth factor-beta1. Proc Assoc Am Physicians 110 : 197-206, 1998.
PubMed
8) Fujita Y, et al : Increased intestinal glucose absorption and postprandial hyperglycaemia at the early step of glucose intolerance in Otsuka Long-Evans Tokushima Fatty rats. Diabetologia 41 : 1459-1466, 1998.
PubMed
9) 藤田恒夫, ほか : パラニューロンと生体調節. 蛋白質核酸酵素 35 : 417-425, 1990.
 
10) Pearse AG : The diffuse neuroendocrine system and the apud concept : related "endocrine" peptides in brain, intestine, pituitary, placenta, and anuran cutaneous glands. Med Biol 55 : 115-125, 1977.
PubMed
11) Filipi CJ, et al : Diagnosis and management of insulinoma. Am J Surg 125 : 231-239, 1973.
PubMed
12) Morgello S, et al : Ectopic insulin production by a primary ovarian carcinoid. Cancer 61 : 800-805, 1988.
PubMed
13) Seckl MJ, et al : Hypoglycemia due to an insulin-secreting small-cell carcinoma of the cervix. N Engl J Med 341 : 733-736, 1999.
 
14) Shames JM, et al : Insulin-secreting bronchial carcinoid tumor with widespread metastases. Am J Med 44 : 632-637, 1968.
PubMed
15) Fujino K, et al : Paraganglioma associated with hypoglycemia. Intern Med 31 : 1239-1241, 1992.
PubMed
16) Uysal M, et al : Hypoglycemia due to ectopic release of insulin from a paraganglioma. Horm Res 67 : 292-295, 2007.
PubMed
17) Frankton S, et al : Phaeochromocytoma crisis presenting with profound hypoglycaemia and subsequent hypertension. Hormones (Athens) 8 : 65-70, 2009.
PubMed
18) Ramkumar S, et al : Ectopic insulin secreting neuroendocrine tumor of kidney with recurrent hypoglycemia : adiagnostic dilemma. BMC Endocr Disord 14 : 36, 2014.
 
19) Li TN, et al : Ectopic insulinomas in the pelvic secondary to rectum neuroendocrine tumor. BMJ Case Rep 2018. pii : bcr-2018-224281, 2018.
 
20) Shetty MR, et al : Tumor-induced hypoglycemia : a result of ectopic insulin production. Cancer 49 : 1920-1923, 1982.
PubMed
21) Battocchio M, et al : Ovarian tumors secreting insulin. Endocrine 49 : 611-619, 2015.
PubMed
22) Iglesias P, Diez JJ : Management of endocrine disease : a clinical update on tumor-induced hypoglycemia. Eur J Endocrinol 170 : R147-157, 2014.
PubMed
23) Kageyama K, et al : Hypoglycemia associated with big insulin-like growth factor II produced during development of malignant fibrous histiocytoma. Endocr J 50 : 753-758, 2003.
PubMed
P.229 掲載の参考文献
1) 大原毅, ほか : 全体像を把握する. 看護のための最新医学講座 (第2版) 8. 糖尿病と合併症 (南條輝志男編), 中山書店, 2006.
 
2) Glaser B, Leibowitz G : Hypoglycemia. In : Joslin's Diabetes Mellitus, 14th ed (ed by Kahn CR, et al), p1147-1171, Lippincott Williams & Wilkins, Philadelphia, 2005.
 
3) Furuta M, et al : Defective prohormone processing and altered pancreatic islet morphology in mice lacking active SPC2. Proc Natl Acad Sci USA 94 : 6646-6651, 1997.
PubMed
4) Gerich JE : Hypoglycemia. In : Endocrinology, 4th ed (ed by DeGroot LJ, et al), p921-940, WB Saunders, Philadelphia, 2001.
 
5) Kollee LA, et al : Persistent neonatal hypoglycaemia due to glucagon deficiency. Arch Dis Child 53 : 422-424, 1978.
PubMed
6) Starke AA, et al : Glucagon deficiency associated with hypoglycaemia and the absence of islet cell antibodies in the polyglandular failure syndrome before the onset of insulin-dependent diabetes mellitus : a case report. Diabetologia 25 : 336-339, 1983.
PubMed
7) Kraus-Friedmann N : Hormonal regulation of hepatic gluconeogenesis. Physiol Rev 64 : 170-259, 1984.
PubMed
8) Kerr DS, et al : Fasting energy utilization in the smaller of twins with epinephrine-deficient hypoglycemia. Metab Clin Exp 30 : 6-17, 1981.
PubMed
9) Bougneres PF, et al : Effects of hypopituitarism and growth hormone replacement therapy on the production and utilization of glucose in childhood. J Clin Endocrinol Metab 61 : 1152-1157, 1985.
PubMed
10) Voorhess ML, MacGillivray MH : Low plasma norepinephrine responses to acute hypoglycemia in children with isolated growth hormone deficiency. J Clin Endocrinol Metab 59 : 790-793, 1984.
PubMed
11) Bolli GB, Fanelli CG : Physiology of glucose counterregulation to hypoglycemia. Endocrinol Metab Clin North Am 28 : 467-493, 1999.
PubMed
12) Boyle PJ, Cryer PE : Growth hormone, cortisol, or both are involved in defense against, but are not critical to recovery from, hypoglycemia. Am J Physiol 260 : E395-402, 1991.
 
13) Clausen N, et al : Counterregulation of insulin-induced hypoglycaemia in primary hypothyroidism. Acta Endocrinol 111 : 516-521, 1986.
PubMed
14) Forester CF : Coma in myxedema. Report of a case and review of the world literature. Arch Intern Med 111 : 734-743, 1963.
PubMed
15) Kalra S, et al : The hypoglycemic side of hypothyroidism. Indian J Endocrinol Metab 18 : 1-3, 2014.
PubMed
16) Izumi K, et al : A case of atypical thyroid storm with hypoglycemia and lactic acidosis. Endocr J 56 : 747-752, 2009.
PubMed
17) Kobayashi C, et al : Severe starvation hypoglycemia and congestive heart failure induced by thyroid crisis, with accidentally induced severe liver dysfunction and disseminated intravascular coagulation. Intern Med 44 : 234-239, 2005.
PubMed
18) Yamamoto T, et al : Prevalence of maturity-onset isolated ACTH deficiency (IAD) in 2005 : Japanese cohort studies. Endocr J 55 : 939-941, 2008.
PubMed
19) 片上秀喜, ほか : ACTH単独欠損症 (IAD) の疫学研究 : 人口100万人あたりの発症頻度と臨床像. 日本内分泌学会雑誌 84 : 123-125, 2008.
Medical*Online
20) 橋本浩三, ほか : 本邦ACTH単独欠損症に於けるTSH, Prolactinの過剰反応性及びGHの低反応性に関する検討. 日本内分泌学会雑誌 68 : 1096-1111, 1992.
Medical*Online
P.233 掲載の参考文献
1) Holton JB, et al : Galactosemia. In : The Metabolic&Molecular Bases of Inherited Disease, 8th ed (ed by Scriver CR, et al), p1807-1820, McGraw-Hill, New York, 2001.
 
2) Wada Y, et al : Biallelic GALM pathogenic variants cause a novel type of galactosemia. Genet Med, 2018. [Epub ahead of print]
 
3) 青木菊麿 : 新生児マススクリーニングで発見された疾患の追跡調査. 小児内科 23 : 1887-1891, 1991.
 
4) 岡野善行 : UDPガラクトース-4-エピメラーゼ欠損症 : 糖質代謝異常. ガラクトース血症. 別冊日本臨牀新領域別症候群シリーズ No. 19 先天代謝異常症候群 (第2版) (上), p29-31, 日本臨牀社, 2012.
 
5) 日本先天代謝異常学会 (編) : ガラクトース血症. 新生児マススクリーニング対象疾患等診療ガイドライン 2015, p174-180, 診断と治療社, 2015.
 
6) 岡野善行 : ガラクトース-1-リン酸ウリジルトランスフェラーゼ欠損症 : 糖質代謝異常. ガラクトース血症. 別冊日本臨牀新領域別症候群シリーズ No. 19 先天代謝異常症候群 (第2版) (上), p20-25, 日本臨牀社, 2012.
 
7) 岡野善行 : ガラクトキナーゼ欠損症 : 糖質代謝異常. ガラクトース血症. 別冊日本臨牀新領域別症候群シリーズ No. 19 先天代謝異常症候群 (第2版) (上), p26-28, 日本臨牀社, 2012.
 
8) 但馬剛, ほか : 先天性門脈-体循環シャントによる高ガラクトース血症 : 糖質代謝異常. ガラクトース血症. 別冊日本臨牀新領域別症候群シリーズ No. 19 先天代謝異常症候群 (第2版) (上), p32-39, 日本臨牀社, 2012.
 
9) Welling L, et al : International clinical guideline for the management of classical galactosemia : diagnosis, treatment, and follow-up. J Inherit Metab Dis 40 : 171-176, 2017.
PubMed
10) Schweitzer S, et al : Long-term outcome in 134 patients with galactosaemia. Eur J Pediatr 152 : 36-43, 1993.
PubMed
11) Manis FR, et al : A longitudinal study of cognitive functioning in patients with classical galactosaemia, including a cohort treated with oral uridine. J Inherit Metab Dis 20 : 549-555, 1997.
PubMed
12) Kaufman FR, et al : Cognitive functioning, neurologic status and brain imaging in classical galactosemia. Eur J Pediatr 154 (7 Suppl 2) : S2-5, 1995.
 
13) Fridovich-Keil JL, et al : Ovarian function in girls and women with GALT-deficiency galactosemia. J Inherit Metab Dis 34 : 357-366, 2011.
PubMed
14) Gubbels CS, et al : Primary ovarian insufficiency in classic galactosemia : role of FSH dysfunction and timing of the lesion. J Inherit Metab Dis 36 : 29-34, 2013.
PubMed
P.238 掲載の参考文献
1) Baker P II, et al : Hereditary Fructose Intolerance. GeneReviews(R) [Internet], University of Washington, Seattle, Initial Posting : December 17, 2015. [https://www.ncbi.nlm.nih.gov/books/NBK333439/#hfi.Molecular_Genetics] (2019年2月閲覧)
 
2) Bouteldja N, Timson DJ : The biochemical basis of hereditary fructose intolerance. J Inherit Metab Dis 33 : 105-112, 2010.
PubMed
3) Nakamura N, et al : Enzymatic analysis of hereditary fructosemia. J Jpn Pediatr Soc (in Japanese) 82 : 132, 1978.
 
4) Henry I, et al : The structural gene for aldolase B (ALDB) maps to 9q13-32. Ann Hum Genet 49 : 173-180, 1985.
PubMed
5) Rottmann WH, et al : Complete amino acid sequence for human aldolase B derived from cDNA and genomic clones. Proc Natl Acad Sci USA 81 : 2738-2742, 1984.
PubMed
6) Cross NC, et al : Catalytic deficiency of human aldolase B in hereditary fructose intolerance caused by a common missense mutation. Cell 53 : 881-885, 1988.
PubMed
7) ALDOB : The Human Gene Mutation Database (HGMD(R)) [Internet]. [http://www.hgmd.cf.ac.uk/ac/introduction.php?lang] (2019年2月閲覧)
 
8) Davit-Spraul A, et al : Hereditary fructose intolerance : frequency and spectrum mutations of the aldolase B gene in a large patients cohort from France-identification of eight new mutations. Mol Genet Metab 94 : 443-447, 2008.
 
9) Kajihara S, et al : Hereditary fructose intolerance caused by a nonsense rnutation of the aldolase Bgene. Am J Hum Genet 47 : 562-567, 1990.
 
10) Cornblath M, et al : Hereditary fructose intolerance. N Engl J Med 269 : 1271-1278, 1963.
PubMed
11) Howarth D : Sugar intake and dental caries. Lancet 1 : 827-828, 1983.
PubMed
12) Esposito G, et al : Hereditary fructose intolerance : functional study of two novel ALDOB natural variants and characterization of a partial gene deletion. Hum Mutat 31 : 1294-1303, 2010.
PubMed
P.243 掲載の参考文献
1) Andreasen JJ, et al : Secretion of glucagon-like peptide-1 and reactive hypoglycemia after partial gastrectomy. Digestion 55 : 221-228, 1994.
PubMed
2) Toft-Nielsen M, et al : Exaggerated secretion of glucagon-like peptide-1 (GLP-1) could cause reactive hypoglycaemia. Diabetologia 41 : 1180-1186, 1998.
PubMed
3) 森豊 : 持続血糖測定 (CGM). 治療 92 : 569-576, 2010.
Medical*Online
4) McLoughlin JC, et al : A glycoside-hydrolase inhibitor in treatment of dumping syndrome. Lancet 2 : 603-605, 1979.
PubMed
5) Hasegawa T, et al : Long-term effect of alpha-glucosidase inhibitor on late dumping syndrome. J Gastroenterol Hepatol 13 : 1201-1206, 1998.
PubMed
6) Imhof A, et al : Reactive hypoglycaemia due to late dumping syndrome : successful treatment with acarbose. Swiss Med Wkly 131 : 81-83, 2001.
PubMed
7) Kondo Y, et al : A patient who developed symptomatic reactive hypoglycemia 14 years after total gastrectomy and was successfully treated with miglitol. Diabetol Int 4 : 66-70, 2013. (doi : 10.1007/s13340-012-0082-y)
 
8) Fujita Y, et al : Successful treatment of reactive hypoglycemia secondary to late dumping syndrome using miglitol. Intern Med 51 : 2581-2585, 2012.
PubMed
9) Ranawana V, et al : Liquid and solid carbohydrate foods : comparative effects on glycemic and insulin responses, and satiety. Int J Food Sci Nutr 62 : 71-81, 2011.
PubMed
10) 森豊 : 経腸栄養における血糖日内変動抑制の重要性. 臨床栄養 132 : 1005-1013, 2018.
Medical*Online
11) Mori Y, et al : Effects of a low-carbohydrate diabetes-specific formula in type 2 diabetic patients during tube feeding evaluated by continuous glucose monitoring. E Spen Eur E J Clin Nutr Metab 6 : e68-e73, 2011.
 
12) Yokoyama J, et al : Effects of high-monounsaturated fatty acid enteral formula versus high-carbohydrate enteral formula on plasma glucose concentration and insulin secretion in healthy individuals and diabetic patients. J Int Med Res 36 : 137-146, 2008.
PubMed
P.247 掲載の参考文献
1) Brun JF, et al : Postprandial reactive hypoglycemia. Diabetes Metab 26 : 337-351, 2000.
PubMed
2) Hofeldt FD : Reactive hypoglycemia. Endocrinol Metab Clin North Am 18 : 185-201, 1989.
PubMed
3) Ahmadpour S, et al : Pancreatic alpha-cell function in idiopathic reactive hypoglycemia. Metab Clin Exp 46 : 639-643, 1997.
PubMed
4) Lupoli R, et al : Role of the Entero-Insular Axis in the Pathogenesis of Idiopathic Reactive Hypoglycemia : A Pilot Study. J Clin Endocrinol Metab 100 : 4441-4446, 2015.
PubMed
5) Berlin I, et al : Suspected postprandial hypoglycemia is associated with beta-adrenergic hypersensitivity and emotional distress. J Clin Endocrinol Metab 79 : 1428-1433, 1994.
PubMed
6) 北原亮, ほか : 夫婦間のストレスが影響したと考えられた特発性反応性低血糖症の1例. 糖尿病 47 : 825-830, 2004.
 
7) Cryer PE, et al : Evaluation and management of adult hypoglycemic disorders : an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 94 : 709-728, 2009.
PubMed
8) Colagiuri S, et al : Comparability of venous and capillary glucose measurements in blood. Diabet Med 20 : 953-956, 2003.
PubMed
9) Lefebvre pJ, et al : Statement on postprandial or reactive hypoglycemia (Letter). Diabetes Care 11 : 439-440, 1988.
 
10) Service FJ, et al : Noninsulinoma pancreatogenous hypoglycemia : anovel syndrome of hyperinsulinemic hypoglycemia in adults independent of mutations in Kir6.2 and SUR1 genes. J Clin Endocrinol Metab 84 : 1582-1589, 1999.
 
11) Witteles RM, et al : Adult-onset nesidioblastosis causing hypoglycemia : an important clinical entity and continuing treatment dilemma. Arch Surg 136 : 656-663, 2001.
PubMed
12) Palardy J, et al : Blood glucose measurements during symptomatic episodes in patients with suspected postprandial hypoglycemia. N Engl J Med 321 : 1421-1425, 1989.
PubMed
13) Peter S : Acarbose and idiopathic reactive hypoglycemia. Horm Res 60 : 166-167, 2003.
PubMed

IX ホルモン異常による先天性肥満症

P.255 掲載の参考文献
1) Montague CT, et al : Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 387 : 903-908, 1997.
PubMed
2) Strobel A, et al : A leptin missense mutation associated with hypogonadism and morbid obesity. Nat Genet 18 : 213-215, 1998.
PubMed
3) Clement K, et al : A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature 392 : 398-401, 1998.
 
4) Zhang Y, et al : Positional cloning of the mouse obese gene and its human homologue. Nature 372 : 425-432, 1994.
PubMed
5) Funcke JB, et al : Monogenic forms of childhood obesity due to mutations in the leptin gene. Mol Cell Pediatr 1 : 3, 2014.
PubMed
6) Wabitsch M, et al : Biologically inactive leptin and early-onset extreme obesity. N Engl J Med 372 : 48-54, 2015.
PubMed
7) Farooqi IS, et al : Clinical and molecular genetic spectrum of congenital deficiency of the leptin receptor. N Engl J Med 356 : 237-247, 2007.
PubMed
8) Farooqi IS, et al : Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med 341 : 879-884, 1999.
 
9) Farooqi IS, et al : Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 110 : 1093-1103, 2002.
PubMed
10) Licinio J, et al : Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults. Proc Natl Acad Sci USA 101 : 4531-4536, 2004.
PubMed
11) Farooqi IS, et al : Leptin regulates striatal regions and human eating behavior. Science 317 : 1355, 2007.
PubMed
12) Minokoshi Y, et al : Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 415 : 339-343, 2002.
PubMed
P.259 掲載の参考文献
1) Zhang Y, et al : Positional cloning of the mouse obese gene and its human homologue, Nature 372 : 425-432, 1994.
PubMed
2) Tartaglia LA, et al : Identification and expression cloning of a leptin receptor, OB-R. Cell 83 : 1263-1271, 1995.
PubMed
3) Mercer JG, et al : Localization of leptin receptor mRNA and the long form splice variant (Ob-Rb) in mouse hypothalamus and adjacent brain regions by in situ hybridization. FEBS Lett 387 : 113-116, 1996.
 
4) Fei H, et al : Anatomic localization of alternatively spliced leptin receptors (Ob-R) in mouse brain and other tissues. Proc Natl Acad Sci USA 94 : 7001-7005, 1997.
PubMed
5) Lee GH, et al : Abnormal splicing of the leptin receptor in diabetic mice. Nature 379 : 632-635, 1996.
PubMed
6) Chen H, et al : Evidence that the diabetes gene encodes the leptin receptor : identification of a mutation in the leptin receptor gene in db/db mice. Cell 84 : 491-495, 1996.
PubMed
7) Ronti T, et al : The endocrine function of adipose tissue : an update. Clin Endocrinol (Oxf) 64 : 355-365, 2006.
PubMed
8) Satoh N, et al : The arcuate nucleus as a primary site of satiety effect of leptin in rats. Neurosci Lett 224 : 149-152, 1997.
 
9) Clement K, et al : A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature 392 : 398-401, 1998.
 
10) Farooqi IS, et al : Clinical and molecular genetic spectrum of congenital deficiency of the leptin receptor. N Engl J Med 356 : 237-247, 2007.
PubMed
11) Mazen I, et al : Homozygosity for a novel missense mutation in the leptin receptor gene (P316T) in two Egyptian cousins with severe early onset obesity. Mol Genet Metab 102 : 461-464, 2011.
PubMed
12) Saeed S, et al : Novel LEPR mutations in obese Pakistani children identified by PCR-based enrichment and next generation sequencing. Obesity (Silver Spring) 22 : 1112-1117, 2014.
PubMed
13) Gloaguen I, et al : Ciliary neurotrophic factor corrects obesity and diabetes associated with leptin deficiency and resistance. Proc Natl Acad Sci USA 94 : 6456-6461, 1997.
PubMed
P.264 掲載の参考文献
1) Seidah NG, et al : Cloning and primary sequence of a mouse candidate prohormone convertase PC1 homologous to PC2, Furin, and Kex2 : distinct chromosomal localization and messenger RNA distribution in brain and pituitary compared to PC2. Mol Endocrinol 5 : 111-122, 1991.
PubMed
2) Smeekens SP, et al : Identification of a cDNA encoding a second putative prohormone convertase related to PC2 in AtT20 cells and islets of Langerhans. Proc Natl Acad Sci USA 88 : 340-344, 1991.
PubMed
3) O'Rahilly S, et al : Brief report : impaired processing of prohormones associated with abnormalities of glucose homeostasis and adrenal function. N Engl J Med 333 : 1386-1390, 1995.
PubMed
4) Jackson RS, et al : Obesity and impaired prohormone processing associated with mutations in the human prohormone convertase 1 gene. Nat Genet 16 : 303-306, 1997.
PubMed
5) Naggert JK, et al : Hyperproinsulinaemia in obese fat/fat mice associated with a carboxypeptidase E mutation which reduces enzyme activity. Nat Genet 10 : 135-142, 1995.
PubMed
6) Berman Y, et al : Impaired prohormone convertases in Cpe (fat) /Cpe (fat) mice. J Biol Chem 276 : 1466-1473, 2001.
PubMed
7) Jackson RS, et al : Small-intestinal dysfunction accompanies the complex endocrinopathy of human proprotein convertase 1 deficiency. J Clin Invest 112 : 1550-1560, 2003.
PubMed
8) Martin MG, et al : Congenital proprotein convertase 1/3 deficiency causes malabsorptive diarrhea and other endocrinopathies in a pediatric cohort. Gastroenterology 145 : 138-148, 2013.
 
9) Steiner DF, et al : Lessons learned from molecular biology of insulin-gene mutations. Diabetes Care 13 : 600-609, 1990.
PubMed
10) Haneda M, et al : Familial hyperinsulinemia due to a structurally abnormal insulin. Definition of an emerging new clinical syndrome. N Engl J Med 310 : 1288-1294, 1984.
PubMed
11) Nanjo K, et al : Insulin Wakayama : familial mutant insulin syndrome in Japan. Diabetologia 30 : 87-92, 1987.
PubMed
12) Stijnen P, et al : PCSK1 Mutations and Human Endocrinopathies : From Obesity to Gastrointestinal Disorders. Endocr Rev 37 : 347-371, 2016.
PubMed
13) Creemers JW, et al : Heterozygous mutations causing Partial prohormone convertase 1 deficiency contribute to human obesity. Diabetes 61 : 383-390, 2012.
PubMed
14) Nead KT, et al : Contribution of common non-synonymous variants in PCSK1 to body mass index variation and risk of obesity : a systematic review and meta-analysis with evidence from up to 331 175 individuals. Hum Mol Genet 24 : 3582-3594, 2015.
PubMed
P.269 掲載の参考文献
1) Barsh GS, et al : Genetics of body-weight regulation. Nature 404 : 644-651, 2000.
PubMed
2) Krude H, et al : Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet 19 : 155-157, 1998.
 
3) Clark AJ : 60 YEARS OF POMC : The proopiomelanocortin gene : discovery, deletion and disease. J Mol Endocrinol 56 : T27-37, 2016.
 
4) Novoselova TV, et al : Pathophysiology of melanocortin receptors and their accessory proteins. Best Pract Res Clin Endocrinol Metab 32 : 93-106, 2018.
PubMed
5) Krude H, et al : Obesity due to proopiomelanocortin deficiency : three new cases and treatment trials with thyroid hormone and ACTH4-10. J Clin Endocrinol Metab 88 : 4633-4640, 2003.
PubMed
6) 服部重人, ほか : POMC遺伝子異常による先天性ACTH単独欠損症の1例. ホルモンと臨床 47 : 23-26, 1999.
 
7) Challis BG, et al : A missense mutation disrupting a dibasic prohormone processing site in pro-opiomelanocortin (POMC) increases susceptibility to early-onset obesity through a novel molecular mechanism. Hum Mol Genet 11 : 1997-2004, 2002.
PubMed
8) Buono P, et al : Six novel mutations in the proopiomelanocortin and melanocortin receptor 4 genes in severely obese adults living in southern Italy. Clin Chem 51 : 1358-1364, 2005.
PubMed
9) POMC gene, Genetics Home Reference. [https://ghr.nlm.nih.gov/gene/POMC#resources] (2019年2月閲覧)
 
10) Yaswen L, et al : Obesity in the mouse model of pro-opiomelanocortin deficiency responds to peripheral melanocortin. Nat Med 5 : 1066-1070, 1999.
PubMed
11) Clement K, et al : Unexpected endocrine features and normal pigmentation in a young adult patient carrying a novel homozygous mutation in the POMC gene. J Clin Endocrinol Metab 93 : 4955-4962, 2008.
 
12) Samuels ME, et al : Bioinactive ACTH causing glucocorticoid deficiency. J Clin Endocrinol Metab 98 : 736-742, 2013.
PubMed
13) Anisimova AS, et al : Late Diagnosis of POMC Deficiency and In Vitro Evidence of Residual Translation From Allele With c. -11C > A Mutation. J Clin Endocrinol Metab 102 : 359-362, 2017.
 
14) Lamolet B, et al : A pituitary cell-restricted T box factor, Tpit, activates POMC transcription in cooperation with Pitx homeoproteins. Cell 104 : 849-859, 2001.
PubMed
P.274 掲載の参考文献
1) Zhang Y, et al : Positional cloning of the mouse obese gene and its human homologue. Nature 372 : 425-432, 1994.
PubMed
2) 小林宏正 : 単一遺伝子異常による肥満. 別冊医学のあゆみ 糖尿病・代謝症候群state of arts 2004-2006 (門脇孝, ほか編), p394-396, 医歯薬出版, 2004.
 
3) Ohshiro Y, et al : Molecular scanning for mutations in the melanocortin-4 receptor gene in obese/diabetic Japanese. Ann Hum Genet 63 : 483-487, 1999.
PubMed
4) Montague CT, et al : Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 387 : 903-908, 1997.
PubMed
5) Strobel A, et al : A leptin missense mutation associated with hypogonadism and morbid obesity. Nat Genet 18 : 213-215, 1998.
PubMed
6) Clement K, et al : A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature 392 : 398-401, 1998.
 
7) Krude H, et al : Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet 19 : 155-157, 1998.
 
8) Jackson RS, et al : Obesity and impaired prohormone processing associated with mutations in the human prohormone convertase 1 gene. Nat Genet 16 : 303-306, 1997.
PubMed
9) Kobayashi H, et al : A Novel homozygous missense mutation of melanocortin-4 receptor (MC4R) in a Japanese woman with severe obesity. Diabetes 51 : 243-246, 2002.
 
10) Tao YX : Molecular mechanisms of the neural melanocortin receptor dysfunction in severe early onset obesity. Mol Cell Endocrinol 239 : 1-14, 2005.
PubMed
11) Geller F, et al : Melanocortin-4 receptor gene variant I103 is negatively associated with obesity. Am J Hum Genet 74 : 572-581, 2004.
PubMed
12) Tan KM, et al : Functional characterization of variants in MC4R gene promoter region found in obese children. J Clin Endocrinol Metab 99 : E931-935, 2014.
 
13) Marsh DJ, et al : Response of melanocortin-4 receptor-deficient mice to anorectic and orexigenic peptides. Nat Genet 21 : 119-122, 1999.
PubMed
14) Collet TH, et al : Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency. Mol Metab 6 : 1321-1329, 2017.
PubMed
15) Valette M, et al : Melanocortin-4 receptor mutations and polymorphisms do not affect weight loss after bariatric surgery. PLoS One 7 : e48221, 2012.
 
P.278 掲載の参考文献
1) Takahashi M, et al : Genomic structure and mutations in adipose-specific gene, adiponectin. Int J Obes Relat Metab Disord 24 : 861-868, 2000.
PubMed
2) Hara K, et al : Genetic variation in the gene encoding adiponectin is associated with an increased risk of type 2 diabetes in the Japanese population. Diabetes 51 : 536-540, 2002.
PubMed
3) Kadowaki T, et al : Molecular mechanism of insulin resistance and obesity. Exp Biol Med (Maywood) 228 : 1111-1117, 2003.
PubMed
4) Hou H, et al : An Updated Systematic Review and Meta-analysis of Association Between Adiponectin Gene Polymorphisms and Coronary Artery Disease. OMICS 21 : 340-351, 2017.
PubMed
5) Park JW, et al : ADIPOQ Gene Variants Associated with Susceptibility to Obesity and Low Serum Adiponectin Levels in Healthy Koreans. Epidemiol Health 33 : e2011003, 2011.
PubMed
6) Han LY, et al : Associations between single-nucleotide polymorphisms (+45T > G, +276G > T, -11377C > G, -11391G > A) of adiponectin gene and type 2 diabetes mellitus : a systematic review and meta-analysis. Diabetologia 54 : 2303-2314, 2011.
PubMed
7) Menzaghi C, et al : A haplotype at the adiponectin locus is associated with obesity and other features of the insulin resistance syndrome. Diabetes 51 : 2306-2312, 2002.
PubMed
8) Kondo H, et al : Association of adiponectin mutation with type 2 diabetes : acandidate gene for the insulin resistance syndrome. Diabetes 51 : 2325-2328, 2002.
 
9) Ohashi K, et al : Adiponectin I164T mutation is associated with the metabolic syndrome and coronary artery disease. J Am Coll Cardiol 43 : 1195-1200, 2004.
PubMed
10) Wang H, et al : Adiponectin receptor 1 gene (ADIPOR1) as a candidate for type 2 diabetes and insulin resistance. Diabetes 53 : 2132-2136, 2004.
PubMed
11) Hara K, et al : Absence of an association between the polymorphisms in the genes encoding adiponectin receptors and type 2 diabetes. Diabetologia 48 : 1307-1314, 2005.
PubMed
12) Hug C, et al : T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc Natl Acad Sci USA 101 : 10308-10313, 2004.
PubMed
13) Denzel MS, et al : T-cadherin is critical for adiponectin-mediated cardioprotection in mice. J Clin Invest 120 : 4342-4352, 2010.
PubMed
14) Chung CM, et al : A genome-wide association study reveals a quantitative trait locus of adiponectin on CDH13 that predicts cardiometabolic outcomes. Diabetes 60 : 2417-2423, 2011.
PubMed
15) Li Y, et al : The association of six single nucleotide polymorphisms and their haplotypes in CDH13 with T2DM in a Han Chinese population. Medicine (Baltimore) 96 : e7063, 2017.
 

X 腫瘍とホルモン

P.285 掲載の参考文献
1) Carraway R, Leeman SE : The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami. J Biol Chem 248 : 6854-6861, 1973.
PubMed
2) 人見次郎, ほか : Neurotensin産生腫瘍-腫瘍細胞は多種の生理活性ペプチドを産生する-. 別冊日本臨牀領域別症候群シリーズ No. 2 内分泌症候群 (下巻), p265-270, 日本臨牀社, 1993.
 
3) 佐藤賢一, 下瀬川徹 : ニューロテンシン. 日本臨牀 68 (増刊 : 広範囲 血液・尿化学検査, 免疫学的検査 (第7版) 4) : 269-272, 2010.
 
4) Mazella J : Sortilin/neurotensin receptor-3 : a new tool to investigate neurotensin signaling and cellular trafficking? Cell Signal 13 : 1-6, 2001.
PubMed
5) 小島久美子, 戸塚康男 : ニューロテンシノーマ. 別冊日本臨牀領域別症候群シリーズ No. 2 内分泌症候群 (下巻), p350-352, 日本臨牀社, 1993.
 
6) Bloom SR, et al : Two patients with pancreatic apudomas secreting neurotensin and VIP. Gut 24 : 448-452, 1983.
PubMed
7) Kloppel G, et al : Pancreatic lesions and hormonal profile of pancreatic tumors in multiple endocrine neoplasia type I. An immunocytochemical study of nine patients. Cancer 57 : 1824-1832, 1986.
PubMed
8) Ehlers RA, et al : Gut peptide receptor expression in human pancreatic cancers. Ann Surg 231 : 838-848, 2000.
PubMed
9) Elek J, et al : Relevant genomics of neurotensin receptor in cancer. Anticancer Res 20 : 53-58, 2000.
PubMed
10) Kim JT, et al : Neurotensin Receptor 3/Sortilin Contributes to Tumorigenesis of Neuroendocrine Tumors Through Augmentation of Cell Adhesion and Migration. Neoplasia 20 : 175-181, 2018.
PubMed
11) 上野浩晶, 中里雅光 : 消化管ホルモンによる食欲調節. Diabetes Frontier 28 : 169-173, 2017.
Medical*Online
12) 尾仲達史, 矢田俊彦 : ニューロテンシン. 日本臨牀 61 (増刊 : 肥満症) : 191-194, 2003.
 
13) Feurle GE, et al : A multihormonal tumor of the pancreas producing neurotensin. Dig Dis Sci 26 : 1125-1133, 1981.
PubMed
14) Kapuscinski M, et al : Expression of neurotensin in endocrine tumors. J Clin Endocrinol Metab 70 : 100-106, 1990.
PubMed
15) Solcia E, et al : Tumors of the Pancreas. In : Atlas of Tumor Pathology, Series 3, Fasc 20, p145-163, Armed Forces Institute of Pathology, Washington, DC, 1997.
 
P.289 掲載の参考文献
1) 名和田新, ほか : 副腎ホルモン産生異常症の全国疫学調査. 厚生省特定疾患「副腎ホルモン産生異常症」調査研究班, 平成10年度研究報告書, p11-55, 1999.
 
2) Meinardi JR : Cyclic Cushing's syndrome : a clinical challenge. Eur J Endocrinol 157 : 245-254, 2007.
PubMed
3) 井村裕夫 : 異所性ホルモン産生腫瘍. 現代外科学大系 (年刊追補), p149-190, 中山書店, 1975.
 
4) 井村裕夫 : 機能性腫瘍の問題点-とくに異所性ホルモン産生腫瘍を中心に. 蛋白質核酸酵素 23 : 641-656, 1978.
 
5) Yalow RS, et al : Radioimmunoassay of Human Plasma ACTH. J Clin Endocrinol Metab 24 : 1219-1225, 1964.
PubMed
6) 片上秀喜 : big ACTH測定系の開発と臨床応用 (1) : ヒトγ3-MSH RIAの開発. ACTH RELATED PEPTIDES 19 : 27-30, 2008.
 
7) 片上秀喜, ほか : クッシング病と異所性ACTH産生症候群との鑑別診断 : big ACTHとproγMSHに対する超高感度・高感度測定法の開発と臨床応用. 日本内分泌学会雑誌 88 (Suppl) : 49-58, 2012.
 
8) Isidori AM, et al : Conventional and Nuclear Medicine Imaging in Ectopic Cushing's Syndrome : A Systematic Review. J Clin Endocrinol Metab 100 : 3231-3244, 2015.
PubMed
9) Khan MS, et al : Therapeutic management of patients with gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer 18 (Suppl 1) : S53-74, 2011.
 
P.293 掲載の参考文献
1) Guillemin R, et al : Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. Science 218 : 585-587, 1982.
PubMed
2) Thorner MO, et al : Extrahypothalamic growth-hormone-releasing factor (GRF) secretion is a rare cause of acromegaly : plasma GRF levels in 177 acromegalic patients. J Clin Endocrinol Metab 59 : 846-849, 1984.
PubMed
3) Asa SL, et al : Immunohistological localization of growth hormone-releasing hormone in human tumors. J Clin Endocrinol Metab 60 : 423-427, 1985.
PubMed
4) Ghazi AA, et al : Ectopic acromegaly due to growth hormone releasing hormone. Endocrine 43 : 293-302, 2013.
PubMed
5) Katakami H, et al : Development and clinical application of a highly sensitive enzyme immunoassay (EIA) for human growth hormone-releasing hormone (hGHRH) in plasma. Endocr J 45 (Suppl 1) : S67-70, 1998.
 
6) Daly AF, et al : GHRH excess and blockade in X-LAG syndrome. Endocr Relat Cancer 23 : 161-170, 2016.
 
7) Kawa S, et al : Growth hormone-releasing hormone (GRH) -producing pancreatic tumor with no evidence of multiple endocrine neoplasia type 1. Dig Dis Sci 42 : 1480-1485, 1997.
PubMed
8) Garby L, et al : Clinical characteristics and outcome of acromegaly induced by ectopic secretion of growth hormone-releasing hormone (GHRH) : a French nationwide series of 21 cases. J Clin Endocrinol Metab 97 : 2093-2104, 2012.
 
9) Drange MR, Melmed S : Long-acting lanreotide induces clinical and biochemical remission of acromegaly caused by disseminated growth hormone-releasing hormone-secreting carcinoid. J Clin Endocrinol Metab 83 : 3104-3109, 1998.
PubMed
10) van Hoek M, et al : Effects of somatostatin analogs on a growth hormone-releasing hormone secreting bronchial carcinoid, in vivo and in vitro studies. J Clin Endocrinol Metab 94 : 428-433, 2009.
PubMed
11) Rekasi Z, et al : Isolation and sequencing of cDNAs for splice variants of growth hormone-releasing hormone receptors from human cancers. Proc Natl Acad Sci USA 97 : 10561-10566, 2000.
PubMed
12) Wang H, et al : Inhibition of experimental small-cell and non-small-cell lung cancers by novel antagonists of growth hormone-releasing hormone. Int J Cancer 142 : 2394-2404, 2018.
PubMed
13) Gesmundo I, et al : Growth hormone-releasing hormone attenuates cardiac hypertrophy and improves heart function in pressure overload-induced heart failure. Proc Natl Acad Sci USA 114 : 12033-12038, 2017.
PubMed
P.296 掲載の参考文献
1) Waldmann TA, Roose W : Tumors producing erythropoiesis stimulating factors. In : Hemoglobin-Its Precursors and Metabolites (ed by Sunderman FW, Sunderman FW Jr), p276-280, JB Lippincott, Philadelphia, 1964.
 
2) McFadzean AJ, et al : Polycythemia in primary carcinoma of the liver. Blood 13 : 427-435, 1958.
PubMed
3) LevGur M, Levie MD : The myomatous erythrocytosis syndrome : a review. Obstet Gynecol 86 : 1026-1030, 1995.
PubMed
4) Pollio F, et al : Erythropoietin and erythropoietin receptor system in a large uterine myoma of a patient with myomatous erythrocytosis syndrome : possible relationship with the pathogenesis of unusual tumor size. Hum Pathol 36 : 120-127, 2005.
 
5) Lappin TR, et al : EPO's alter ego : erythropoietin has multiple actions. Stem Cells 20 : 485-492, 2002.
PubMed
6) 朝野晃, ほか : 子宮筋腫からのエリスロポエチン産生によると思われた赤血球増多症の1例. 仙台医療センター医学雑誌 3 : 47-51, 2013.
 
7) Ribatti D, et al : Erythropoietin/erythropoietin-receptor system is involved in angiogenesis in human hepatocellular carcinoma. Histopathology 50 : 591-596, 2007.
PubMed
8) 鈴木光明, ほか : 異所性エリスロポエチン産生腫瘍 ; 腫瘍とホルモン, 異所性ホルモン産生腫瘍. 別冊日本臨牀新領域別症候群シリーズ No. 3 内分泌症候群 (第2版) III, p283-286, 日本臨牀社, 2006.
 
9) 廣瀬泰彦, ほか : 赤血球増多症を伴ったエリスロポエチン産生腎細胞癌の1例. 泌尿器外科 24 : 187-190, 2011.
Medical*Online
10) 永田智子, ほか : 子宮筋腫赤血球増多症候群を呈した巨大子宮筋腫の1例. 日本産科婦人科学会関東連合地方部会会報 43 : 294, 2006.
 
11) 大矢妙子, ほか : 多血症を来した原発性肝癌の1例. 日本消化器病学会雑誌 89 : 1002, 1992.
 
12) Vlasveld LT, et al : Myomatous erythrocytosis syndrome : further proof for the pathogenic role of erythropoietin. Neth J Med 66 : 283-285, 2008.
PubMed
13) 小松則夫 : 赤血球増多症の原因と分類. 内科学 [第9版] IV (杉本恒明, 矢崎義雄編), p1604-1606, 朝倉書店, 2007.
 
14) 伊禮俊充, ほか : 著明な赤血球増多症を合併したエリスロポエチン産生巨大肝細胞癌の1切除例. 日本消化器外科学会雑誌 47 : 18-25, 2014.
 
15) Michael A, et al : Prognostic significance of erythropoietin expression in human renal cell carcinoma. BJU Int 100 : 291-294, 2007.
PubMed
P.300 掲載の参考文献
1) Copp DH, et al : Evidence for a New Parathyroid Hormone Which Lowers Blood Calcium. Proc Canad Fed Biol Soc 4 : 17, 1961.
 
2) Hirsch PF, et al : Thyrocalcitonin : Hypocalcemic Hypophosphatemic Principle of the Thyroid Gland. Science 146 : 412-413, 1964.
PubMed
3) Foster GV, et al : Calcitonin Production and the Mitochondrion-Rich Cells of the Dog Thyroid. Nature 203 : 1029-1030, 1964.
PubMed
4) Pearse AGE : The thyroid parenchymatous cells of baber, and the nature and function of their C cell successors in thyroid, parathyroid, and ultimobranchial bodies. In : Calcitonin. Proceedings of the Symposium on Thyrocalcitonin and the C Cells, p98-109, Butterworth-Heinemann, London, 1968.
 
5) Silva OL, Becker KL : Immunoreactive calcitonin in extra-thyroid tissues. In : Calcitonin (ed by Pecile A), p144-153, Excerpta Medica, Amsterdam, 1980.
 
6) Pearse AG : The APUD concept and hormone production. Clin Endocrinol Metab 9 : 211-222, 1980.
PubMed
7) Milhaud G, et al : [Thyrocalcitonin-secreting carcinoid]. C R Acad Sci Hebd Seances Acad Sci D 4 : 2195-2198, 1970.
 
8) Coombes RC, et al : Plasma-immunoreactive-calcitonin in patients with non-thyroid tumours. Lancet 1 : 1080-1083, 1974.
PubMed
9) Berner A, Nesland JM : Endocrine profile in gastric carcinomas. An immunohistochemical study. Histol Histopathol 6 : 317-323, 1991.
PubMed
10) Leboulleux S, et al : Gastroenteropancreatic neuroendocrine tumor metastases to the thyroid gland : differential diagnosis with medullary thyroid carcinoma. Eur J Endocrinol 140 : 187-191, 1999.
 
11) Bertagna XY, et al : Corticotropin, lipotropin, and beta-endorphin production by a human nonpituitary tumor in culture : evidence for a common precursor. Proc Natl Acad Sci USA 75 : 5160-5164, 1978.
PubMed
12) Uccella S, et al : Calcitonin-Producing Neuroendocrine Neoplasms of the Pancreas : Clinicopathological Study of 25 Cases and Review of the Literature. Endocr Pathol 28 : 351-361, 2017.
PubMed
13) Conte-Devolx B, et al : Could primary hyperparathyroidism-related hypercalcemia induce hypercalcitoninemia? Horm Res Paediatr 73 : 372-375, 2010.
PubMed
14) Heath H 3rd, Sizemore GW : Plasma calcitonin in normal man. Differences between men and women. J Clin Invest 60 : 1135-1140, 1977.
PubMed
15) Hillyard CJ, et al : Normal plasma calcitonin : circadian variation and response to stimuli. Clin Endocrinol (Oxf) 6 : 291-298, 1977.
PubMed
P.305 掲載の参考文献
1) 吉本貴宣 : 異所性ホルモン産生腫瘍の疾患概念. 日本臨牀 69 (増刊 : 内分泌腺腫瘍) : 697-699, 2011.
 
2) Carcangiu ML : Thyroid. In : Histology for Pathologists, 2nd ed (ed by Sternberg SS), p1075-1092, Lippincott Williams & Wilkins, Philadelphia, 1997.
 
3) LiVolsi V : Thyroid tumors in unUsual places. In : Surgical Pathology of the Thyroid (ed by LiVolsi V), p351-363, WB Saunders, Philadelphia, 1990.
 
4) LiVolsi V : Thyroid tumors in unusual locations. In : Diagnostic Surgical Pathology (ed by Sternberg SS), p557-558, Lippincott Williams & Wilkins, Philadelphia, 1999.
 
5) 寺畑信太郎 : 異所性甲状腺組織. 腫瘍病理鑑別診断アトラス 甲状腺癌 (坂本穆彦, 廣川満良編), p170-175, 文光堂, 2011.
 
6) Kumar R, et al : Thyrotoxicosis in a patient with submandibular thyroid. Thyroid 10 : 363-365, 2000.
 
7) Wei S, et al : Pathology of Struma Ovarii : A Report of 96 Cases. Endocr Pathol 26 : 342-348, 2015.
PubMed
8) Anagnostou E, et al : An Unusual Case of Malignant Struma Ovarii Causing Thyrotoxicosis. Eur Thyroid J 5 : 207-211, 2016.
PubMed
9) Robboy SJ, et al : Strumal carcinoid of the ovary : an analysis of 50 cases of a distinctive tumor composed of thyroid tissue and carcinoid. Cancer 46 : 2019-2034, 1980.
PubMed
10) Matsuda K, et al : Malignant struma ovarii with thyrotoxicosis. Gynecol Oncol 82 : 575-577, 2001.
PubMed
11) Dunzendorfer T, et al : Struma ovarii and hyperthyroidism. Thyroid 9 : 499-502, 1999.
PubMed
12) Ozcan A, et al : PAX 8 expression in non-neoplastic tissues, primary tumors, and metastatic tumors : a comprehensive immunohistochemical study. Mod Pathol 24 : 751-764, 2011.
PubMed
13) Cooper DS : Hyperthyroidism. Lancet 362 : 459-468, 2003.
PubMed
14) 長坂徹郎 : 奇形腫. 腫瘍病理鑑別診断アトラス 卵巣腫瘍 (本山悌一, 坂本穆彦編), p130-141, 文光堂, 2012.
 
P.309 掲載の参考文献
1) Sterns RH : Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH). UpToDate 2018.
 
2) Schwartz WB, et al : A syndrome of renal sodium loss and hyponatremia probably resulting from inappropriate secretion of antidiuretic hormone. Am J Med 23 : 529-542, 1957.
PubMed
3) List AF, et al : The syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in small-cell lung cancer. J Clin Oncol 4 : 1191-1198, 1986.
PubMed
4) Verbalis JG : Hypothalamus and pituitary. In : Williams Textbook of Endocrinology, 12th ed (ed by Melmed S, et al), p279-280, Elsevier/Saunders, Philadelphia, 2011.
 
5) 有馬寛 : 内分泌疾患 : 診断と治療の進歩. 下垂体後葉-低Na血症のアプローチ. 日本内科学会雑誌 103 : 849-854, 2014.
 
6) Kavanagh BD, et al : Syndrome of inappropriate secretion of antidiuretic hormone in a patient with carcinoma of the nasopharynx. Cancer 69 : 1315-1319, 1992.
 
7) Kirn JK, et al : Osmotic and non-osmotic regulation of arginine vasopressin (AVP) release, mRNA, and promoter activity in small cell lung carcinoma (SCLC) cells. Mol Cell Endocrinol 123 : 179-186, 1996.
 
P.312 掲載の参考文献
1) Betz D, Fane K : Human Chorionic Gonadotropin (HCG). StatPearls [Internet]. StatPearls Publishing, Treasure Island, 2018.
 
2) Cole LA : hCG, the wonder of today's science. Reprod Biol Endocrinol 10 : 24, 2012.
PubMed
3) Cole LA : HCG variants, the growth factors which drive human malignancies. Am J Cancer Res 2 : 22-35, 2012.
PubMed
4) Murray MJ, et al : The present and future of serum diagnostic tests for testicular germ cell tumours. Nat Rev Urol 13 : 715-725, 2016.
PubMed
5) Oberg K, Wide L : hCG and hCG subunits as tumour markers in patients with endocrine pancreatic tumours and carcinoids. Acta Endocrinol 98 : 256-260, 1981.
PubMed
6) Tachibana O, et al : Immunohistochemicai expression of human chorionic gonadotropin and P-glycoprotein in human pituitary glands and craniopharyngiomas. J Neurosurg 80 : 79-84, 1994.
 
7) Campo E, et al : Placental proteins in high-grade urothelial neoplasms. An immunohistochemical study of human chorionic gonadotropin, human placental lactogen, and pregnancy-specific beta-1-glycoprotein. Cancer 63 : 2497-2504, 1989.
PubMed
8) Martin JE, et al : Human chorionic gonadotrophin expression and histological findings as predictors of response to radiotherapy in carcinoma of the bladder. Virchows Arch A Pathol Anat Histopathol 414 : 273-277, 1989.
PubMed
9) Hotakainen K, et al : The free beta-subunit of human chorionic gonadotropin as a prognostic factor in renal cell carcinoma. Br J Cancer 86 : 185-189, 2002.
PubMed
10) Burt RW, et al : Serum biochemical markers in lung cancer. Br J Cancer 37 : 714-717, 1978.
PubMed
11) Caffier H, Brandau H : Serum tumor markers in metastatic breast cancer and course of disease. Cancer Detect Prev 6 : 451-457, 1983.
PubMed
12) Hedstrom J, et al : Concentration of free hCGbeta subunit in serum as a prognostic marker for squamous-cell carcinoma of the oral cavity and oropharynx. Int J Cancer 84 : 525-528, 1999.
PubMed
13) Hussa RO : The Clinical Marker hCG, Praeger, New York, 1987.
 
14) Alfthan H, et al : Elevation of free beta subunit of human choriogonadotropin and core beta fragment of human choriogonadotropin in the serum and urine of patients with malignant pancreatic and biliary disease. Cancer Res 52 : 4628-4633, 1992.
PubMed
P.316 掲載の参考文献
1) Kyle CV, et al : Growth hormone-like material in normal human tissues. J Clin Endocrinol Metab 53 : 1138-1144, 1981.
PubMed
2) Melmed S : Extrapituitary acromegaly. Endocrinol Metab Clin North Am 20 : 507-518, 1991.
PubMed
3) Greenberg PB, et al : Synthesis and release of human growth hormone from lung carcinoma in cell culture. Lancet 1 : 350-352, 1972.
PubMed
4) Melmed S, et al : Acromegaly due to secretion of growth hormone by an ectopic pancreatic isletcell tumor. N Engl J Med 312 : 9-17, 1985.
PubMed
5) Kaganowicz A, et al : Ectopic human growth hormone in ovaries and breast cancer. J Clin Endocrinoi Metab 48 : 5-8, 1979.
 
6) Sparagana M, et al : Ectopic growth hormone syndrome associated with lung cancer. Metab Clin Exp 20 : 730-736, 1971.
PubMed
7) Leveston SA, et al : Acromegaly and Cushing's syndrome associated with a foregut carcinoid tumor. J Clin Endocrinol Metab 53 : 682-689, 1981.
PubMed
8) Steiner H, et al : Ectopic growth-hormone production and osteoarthropathy in carcinoma of the bronchus. Lancet 1 : 783-785, 1968.
PubMed
9) Beuschlein F, et al : Acromegaly caused by secretion of growth hormone by a non-Hodgkin's lymphoma. N Engl J Med 342 : 1871-1876, 2000.
PubMed
10) Biswal S, et al : Acromegaly caused by ectopic growth hormone : arare manifestation of a bronchial carcinoid. Ann Thorac Surg 85 : 330-332, 2008.
 
11) Ozkaya M, et al : Ectopic acromegaly due to a growth hormone-secreting neuroendocrinedifferentiated tumor developed from ovarian mature cystic teratoma. Wien Klin Wochenschr 127 : 491-493, 2015.
PubMed
12) 吉本貴宣, 平田結喜緒 : 異所性ホルモン産生腫瘍の疾患概念. 日本臨牀 69 (増刊 : 内分泌腺腫瘍) : 697-699, 2011.
 
P.324 掲載の参考文献
1) Mitsuya K, et al : Ectopic growth hormone-releasing adenoma in the cavernous sinus-case report. Neurol Med Chir (Tokyo) 44 : 380-385, 2004.
PubMed
2) Mindermann T, Wilson CB : Age-related and gender-related occurrence of pituitary adenomas. Clin Endocrinol (Oxf) 41 : 359-364, 1994.
PubMed
3) Turkington RW : Ectopic production of prolactin. N Engl J Med. 285 : 1455-1458, 1971.
PubMed
4) Molitch ME, et al : Is prolactin secreted ectopically? Am J Med 70 : 803-807, 1981.
PubMed
5) Hori A : Suprasellar peri-infundibular ectopic adenohypophysis in fetal and adult brains. J Neurosurg 63 : 113-115, 1985.
PubMed
6) Saiardi A, et al : Antiproliferative role of dopamine : loss of D2 receptors causes hormonal dysfunction and pituitary hyperplasia. Neuron 19 : 115-126, 1997.
 
7) Asa SL, et al : Pituitary lactotroph adenomas develop after prolonged lactotroph hyperplasia in dopamine D2 receptor-deficient mice. Endocrinology 140 : 5348-5355, 1999.
PubMed
8) Kelly MA, et al : Pituitary lactotroph hyperplasia and chronic hyperprolactinemia in dopamine D2 receptor-deficient mice. Neuron 19 : 103-113, 1997.
 
9) Schuff KG, et al : Lack of prolactin receptor signaling in mice results in lactotroph proliferation and prolactinomas by dopamine-dependent and-independent mechanisms. J Clin Invest 110 : 973-981, 2002.
PubMed
10) Heaney AP, et al : Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis. Nat Med 5 : 1317-1321, 1999.
PubMed
11) Heaney AP, et al : Functional role of estrogen in pituitary tumor pathogenesis. J Clin Invest 109 : 277-283, 2002.
PubMed
12) Paez-Pereda M, et al : Involvement of bone morphogenetic protein 4 (BMP-4) in pituitary prolactinoma pathogenesis through a Smad/estrogen receptor crosstalk. Proc Natl Acad Sci USA 100 : 1034-1039, 2003.
PubMed
13) 三木伸泰, 小野昌美 : プロラクチン (PRL) : 日常臨床で問題となる高PRL血症, その診断と治療. Hospitalist 4 : 126-134, 2016.
 
P.327 掲載の参考文献
1) Robertson PW, et al : Hypertension due to a renin-secreting renal tumour. Am J Med 43 : 963-976, 1967.
PubMed
2) Hirose S, et al : Immunochemical identification of renin in rat brain and distinction from acid proteases. Nature 274 : 392-393, 197&
 
3) Kurt B, et al : Deletion of von Hippel-Lindau protein converts renin-producing cells into erythropoietin-producing cells. J Am Soc Nephrol 24 : 433-444, 2013.
 
4) Spahr J, et al : Renin producing Wilms' tumor. J Pediatr Surg 16 : 32-34, 1981.
PubMed
5) Hollifield JW, et al : Renin-secreting clear cell carcinoma of the kidney. Arch Intern Med 135 : 859-864, 1975.
PubMed
6) Iimura O, et al : A case of adrenal tumor producing renin, aldosterone, and sex steroid hormones. Hypertension 8 : 951-956, 1986.
PubMed
7) Kawai M, et al : Renin-producing adrenal tumor : report of a case. Surg Today 28 : 974-978, 1998.
PubMed
8) Yamanaka K, et al : A case of renin-producing adrenocortical cancer. Endocr J 47 : 119-125, 2000.
PubMed
9) Arver S, et al : Malignant human renin producing paraganglionoma-localization with 123I-MIBG and treatment with 131I1-MIBG. Clin Endocrinol (Oxf) 51 : 631-635, 1999.
 
10) Langer P, et al : Renin producing neuroendocrine pancreatic carcinoma-a case report and review of the literature. Exp Clin Endocrinol Diabetes 110 : 43-49, 2002.
PubMed
11) Kawai K, et al : A case of renin producing leiomyosarcoma originating in the lung. Endocrinol Jpn 38 : 603-609, 1991.
PubMed
12) Moody AM, et al : Renin-producing leiomyosarcoma originating in the uterus. Clin Oncol (R Coll Radiol) 7 : 52-53, 1995.
PubMed
13) Iwamoto H, et al : Renin-producing serous cystoadenocarcinoma of the ovary : a case report. Eur J Gynaecol Oncol 23 : 183-186, 2002.
PubMed
14) Korzets A, et al : Resistant hypertension associated with a renin-producing ovarian Sertoli cell tumor. Am J Clin Pathol 85 : 242-247, 1986.
PubMed
15) Tetu B, et al : Renin-producing ovarian tumor. A case report with immunohistochemical and electron-microscopic study. Am J Surg Pathol 12 : 634-640, 1988.
PubMed
16) Zabernigg A, et al : An unusual case of a renin-producing tumour of the fallopian tube. Eur J Cancer 33 : 1709, 1997.
PubMed
17) Pursell RN, Quinlan PM : Secondary hypertension due to a renin-producing teratoma. Am J Hypertens 16 : 592-595, 2003.
PubMed
18) Moritake H, et al : Renin-producing hepatoblastoma. J Pediatr Hematol Oncol 22 : 78-80, 2000.
PubMed
19) Tavasoli A, et al : Severe hypertension and encephalopathy due to Renin-producing hepatoblastoma. Iran J Cancer Prev 6 : 227-230, 2013.
PubMed
20) Saito T, et al : Ectopic production of renin by ileal carcinoma. Endocrinol Jpn 36 : 117-124, 1989.
PubMed
21) Lee HJ, et al : Paraneoplastic secondary hypertension due to a renin-secreting desmoplastic small round cell tumor : A case report. Oncol Lett 8 : 1986-1992, 2014.
PubMed
22) Uematsu M, et al : Renin-producing germ cell tumor in the pineal apparatus and mediastinum : A rare case report. J Cancer Res Ther 14 : S806-S808, 2018.
PubMed
23) Yokoyama H, et al : A case of ectopic renin-secreting orbital hemangiopericytoma associated with juvenile hypertension and hypokalemia. Acta Med Okayama 33 : 315-322, 1979.
 
P.331 掲載の参考文献
1) Burtis WJ, et al : Immunochemical characterization of circulating Parathyroid hormone-related protein in patients with humoral hypercalcemia of cancer. N Engl J Med 322 : 1106-1112, 1990.
PubMed
2) Stewart AF : Clinical practice. Hypercalcemia associated with cancer. N Engl J Med 352 : 373-379, 2005.
PubMed
3) Clayton K : Cancer-related hypercalcemia : how to spot it, how to manage it. Am J Nurs 97 : 42-48, quiz 49, 1997.
PubMed
4) Mundy GR Edwards JR : PTH-related peptide (PTHrP) in hypercalcemia. J Am Soc Nephrol 19 : 672-675, 2008.
 
5) Sternlicht H, Glezerman IG : Hypercalcemia of malignancy and new treatment options. Ther Clin Risk Manag 11 : 1779-1788, 2015.
PubMed
6) Nussbaum SR, et al : Hypercalcemia and ectopic secretion of parathyroid hormone by an ovarian carcinoma with rearrangement of the gene for parathyroid hormone. N Engl J Med 323 : 1324-1328, 1990.
PubMed
7) Orloff JJ, et al : Parathyroid hormone-like proteins : biochemical responses and receptor interactions. Endocr Rev 10 : 476-495, 1989.
PubMed
8) Singh RJ, Kumar R : Fibroblast growth factor 23 concentrations in humoral hypercalcemia of malignancy and hyperparathyroidism. Mayo Clin Proc 78 : 826-829, 2003.
PubMed
9) Ogata E : Parathyroid hormone-related protein as a potential target of therapy for cancer-associated morbidity. Cancer 88 : 2909-2911, 2000.
PubMed
10) Pecherstorfer M, et al : Parathyroid hormone-related protein and life expectancy in hypercalcemic cancer patients. J Clin Endocrinol Metab 78 : 1268-1270, 1994.
PubMed
P.337 掲載の参考文献
1) Oberg K : Neuroendocrine Gastrointestinal and Lund Tumors (Carcinoid Tumors), the Carcinoid Syndrome, and Related Disorders. In : Williams Textbook of Endocrinology, 13th ed (ed by Melmed S, et al) p1833-1853, Elsevier, Philadelphia, 2016.
 
2) 長村義之 : 神経内分泌腫瘍 (NET) のWHO分類 (2010) と病理診断. 日本内分泌・甲状腺外科学会雑誌 29 : 210-214, 2012.
 
3) Hendifar AE, et al : Neuroendocrine Tumors of the Lung : Current Challenges and Advances in the Diagnosis and Management of Well-Differentiated Disease. J Thorac Oncol 12 : 425-436, 2017.
 
4) Rindi G, et al : A common classification framework for neuroendocrine neoplasms : an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol 31 : 1770-1786, 2018.
PubMed
5) 稲垣光裕, ほか : C型慢性肝炎経過観察中に指摘された胆嚢小細胞癌の1切除例. 北海道外科雑誌 48 : 158-161, 2003.
Medical*Online
6) Horai T, et al : Malignant melanoma producing serotonin. Cancer 43 : 294-298, 1979.
PubMed
7) Taal BG, Visser O : Epidemiology of neuroendocrine tumours. Neuroendocrinology 80 (Suppl 1) : 3-7, 2004.
 
8) Yao JC, et al : One hundred years after "carcinoid" : epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26 : 3063-3072, 2008.
PubMed
9) Ito T, et al : Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan : a nationwide survey analysis. J Gastroenterol 50 : 58-64, 2015.
PubMed
10) Francis JM, et al : Somatic mutation of CDKNIB in small intestine neuroendocrine tumors. Nat Genet 45 : 1483-1486, 2013.
 
11) Jiao Y, et al : DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 331 : 1199-1203, 2011.
PubMed
12) Modlin IM, et al : Current status of gastrointestinal carcinoids. Gastroenterology 128 : 1717-1751, 2005.
PubMed
13) Meijer WG, et al : Discriminating capacity of indole markers in the diagnosis of carcinoid tumors. Clin Chem 46 : 1588-1596, 2000.
PubMed
14) Modlin IM, et al : A 5-decade analysis of 13,715 carcinoid tumors. Cancer 97 : 934-959, 2003.
PubMed
15) Zandee WT, et al : Effect of hormone secretory syndromes on neuroendocrine tumor prognosis. Endocr Relat Cancer 24 : R261-R274, 2017.
PubMed
P.342 掲載の参考文献
1) NINDS Paraneoplastic Syndromes Information : Archived 2015-01-04 at the Wayback Machine. National Institute of Neurological Disorders and Stroke.
 
2) Efthymiou C, et al : Endocrine paraneoplastic syndromes in lung cancer. Hormones (Athens) 17 : 351-358, 2018.
PubMed
3) Daskalakis K, et al : Endocrine paraneoplastic syndromes in patients with neuroendocrine neoplasms. Endocrine, 2018. [Epub ahead of print]
 
4) Viau M, et al : Paraneoplastic syndromes associated with gynecological cancers : A systematic review. Gynecol Oncol 146 : 661-671, 2017.
PubMed
5) Sedhom R, et al : Symptomatic Cushing's syndrome and hyperandrogenemia in a steroid cell ovarian neoplasm : a case report. J Med Case Rep 10 : 278, 2016.
 
6) Dimitriadis GK, et al : Paraneoplastic endocrine syndromes. Endocr Relat Cancer 24 : R173-R190, 2017.
PubMed
P.346 掲載の参考文献
1) Marx SJ : Recent Topics Around Multiple Endocrine Neoplasia Type 1. JClin Endocrinol Metab 103 : 1296-1301, 2018.
 
2) Sakurai A, et al : Multiple endocrine neoplasia type 1 in Japan : Establishment and analysis of a multicentre database. Clin Endocrinol (Oxf) 76 : 533-539, 2012.
PubMed
3) Thakker RV, et al : Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab 97 : 2990-3011, 2012.
PubMed
4) Agarwal SK, et al : Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states. J Clin Endocrinol Metab 94 : 1826-1834, 2009.
 
5) de Laat JM, et al : Low accuracy of tumor markers for diagnosing pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1 patients. J Clin Endocrinol Metab 98 : 4143-4151, 2013.
PubMed
6) 多発性内分泌腫瘍症診療ガイドブック編集委員会 (編) : 多発性内分泌腫瘍症診療ガイドブック (櫻井晃洋, ほか編), 金原出版, 2013.
 
7) van Leeuwaarde RS, et al : High fear of disease occurrence is associated with low quality of life in patients with multiple endocrine neoplasia type 1 : Results from the Dutch MEN1 study group. J Clin Endocrinol Metab 103 : 2354-2361, 2018.
 
8) Pieterman CRC, et al : Long-Term Natural Course of Small Nonfunctional Pancreatic Neuroendocrine Tumors in MEN1-Results From the Dutch MEN1 Study Group. J Clin Endocrinol Metab 102 : 3795-3805, 2017.
 
P.351 掲載の参考文献
1) Wells SA, et al : Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 25 : 567-610, 2015.
PubMed
2) Wang X : Structural studies of GDNF family ligands with their receptors-insights into ligand recognition and activation of receptor tyrosine kinase RET. Biochim Biophys Acta 1834 : 2205-2212, 2013.
PubMed
3) Moore SW : Genetic impact on the treatment & management of Hirschsprung disease. J Pediatr Surg 52 : 218-222, 2017.
PubMed
4) Imai T, et al : High penetrance of pheochromocytoma in multiple endocrine neoplasia 2 caused by germ line RET codon 634 mutation in Japanese patients. Eur J Endocrinol 168 : 683-687, 2013.
PubMed
5) Asai N, et al : RET receptor signaling : dysfunction in thyroid cancer and Hirschsprung's disease. Pathol Int 56 : 164-172, 2006.
PubMed
6) 多発性内分泌腫瘍症診療ガイドブック (多発性内分泌腫瘍症診療ガイドブック編集委員会編), p1-155, 金原出版, 2013.
 
7) Machens A, Dralle H : Biomarker-based risk stratification for previously untreated medullary thyroid cancer. J Clin Endocrinol Metab 95 : 2655-2663, 2010.
PubMed
8) Ito Y, et al : Calcitonin doubling time in medullary thyroid carcinoma after the detection of distant metastases keenly predicts patients' carcinoma death. Endocr J 63 : 663-667, 2016.
PubMed
9) Rodrigues KC, et al : Assessment of Depression, Anxiety, Quality of Life, and Coping in Long-Standing Multiple Endocrine Neoplasia Type 2 Patients. Thyroid 27 : 693-706, 2017.
PubMed
P.355 掲載の参考文献
1) Oberg K : The genetics of neuroendocrine tumors. Semin Oncol 40 : 37-44, 2013.
PubMed
2) Iwashita T, et al : Biological and biochemical properties of Ret with kinase domain mutations identified in multiple endocrine neoplasia type 2B and familial medullary thyroid carcinoma. Oncogene 18 : 3919-3922, 1999.
PubMed
3) Wray CJ, et al : Failure to recognize multiple endocrine neoplasia 2B : more common than we think? Ann Surg Oncol 15 : 293-301, 2008.
PubMed
4) Brauckhoff M, et al : Surgical curability of medullary thyroid cancer in multiple endocrine neoplasia 2B : achanging perspective. Ann Surg 259 : 800-806, 2014.
 
5) Imai T, et al : High penetrance of pheochromocytoma in multiple endocrine neoplasia 2 caused by germ line RET codon 634 mutation in Japanese patients. Eur J Endocrinol 168 : 683-687, 2013.
PubMed
6) Wells SA, et al : Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 25 : 567-610, 2015.
PubMed
7) 多発性内分泌腫瘍症診療ガイドブック (多発性内分泌腫瘍症診療ガイドブック編集委員会編), p1-155, 金原出版, 2013.
 
P.359 掲載の参考文献
1) Friedman JM : Neurofibromatosis l. Genereviews(R) [Internet], Initial Posting : October 2, 1998 ; Last Revision : May 17, 2018. [https://www.ncbi.nlm.nih.gov/] (2018年12月閲覧)
 
2) Viskochil D : Neurofibromatosis type 1. In : Management of Genetic Syndromes, 3rd ed (ed by Cassidy SB, Allanson JE), p549-568, John Wiley and Sons, Hoboken, 2010.
 
3) Korf BR : Neurofibromatosis type 1 (NF1) : Pathogenesis, clinical features, and diagnosis. UpToDate(R) [Internet]. [https://www.uptodate.com/] (2018年12月閲覧)
 
4) 倉持朗 : 神経線維腫症1型 (Von Recklinghausen病) ; 先天異常/先天奇形. 神経皮膚症候群 (母斑症). 神経線維腫症. 別冊日本臨牀新領域別症候群シリーズ No. 29 神経症候群 (第2版) IV, p785-796, 日本臨牀社, 2014.
 
5) Kehrer-Sawatzki H, et al : Emerging genotype-phenotype relationships in patients with large NF1 deletions. Hum Genet 136 : 349-376, 2017.
PubMed
6) Koczkowska M, et al : Expanding the clinical phenotype of individuals with a 3-bp in-frame deletion of the NF1 gene (c. 2970_2972del) : an update of genotype-phenotype correlation. Genet Med, 2018. [Epub ahead of print]
 
7) Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol 45 : 575-578, 1988.
PubMed
8) 吉田雄一, ほか : 日本皮膚科学会ガイドライン 神経線維腫症1型 (レックリングハウゼン病) 診療ガイドライン 2018. 日本皮膚科学会雑誌 128 : 17-34, 2018.
 
9) Wimmer K, et al : Connections between constitutional mismatch repair deficiency syndrome and neurofibromatosis type 1. Clin Genet 91 : 507-519, 2017.
PubMed
10) Dunning-Davies BM, Parker AP : Annual review of children with neurofibromatosis type 1. Arch Dis Child Educ Pract Ed 101 : 102-111, 2016.
PubMed
11) Williams VC, et al : Neurofibromatosis type 1 revisited. Pediatrics 123 : 124-133, 2009.
PubMed
12) Korf BR : Neurofibromatosis type 1 (NF1) : Management and prognosis. UpToDate(R). [Internet], [https://www.uptodate.com/] (2018年12月閲覧)
 
13) Hirbe AC, et al : Neurofibromatosis type 1 : a multidisciplinary approach to care. Lancet Neurol 13 : 834-843, 2014.
PubMed
14) Joensuu H, et al : Gastrointestinal stromal tumour. Lancet 382 : 973-983, 2013.
PubMed
15) Allaway RJ, et al : Cutaneous neurofibromas in the genomics era : current understanding and open questions. Br J Cancer 118 : 1539-1548, 2018.
PubMed
P.365 掲載の参考文献
1) Lamiell JM, et al : von Hippel-Lindau disease affecting 43 members of a single kindred. Medicine (Baltimore) 68 : 1-29, 1989.
PubMed
2) Latif F, et al : Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260 : 1317-1320, 1993.
PubMed
3) Maher ER, et al : Von Hippel-Lindau disease : a genetic study. J Med Genet 28 : 443-447, 1991.
PubMed
4) 山崎一郎, ほか : VHL病-疫学研究と診療ガイドライン-. 泌尿器外科 28 : 1601-1606, 2015.
Medical*Online
5) Maxwell PH, et al : The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399 : 271-275, 1999.
PubMed
6) Manalo DJ, et al : Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood 105 : 659-669, 2005,
PubMed
7) Richards FM, et al : Molecular analysis of de novo germline mutations in the von Hippel-Lindau disease gene. Hum Mol Genet 4 : 2139-2143, 1995.
PubMed
8) Nordstrom-O'Brien M, et al : Genetic analysis von Hippel-Lindau disease. Hum Mutat 31 : 521-537, 2010.
PubMed
9) Lonser RR, et al : von Hippel-Lindau disease. Lancet 361 : 2059-2067, 2003.
PubMed
10) Rednam SP, et al : Von Hippel-Lindau and Hereditary Pheochromocytoma/Paraganglioma syndromes : Clinical Features, Genetics, and Surveillance Recommendations in childhood. Clin Cancer Res 23 : e68-e75, 2017.
 
11) Maher ER, et al : Clinical features and natural history of von Hippel-Lindau disease. Q J Med 77 : 1151-1163, 1990.
PubMed
P.368 掲載の参考文献
1) Kimmel JR, et al : Isolation and characterization of chicken insulin. Endocrinology 83 : 1323-1330, 1968.
PubMed
2) Yonekura H, et al : Mosaic evolution of prepropancreatic polypeptide. II. Structural conservation and divergence in pancreatic polypeptide gene. J Biol Chem 263 : 2990-2997, 1988.
 
3) 船越顕博 : パンクレアティック・ポリペプチド (PP) -基礎的事項を中心に. 日本臨牀 57 (増刊 : 広範囲血液・尿化学検査, 免疫学的検査 (4)) : 349-352, 1999.
 
4) 松谷朗 : PP産生腫瘍. 肝胆膵 38 : 1003-1006, 1999.
 
5) Maxwell JE, et al : Biochemical Diagnosis and Preoperative Imaging of Gastroenteropancreatic Neuroendocrine Tumors. Surg Oncol Clin N Am 25 : 171-194, 2016.
PubMed
6) Delcore R, Friesen SR : Gastrointestinal neuroendocrine tumors. J Am Coll Surg 178 : 187-211, 1994.
PubMed
7) Bellows C, et al : Pancreatic polypeptide islet cell tumor : case report and review of the literature. J Gastrointest Surg 2 : 526-532, 1998.
PubMed
8) Soga J, Yakuwa Y : Pancreatic polypeptide (PP) -producing tumors (PPomas) : A review of the literature and statistical analysis of 58 cases. J Hep Bil Pancr Surg 1 : 556-563, 1994.
 
9) Choksi UA, et al : An unusual skin rash associated with a pancreatic polypeptide-producing tumor of the pancreas. Ann Intern Med 108 : 64-65, 1988.
PubMed
10) Raffel A, et al : Symptomatic pure pancreatic polypeptide-containing tumor of the pancreas. Pancreas 29 : 83, 2004.
PubMed
11) Mortenson M, Bold RJ : Symptomatic pancreatic polypeptide-secreting tumor of the distal pancreas (PPoma). Int J Gastrointest Cancer 32 : 153-156, 2002.
PubMed
12) Tomita T, et al : Pancreatic polypeptide-secreting islet cell tumor. A follow-up report. Cancer 57 : 129-133, 1986.
PubMed
13) Sanchez-Margalet V, et al : Pancreastatin, a chromogranin A-derived peptide, inhibits DNA and protein synthesis by producing nitric oxide in HTC rat hepatoma cells. J Hepatol 35 : 80-85, 2001.
 
14) Pathak RD, et al : A case of dopamine agonists inhibiting pancreatic polypeptide secretion from an islet cell tumor. J Clin Endocrinol Metab 89 : 581-584, 2004.
PubMed
15) Ligiero Braga T, Santos-Oliveira R : PPoma Review : Epidemiology, Aetiopathogenesis, Prognosis and Treatment. Diseases 6. pii : E8, 2018.
 
P.374 掲載の参考文献
1) Verner JV, Morrison AB : Islet cell tumor and a syndrome of refractory watery diarrhea and hypokalemia. Am J Med 25 : 374-380, 1958.
 
2) Said SI, Mutt V : Polypeptide with broad biological activity : isolation from small intestine. Science 169 : 1217-1218, 1970.
PubMed
3) Said SI, Mutt V : Potent peripheral and splanchnic vasodilator peptide from normal gut. Nature 225 : 863-864, 1970.
PubMed
4) Swift PG, et al : Watery diarrhoea and ganglioneuroma with secretion of vasoactive intestinal peptide. Arch Dis Child 50 : 896-899, 1975.
PubMed
5) Doi R, et al : Pancreatic endocrine tumor in Japan. Pancreas 28 : 247-252, 2004.
PubMed
6) 荒谷英二 : VIPoma-WDHA症候群. 肝胆膵 38 : 995-1001, 1999.
 
7) Friesen SR : Update on the diagnosis and treatment of rare neuroendocrine tumors. Surg Clin North Am 67 : 379-393, 1987.
PubMed
8) Perry RR, Vinik AL : Clinical review 72 : diagnosis and management of functioning islet cell tumors. J Clin Endocrinol Metab 80 : 2273-2278, 1995.
 
9) Igarashi H, et al : Vasoactive Intestinal Peptide (VIP) and VIP Receptors-Elucidation of Structure and Function for Therapeutic Applications Int J Clin Med 2 : 500-508, 2011.
 
10) Park SK, et al : Vasoactive intestinal polypeptide-secreting tumours : biology and therapy. Baillieres Clin Gastroenterol 10 : 673-696, 1996.
PubMed
11) 渡辺伸一郎 : バソアクティブ・インテスティナール・ポリペプチド (VIP). 日本臨牀 63 (増刊 : 広範囲 血液・尿化学検査, 免疫学的検査 [第6版] (4)) : 502-504, 2005.
 
12) Lamberts SW, et al : The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev 12 : 450-482, 1991.
PubMed
13) Soga J, Yakuwa Y : Vipoma/diarrheogenic syndrome : a statistical evaluation of 241 reported cases. J Exp Clin Cancer Res 17 : 389-400, 1998.
 
P.377 掲載の参考文献
1) Zollinger RM, Ellison EH : Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas. Ann Surg 142 : 709-723 ; discussion, 724-728, 1955.
 
2) Ito T, et al : Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan : a nationwide survey analysis. J Gastroenterol 50 : 58-64, 2015.
PubMed
3) Jensen RT, et al : ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms : functional pancreatic endocrine tumor syndromes. Neuroendocrinology 95 : 98-119, 2012.
PubMed
4) Ito T, et al : Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol 45 : 234-243, 2010.
PubMed
5) Eubanks PJ, et al : Putative tumor-suppressor gene on chromosome 11 is important in sporadic endocrine tumor formation. Am J Surg 167 : 180-185, 1994.
PubMed
6) Roy PK, et al : Zollinger-Ellison syndrome. Clinical presentation in 261 patients. Medicine (Baltimore) 79 : 379-411, 2000.
PubMed
7) Berna MJ, et al : Serum gastrin in Zollinger-Ellison syndrome : I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature. Medicine (Baltimore) 85 : 295-330, 2006.
PubMed
8) 河本泉, 今村正之 : 機能性膵神経内分泌腫瘍における機能的診断. ガストリノーマ. 胆と膵 37 : 865-869, 2016.
Medical*Online
9) Roy PK, et al : Gastric secretion in Zollinger-Ellison syndrome. Correlation with clinical expression, tumor extent and role in diagnosis--a prospective NIH study of 235 patients and a review of 984 cases in the literature. Medicine (Baltimore) 80 : 189-222, 2001.
 
10) Imamura M, et al : Biochemically curative surgery for gastrinoma in multiple endocrine neoplasia type 1 patients. World J Gastroenterol 17 : 1343-1353, 2011.
PubMed
11) Wada M, et al : Intravenous calcium injection test is a novel complementary procedure in differential diagnosis for gastrinoma. World J Surg 26 : 1291-1296, 2002.
PubMed
12) Ruf J, et al : 68Ga-DOTATOC PET/CT of neuroendocrine tumors : spotlight on the CT phases of a triple-phase protocol. J Nucl Med 52 : 697-704, 2011.
PubMed
13) Imamura M, et al : Curative resection of multiple gastrinomas aided by selective arterial secretin injection test and intraoperative secretin test. Ann Surg 210 : 711-718, 1989.
 
14) Yao JC, et al : Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364 : 514-523, 2011.
PubMed
15) 土井隆一郎 : ガストリノーマ, 新膵臓病学 (下瀬川徹編), p405, 南江堂, 2017.
 
P.381 掲載の参考文献
1) John AM, Schwartz RA : Glucagonoma syndrome : a review and update on treatment. J Eur Acad Dermatol Venereol 30 : 2016-2022, 2016.
PubMed
2) Ito T, et al : Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol 45 : 234-243, 2010.
PubMed
3) Song X, et al : Glucagonoma and the glucagonoma syndrome. Oncol Lett 15 : 2749-2755, 2018.
PubMed
4) 日本神経内分泌腫瘍研究会 (JNETS) 膵・消化管神経内分泌腫瘍診療ガイドライン作成委員会編 : CQ3-3グルカゴノーマの手術適応と術式は? 膵・消化管神経内分泌腫瘍 (NET) 診療ガイドライン, p62, 金原出版, 2015.
 
5) Chastain MA : The glucagonoma syndrome : a review of its features and discussion of new perspectives. Am J Med Sci 321 : 306-320, 2001.
PubMed
6) 日本神経内分泌腫瘍研究会 (JNETS) 膵・消化管神経内分泌腫瘍診療ガイドライン作成委員会編 : CQ1-3 Aグルカゴノーマを疑う症状は何か? B推奨される検査は何か? 膵・消化管神経内分泌腫瘍 (NET) 診療ガイドライン, p29, 金原出版, 2015.
 
7) Matsuo T, et al : Postabsorptive hyperglucagonemia in patients with type 2 diabetes mellitus analyzed with a novel enzyme-linked immunosorbent assay. J Diabetes Investig 7 : 324-331, 2016.
PubMed
8) Adams DR, et al : Glucagonoma syndrome. J Am Acad Dermatol 53 : 690-691, 2005.
PubMed
9) Leichter SB : Clinical and metabolic aspects of glucagonoma. Medicine (Baltimore) 59 : 100-113, 1980.
PubMed
10) Lv WF, et al : Imaging features of glucagonoma syndrome : A case report and review of the literature. Oncol Lett 9 : 1579-1582, 2015.
PubMed
11) Volmar KE, et al : Pancreatic FNA in 1000 cases : a comparison of imaging modalities. Gastrointest Endosc 61 : 854-861, 2005.
 
12) Plockinger U, et al : Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology 80 : 394-424, 2004.
 
P.385 掲載の参考文献
1) Ganda OP, et al : "Somatostatinoma" : a somatostatin-containing tumor of the endocrine pancreas. N Engl J Med 296 : 963-967, 1977.
PubMed
2) Krejs GJ, et al : Somatostatinoma syndrome. Biochemical, morphologic and clinical features. N Engl J Med 301 : 285-292, 1979.
PubMed
3) Garbrecht N, et al : Somatostatin-producing neuroendocrine tumors of the duodenum and pancreas : incidence, types, biological behavior, association with inherited syndromes, and functional activity. Endocr Relat Cancer 15 : 229-241, 2008.
PubMed
4) Usui M, et al : Somatostatinoma of the papilla of Vater with multiple gastrointestinal stromal tumors in a patient with von Recklinghausen's disease. J Gastroenterol 37 : 947-953, 2002.
 
5) Sreenarasimhaiah J, et al : Pancreatic somatostatinoma and tuberous sclerosis : case report of an exceedingly rare association. Gastrointest Endosc 69 : 379-381, 2009.
PubMed
6) Pacak K, et al : New syndrome of paraganglioma and somatostatinoma associated with polycythemia. J Clin Oncol 31 : 1690-1698, 2013.
PubMed
7) Zhuang Z, et al : Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia. N Engl J Med 367 : 922-930, 2012.
PubMed
8) Vinik A, et al : Somatostatinoma. In : Endotext [internet] (ed by De Groot LJ, et al), 2000-, South Dartmouth, MDText, 2017.
 
9) Soga J, Yakuwa Y : Somatostatinoma/inhibitory syndrome : astatistical evaluation of 173 reported cases as compared to other pancreatic endocrinomas. J Exp Clin Cancer Res 18 : 13-22, 1999.
 
10) Darr R, et al : Novel insights into the polycythemia-paraganglioma-somatostatinoma syndrome. Endocr Relat Cancer 23 : 899-908, 2016.
PubMed
11) Tanaka S, et al : Duodenal somatostatinoma : a case report and review of 31 cases with special reference to the relationship between tumor size and metastasis. Pathol Int 50 : 146-152, 2000.
 
12) Fendrich V, et al : An aggressive surgical approach leads to long-term survival in patients with pancreatic endocrine tumors. Ann Surg 244 : 845-851 ; discussion 852-853, 2006.
 
13) King J, et al : Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer 113 : 921-929, 2008.
PubMed
14) Angeletti S, et al : Use of the somatostatin analogue octreotide to localise and manage somatostatin-producing tumours. Gut 42 : 792-794, 1998.
PubMed
15) Caplin ME, et al : Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 371 : 224-233, 2014.
PubMed
P.388 掲載の参考文献
1) 今井康雄, 大村英治 : パラニューローマ (APUDoma) ; 腫瘍とホルモン. 消化管神経内分泌腫瘍. 別冊日本臨牀新領域別症候群シリーズ No. 3 内分泌症候群 (第2版) III, p375-378, 日本臨牀社, 2006.
 
2) Rindi G, et al : Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In : WHO Classification of Tumours of the Digestive System, 4th ed (ed by Bosman FT, et al), p13-14, IARC Press, Lyon, 2010.
 
3) Ito T, et al : Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan : a nationwide survey analysis. J Gastroenterol 50 : 58-64, 2015.
PubMed
4) Ito T, et al : Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol 45 : 234-243, 2010.
PubMed
5) Massironi S, et al : Somatostatin analogues in functioning gastroenteropancreatic neuroendocrine tumours : literature review, clinical recommendations and schedules. Scand J Gastroenterol 51 : 513-523, 2016.
PubMed
6) Shebani KO, et al : Prognosis and survival in patients with gastrointestinal tract carcinoid tumors. Ann Surg 229 : 815-821 ; discussion 822-823, 1999.
 
7) 高野幸路 : 機能性神経内分泌腫瘍の特徴と緊急時の治療. Mebio 34 : 32-41, 2017.
Medical*Online
8) Hassan SA, et al : Carcinoid heart disease. Heart 103 : 1488-1495, 2017.
PubMed
9) 膵・消化管神経内分泌腫瘍 (NET) 診療ガイドライン (日本神経内分泌腫瘍研究会 (JNETS) 編), 金原出版, 2015.
 
10) 岩佐勉, ほか : 消化管神経内分泌腫瘍の診断と内視鏡治療. Mebio 34 : 68-76, 2017.
Medical*Online
11) 五十嵐久人, ほか : 膵・消化管神経内分泌腫瘍のソマトスタチンアナログ療法. Mebio 34 : 94-99, 2017.
Medical*Online
12) Pokuri VK, et al : Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors. Curr Oncol Rep 18 : 7, 2016.
PubMed
P.393 掲載の参考文献
1) 国立がんセンター : 最新がん統計, 2018. [https://ganjoho.jp/reg_stat/statistics/stat/summary.html] (2019年2月閲覧).
 
2) 岩瀬弘敬ほか : ESR1遺伝子変化とホルモン療法抵抗性. 癌と化学療法 43 : 2499-2501, 2016.
Medical*Online
3) Sugano K, et al : Cross-sectional analysis of germline BRCA1 and BRCA2 mutations in Japanese patients suspected to have hereditary breast/ovarian cancer. Cancer Sci 99 : 1967-1976, 2008.
PubMed
4) Akiyama E Iwase H : Triple negative breast cancer : clinicopathological characteristics and treatment strategies. Breast Cancer 16 : 252-253, 2009.
 
5) 日本乳癌学会 (編) : 初期治療. 乳癌診療ガイドライン 1 治療編 [2018年版] (第4版), p12-17, 金原出版, 2018.
 
6) 岩瀬弘敬 : 閉経後エストロゲン受容体陽性転移乳癌の治療戦略-逐次内分泌療法と分子標的療法の併用-. 医学のあゆみ 261 : 457-461, 2017.
Medical*Online
7) Miles D, et al : Overall survival in MERiDiAN, a double-blind placebo-controlled randomised phase III trial evaluating first-line bevacizumab plus paclitaxel for HER2-negative metastatic breast cancer. Eur J Cancer 90 : 153-155, 2018.
 
8) Iwase H : Treatment strategy for metastatic breast cancer with estrogen receptor-positive turnor. Int J Clin Oncol 20 : 249-252, 2015.
 
9) Rugo HS, et al : Improving Response to Hormone Therapy in Breast Cancer : New Targets, New Therapeutic Options. Am Soc Clin Oncol Educ Book 35 : e40-54, 2016.
PubMed
P.398 掲載の参考文献
1) 国立がん研究センター がん対策情報センター : 最新がん統計. [https://ganjoho.jp/reg_stat/statistics/stat/summary.html] (2019年2月閲覧)
 
2) 日本産科婦人科学会婦人科腫瘍委員会 : 2016年度患者年報. [http://fa.kyorin.co.jp/jsog/readPDF.php?file=70/4/070041317.pdf] (2019年2月閲覧)
 
3) Cancer Genome Atlas Research Network ; Kandoth C, et al : Integrated genomic characterization of endometrial carcinoma. Nature 497 : 67-73, 2013.
 
4) 子宮体癌取扱い規約病理編 [第4版] (日本産科婦人科学会, 日本病理学会編), 金原出版, 2017.
 
5) 子宮体がん治療ガイドライン 2018年版 (日本婦人科腫瘍学会編), 金原出版, 2018.
 
6) 日本産科婦人科学会婦人科腫瘍委員会 : 第59回治療年報. [http://fa.kyorin.co.jp/jsog/readPDF.php?file=70/4/070041372.pdf] (2019年2月閲覧)
 
P.403 掲載の参考文献
1) 国立がん研究センター がん情報サービス「がん登録・統計」 [https://ganjoho.jp/reg_stat/statistics/stat/index.html] (2019年2月閲覧).
 
2) Johns LE, Houlston RS : A systematic review and meta-analysis of familial prostate cancer risk. BJU Int 91 : 789-794, 2003.
PubMed
3) Thompson D, Faston DF : Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst 94 : 1358-1365, 2002.
 
4) Parkin DM, et al : Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors, Prostate (C61). In : Cancer Incidence in Five Continents, Vol VIII (ed by Parkin DM, et al), p633-635, International Agency for Research on Cancer, Lyon, 2002.
 
5) Eichler K, et al : Diagnostic value of systematic biopsy methods in the investigation of prostate cancer : a systematic review. J Urol 175 : 1605-1612, 2006.
PubMed
6) Weinreb JC, et al : PI-RADS Prostate Imaging-Reporting and Data System : 2015, Version 2. Eur Urol 69 : 16-40, 2016.
 
7) Epstein JI, et al : The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma : Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol 40 : 244-252, 2016.
PubMed
8) 前立腺癌取扱い規約 [第4版] (日本泌尿器科学会, ほか編), 金原出版, 2010.
 
9) D'Amico AV, et al : Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280 : 969-974, 1998.
 
10) Zaorsky NG, et al : What is the ideal radiotherapy dose to treat prostate cancer? Ametaanalysis of biologically equivalent dose escalation. Radiother Oncol 115 : 295-300, 2015.
 
11) Schally AV, et al : Gonadotropin-releasing hormone : one polypeptide regulates secretion of luteinizing and follicle-stimulating hormones. Science 173 : 1036-1038, 1971.
PubMed
12) Beer TM, et al : Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371 : 424-433, 2014.
PubMed
13) Ryan CJ, et al : Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368 : 138-148, 2013.
PubMed

XI 低身長を伴う遺伝性 ( 先天性 ) 症候群

P.408 掲載の参考文献
1) Aarskog D : A familial syndrome of short stature associated with facial dysplasia and genital anomalies. J Pediatr 77 : 856-861, 1970.
PubMed
2) Scott CI : Unusual facies, joint hypermobility, genital anomaly and short stature : a new dysmorphic syndrome. Birth Defects Orig Artic Ser 7 : 240-246, 1971.
PubMed
3) Stevenson RE : Aarskog syndrome. In : Management of Genetic Syndromes, 3rd ed (ed by Cassidy SB, Allanson JE), p9-15, John Wiley & Sons, Hoboken, 2010.
 
4) Gorski JL : FGD1 and faciogenital dysplasia (Aarskog-Scott syndrome) ; McKusick#305400. In : Epstein's Inborn Errors of Development : The Molecular Basis of Clinical Disorders of Morphogenesis, 3rd ed (ed by Erickson RP, Wynshaw-Boris AJ), p1183-1189, Oxford University Press, New York, 2016.
 
5) Orrico A, et al : Clinical utility gene card for : Aarskog-Scott Syndrome (faciogenital dysplasia) -update 2015. Eur J Hum Genet 23, 2015. doi : 10.1038/ejhg.2014.178.
 
6) Pasteris NG, et al : Isolation and characterization of the faciogenital dysplasia (Aarskog-Scott syndrome) gene : a putative Rho/Rac guanine nucleotide exchange factor. Cell 79 : 669-678, 1994.
PubMed
7) Orrico A, et al : Phenotypic and molecular characterisation of the Aarskog-Scott syndrome : a survey of the clinical variability in light of FGD1 mutation analysis in 46 patients. Eur J Hum Genet 12 : 16-23, 2004.
PubMed
8) Pilozzi-Edmonds L, et al : Fraternal twins with Aarskog-Scott syndrome due to maternal germline mosaicism. Am J Med Genet A 155A : 1987-1990, 2011.
PubMed
9) Al-Semari A, et al : Novel FGD1 mutation underlying Aarskog-Scott syndrome with myopathy and distal arthropathy. Clin Dysmorphol 22 : 13-17, 2013.
PubMed
10) Orrico A, et al : Aarskog-Scott syndrome : clinical update and report of nine novel mutations of the FGD1 gene. Am J Med Genet A 152A : 313-318, 2010.
PubMed
11) 清水健司 : X連鎖劣性遺伝疾患, (Aarskog症候群). 小児科診療 80 (増刊号) : 17-20, 2017.
 
12) Kaname T, et al : Neurobehavioral disorders in patients with Aarskog-Scott syndrome affected by novel FGD1 rnutations. Am J Med Genet A 140 : 1331-1332, 2006.
PubMed
13) Kodama M, et al : Aarskog syndrome with isolated growth hormone deficiency. Eur J Pediatr 135 : 273-276, 1981.
PubMed
P.413 掲載の参考文献
1) Bloom D : Congenital telangiectatic erythema resembling lupus erythematosus in dwarfs ; probably a syndrome entity. AMA Am J Dis Child 88 : 754-75&1954.
 
2) Ellis NA, et al : The Bloom's syndrome gene product is homologous to RecQ helicases. Cell 83 : 655-666, 1995.
PubMed
3) German J : Bloom syndrome : amendelian prototype of somatic mutational disease. Medicine (Baltimore) 72 : 393-406, 1993.
 
4) 金子英雄 (研究代表者) : 遺伝子修復異常症 (Bloom症候群, Rothmund-Thomson症候群, RAPADILINO症候群, Baller-Gerold症候群) の実態調査, 早期診断法の確立に関する研究. 厚生労働科学研究費補助金難治性疾患克服研究事業, 平成23年度総括・分担研究報告書, 2012.
 
5) Sokolenko AP, et al : High prevalence and breast cancer predisposing role of the BLM c.1642 C > T (Q548X) mutation in Russia. Int J Cancer 130 : 2867-2873, 2012.
 
6) Bogdanova N, et al : Prevalence of the BLM nonsense mutation, p. Q548X, in ovarian cancer patients from Central and Eastern Europe. Fam Cancer 14 : 145-149, 2015.
PubMed
7) Nakayama H : RecQ family helicases : roles as tumor suppressor proteins. Oncogene 21 : 9008-9021, 2002.
PubMed
8) Martin CA, et al : Mutations in TOP3A Cause a Bloom Syndrome-like Disorder. Am J Hum Genet 103 : 221-231, 2018.
 
9) Hudson DF, et al : Loss of RMI2 Increases Genome Instability and Causes a Bloom-Like Syndrome. PLoS Genet 12 : e1006483, 2016.
PubMed
10) Kaneko H, et al : BLM (the causative gene of Bloom syndrome) protein translocation into the nucleus by a nuclear localization signal. Biochem Biophys Res Commun 240 : 348-353, 1997.
PubMed
11) Wang Y, et al : BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes Dev 14 : 927-939, 2000.
PubMed
12) German J, et al : Syndrome-causing mutations of the BLM gene in persons in the Bloom's Syndrome Registry. Hum Mutat 28 : 743-753, 2007.
PubMed
13) Knoch J, et al : Rare hereditary diseases with defects in DNA-repair. Eur J Dermatol 22 : 443-455, 2012.
PubMed
14) Brock PR, et al : Malignant disease in Bloom's syndrome children treated with growth hormone. Lancet 337 : 1345-1346, 1991.
PubMed
15) Kaneko H, Kondo N : Clinical features of Bloom syndrome and function of the causative gene, BLM helicase. Expert Rev Mol Diagn 4 : 393-401, 2004.
PubMed
P.416 掲載の参考文献
1) Borjeson M, et al : An X-linked, recessively inherited syndrome characterized by grave mental deficiency, epilepsy, and endocrine disorder. Acta Med Scand 171 : 13-21, 1962.
 
2) Kubota T, et al : Borjeson-Forssman-Lehmann syndrome in a woman with skewed X-chromosome inactivation. Am J Med Genet 87 : 258-261, 1999.
 
3) Mathews KD, et al : Linkage localization of Borjeson-Forssman-Lehmann syndrome. Am J Med Genet 34 : 470-474, 1989.
PubMed
4) Turner G, et al : Borjeson-Forssman-Lehmann syndrome : clinical manifestations and gene localization to Xq26-27. Am J Med Genet 34 : 463-469, 1989.
PubMed
5) Lower KM, et al : Mutations in PHF6 are associated with Borjeson-Forssman-Lehmann syndrome. Nat Genet 32 : 661-665, 2002.
PubMed
6) Lower KM, et al : 1024C > T (R342X) is a recurrent PHF6 mutation also found in the original Borleson-Forssman-Lehmann syndrome family. Eur J Hum Genet 12 : 787-789, 2004.
PubMed
7) Turner G, et al : The clinical picture of the Borjeson-Forssman-Lehmann syndrome in males and heterozygous females with PHF6 mutations. Clin Genet 65 : 226-232, 2004.
PubMed
8) Jahani-Asl A, et al : Pathogenesis of Borjeson-Forssman-Lehmann syndrome : Insights from PHF6 function. Neurobiol Dis 96 : 227-235, 2016.
PubMed
9) Zhang C, et al : The X-linked intellectual disability protein PHF6 associates with the PAF1 complex and regulates neuronal migration in the mammalian brain. Neuron 78 : 986-993, 2013.
PubMed
10) Cheng C, et al : Characterization of a Mouse Model of Borjeson-Forssman-Lehmann Syndrome. Cell Rep 25 : 1404-1414e6, 2018.
PubMed
11) Baar HS, Galindo J : The Boerjeson-Forssman-Lehmann Syndrome. J Ment Defic Res 9 : 125-130, 1965.
PubMed
12) Robinson LK, et al : The Borjeson-Forssman-Lehmann syndrome. Am J Med Genet 15 : 457-468, 1983.
PubMed
13) Gecz J, et al : Fibroblast growth factor homologous factor 2 (FHF2) : gene structure, expression and mapping to the Borjeson-Forssman-Lehmann syndrome region in Xq26 delineated by a duplication breakpoint in a BFLS-like patient. Hum Genet 104 : 56-63, 1999.
 
14) Skare J, et al : Characterization of three overlapping deletions causing X-linked lymphoproliferative disease. Genomics 16 : 254-255, 1993.
PubMed
15) Lower KM, Gecz J : Characterization of ARHGEF6, a guanine nucleotide exchange factor for Rho GTPases and a candidate gene for X-linked mental retardation : mutation screening in Borjeson-Forssman-Lehmann syndrome and MRX27. Am J Med Genet 100 : 43-48, 2001.
 
P.421 掲載の参考文献
1) Cockayne EA : Dwarfism with retinal atrophy and deafness. Arch Dis Child 11 : 1-8, 1936.
PubMed
2) Nance MA, Berry SA : Cockayne syndrome : review of 140 cases. Am J Med Genet 42 : 68-84, 1992.
PubMed
3) Wilson BT, et al : The Cockayne Syndrome Natural History (CoSyNH) study : clinical findings in 102 individuals and recommendations for care. Genet Med 18 : 483-493, 2016.
PubMed
4) Kubota M, et al : Nationwide survey of Cockayne syndrome in Japan : Incidence, clinical course and prognosis. Pediatr Int 57 : 339-347, 2015.
PubMed
5) Henning KA, et al : The Cockayne syndrome group A gene encodes a WD repeat protein that interacts with CSB protein and a subunit of RNA polymerase II TFIIH. Cell 82 : 555-564, 1995.
 
6) Mallery DL, et al : Molecular analysis of mutations in the CSB (ERCC6) gene in patients with Cockayne syndrome. Am J Hum Genet 62 : 77-85, 1998.
PubMed
7) Karikkineth AC, et al : Cockayne syndrome : Clinical features, model systems and pathways. Ageing Res Rev 33 : 3-17, 2017.
PubMed
8) コケイン症候群研究会ホームページ. [http://www.cockayneresearchcare.jp/] (2019年1月閲覧)
 
9) Wilson BT, et al : Metronidazole Toxicity in Cockayne Syndrome : A Case Series. Pediatrics 136 : e706-708, 2015.
PubMed
10) Wang Y, et al : Pharmacological Bypass of Cockayne Syndrome B Function in Neuronal Differentiation. Cell Rep 14 : 2554-2561, 2016.
PubMed
P.428 掲載の参考文献
1) Cohen MM Jr, Kreiborg S : Birth prevalence studies of the Crouzon syndrome : comparison of direct and indirect methods. Clin Genet 41 : 12-15, 1992.
PubMed
2) Crouzon症候群. 新 先天奇・形症候群アトラス (梶井正, ほか編), p46-47, 南江堂, 1998.
 
3) Reardon W, et al : Mutations in the fibroblast growth factor receptor 2 gene cause Crouzon syndrome. Nat Genet 8 : 98-103, 1994.
PubMed
4) Craniosynostosis : Diagnosis, Evaluation, and Management, 2nd ed (ed by Cohen MM Jr, MacLean RE), p77-94, Oxford University Press, New York, 2000.
 
5) Robin NH, et al : FGFR-Related Craniosynostosis Syndromes. GeneReview(R) [Internet], University of Washington, Seattle, Initial Posting : October 20, 1998 ; Last Update : June 7, 2011. [http://www.ncbi.nlm.nih.gov/books/NBK1455/] (2019年2月閲覧)
 
6) Meyers GA, et al : Fibroblast growth factor receptor 3 (FGFR3) transmembrane mutation in Crouzon syndrome with acanthosis nigricans. Nat Genet 11 : 462-464, 1995.
PubMed
7) Ito S, et al : Phenotypic diversity in patients with craniosynostoses unrelated to Apert syndrome : the role of fibroblast growth factor receptor gene mutations. J Neurosurg 102 : 23-30, 2005.
PubMed
8) Cinalli G, et al : Chronic tonsillar herniation in Crouzon's and Apert's syndromes : the role of premature synostosis of the lambdoid suture. J Neurosurg 83 : 575-582, 1995.
PubMed
9) 島克司, ほか : 頭蓋底-頸椎移行部異常. 最新脳神経外科学 (坪川孝志, ほか編), p690-694, 朝倉書店, 1996.
 
10) The Pediatric Spine : Principles and Practice, 2nd ed (ed by Stuart LW), p219-237, Lippincott Williams & Wilkins, Philadelphia, 2001.
 
11) Papay FA, et al : Laryngotracheal anomalies in children with craniofacial syndromes. J Craniofac Surg 13 : 351-364, 2002.
PubMed
12) Kobayashi S, et al : A novel craniofacial osteogenesis distraction system enabling control of distraction distance and vector for the treatrnent of syndrornic craniosynostosis. J Craniofac Surg 23 : 422-425, 2012.
 
P.434 掲載の参考文献
1) Lobitz S, Velleuer E : Guido Fanconi (1892-1979) : a jack of all trades. Nat Rev Cancer 6 : 893-898, 2006.
 
2) 矢部普正, ほか : Fanconi貧血. 先天性骨髄不全症診療ガイドライン 2017 (日本小児血液・がん学会編), p14-24, 診断と治療社, 2017.
 
3) Nalepa G, Clapp D : Fanconi anaemia and cancer : an intricate relationship. Nat Rev Cancer 18 : 168-185, 2018.
PubMed
4) Hira A, et al : Variant ALDH2 is associated with accelerated progression of bone marrow failure in Japanese Fanconi anemia patients. Blood 122 : 3206-3209, 2013.
PubMed
5) Wang AT, Smogorzewska A : SnapShot : Fanconi anemia and associated proteins. Cell 160 : 354-354.e1, 2015.
 
6) Rose SR, et al : Endocrine phenotype of children and adults with Fanconi anemia. Pediatr Blood Cancer 59 : 690-696, 2012.
PubMed
7) Petryk A, et al : Endocrine disorders in Fanconi anemia : recommendations for screening and treatment. J Clin Endocrinol Metab 100 : 803-811, 2015.
PubMed
8) Wajnrajch MP, et al : Evaluation of growth and hormonal status in patients referred to the International Fanconi Anemia Registry. Pediatrics 107 : 744-754, 2001.
 
9) Dufour C : How I manage patients with Fanconi anaemia. Br J Haematol 178 : 32-47, 2017.
 
10) Sawyer SL, et al : Biallelic mutations in BRCA1 cause a new Fanconi anemia subtype. Cancer Discov 5 : 135-142, 2015.
 
11) Sasaki MS, et al : A high susceptibility of Fanconi's anemia to chromosome breakage by DNA cross-linking agents. Cancer Res 33 : 1829-1836, 1973.
PubMed
12) Yabe H, et al : Allogeneic haematopoietic cell transplantation from alternative donors with a conditioning regimen of low-dose irradiation, fludarabine and cyclophosphamide in Fanconi anaemia. Br J Haematol 134 : 208-212, 2006.
PubMed
13) Alter BP, et al : Cancer in the National Cancer Institute inherited bone marrow failure syndrome cohort after fifteen years of follow-up. Haematologica 103 : 30-39, 2018.
PubMed
14) Forlenza GP, et al : Growth hormone treatment of patients with Fanconi anemia after hematopoietic cell transplantation. Pediatr Blood Cancer 61 : 1142-1143, 2014.
PubMed
P.436 掲載の参考文献
1) Goltz RW, et al : Focal dermal hypoplasia. Arch Dermatol 86 : 708-717, 1962.
PubMed
2) Grzeschik KH, et al : Deficiency of PORCN, a regulator of Wnt signaling, is associated with focal dermal hypoplasia. Nat Genet 39 : 833-835, 2007.
PubMed
3) Wang X, et al : Mutations in X-linked PORCN, a putative regulator of Wnt signaling, cause focal dermal hypoplasia. Nat Genet 39 : 836-838, 2007.
 
4) Maas SM, et al : Phenotype and genotype in 17 patients with Goltz-Gorlin syndrome. J Med Genet 46 : 716-720, 2009.
PubMed
5) Fete TJ, et al : International research symposium on Goltz syndrome. Am J Med Genet C Semin Med Genet 172C : 3-6, 2016.
PubMed
P.442 掲載の参考文献
1) Rao E, et al : Pseudoautosomal deletions encompassing a novel homeobox gene cause growth failure in idiopathic short stature and Turner syndrome. Nat Genet 16 : 54-63, 1997.
PubMed
2) Shima H, et al : Systematic molecular analyses of SHOX in Japanese patients with idiopathic short stature and Leri-Weill dyschondrosteosis. J Hum Genet 61 : 585-591, 2016.
PubMed
3) Fukami M, et al : Identification and characterization of cryptic SHOX intragenic deletions in three Japanese patients with Leri-Weill dyschondrosteosis. J Hum Genet 53 : 454-459, 2008.
PubMed
4) Kosho T, et al : Skeletal features and growth patterns in 14 patients with haploinsufficiency of SHOX : implications for the development of Turner syndrome. J Clin Endocrinol Metab 84 : 4613-4621, 1999.
PubMed
5) Marchini A, et al : A Track Record on SHOX : From Basic Research to Complex Models and Therapy. Endocr Rev 37 : 417-448, 2016.
PubMed
6) Ogata T, et al : Turner syndrome and Xp deletions : clinical and molecular studies in 47 patients. J Clin Endocrinol Metab 86 : 5498-5508, 2001.
PubMed
7) Fukami M, et al : Longitudinal auxological study in a female with SHOX (short stature homeobox containing gene) haploinsufficiency and normal ovarian function. Eur J Endocrinol 149 : 337-341, 2003.
 
P.445 掲載の参考文献
1) Escobar V, et al : Multiple pterygium syndrome. Am J Dis Child 132 : 609-611, 1978.
PubMed
2) Gillin ME, Pryse-Davis J : Pterygium syndrome. J Med Genet 13 : 249-251, 1976.
PubMed
3) Michalk A, et al : Acetylcholine receptor pathway mutations explain various fetal akinesia deformation sequence disorders. Am J Hum Genet 82 : 464-476, 2008.
PubMed
4) Meyer-Cohen J, et al : Lethal multiple pterygium syndrome in four male fetuses in a family : evidence for an X-linked recessive subtype? Am J Med Genet 82 : 97-99, 1999.
 
5) Hall JG, et al : Limb pterygium syndromes : a review and report of eleven patients. Am J Med Genet 12 : 377-409, 1982.
PubMed
6) Thompson EM, et al : Multiple pterygium syndrome : evolution of the phenotype. J Med Genet 24 : 733-749, 1987.
PubMed
7) Vogt J, et al : CHRNG genotype-phenotype correlations in the multiple pterygium syndromes. J Med Genet 49 : 21-26, 2012.
PubMed
8) Hoffmann K, et al : Escobar syndrome is a prenatal myasthenia caused by disruption of the acetylcholine receptor fetal gamma subunit. Am J Hum Genet 79 : 303-312, 2006.
PubMed
9) Morgan NV, et al : Mutations in the embryonal subunit of the acetylcholine receptor (CHRNG) cause lethal and Escobar variants of multiple pterygium syndrome. Am J Hum Genet 79 : 390-395, 2006.
PubMed
10) Vogt J, et al : Mutation analysis of CHRNA1, CHRNB1, CHRND, and RAPSN genes in multiple pterygium syndrome/fetal akinesia patients. Am J Hum Genet 82 : 222-227, 2008.
PubMed
11) Hall JG : The lethal multiple pterygium syndromes. Am J Med Genet 17 : 803-807, 1984.
PubMed
12) Chong JX, et al : Autosomal-Dominant Multiple Pterygium Syndrome Is Caused by Mutations in MYH3. Am J Hum Genet 96 : 841-849, 2015.
PubMed
13) McKie AB, et al : Germline mutations in RYRI are associated with foetal akinesia deformation sequence/lethal multiple pterygium syndrome. Acta Neuropathol Commun 2 : 148, 2014.
 
14) Alkhunaizi E, et al : Homozygous/compound heterozygote RYR1 gene variants : Expanding the clinical spectrum. Am J Med Genet A 179 : 386-396, 2019.
PubMed
15) Ravenscroft G, et al : Whole exome sequencing in foetal akinesia expands the genotypephenotype spectrum of GBE1 glycogen storage disease mutations. Neuromuscul Disord 23 : 165-169, 2013.
PubMed
P.452 掲載の参考文献
1) Cassidy SB : Prader-Willi syndrome. J Med Genet 34 : 917-923, 1997.
PubMed
2) Matsubara K, et al : Maternal age effect on the development of Prader-Willi syndrome resulting from upd (15) mat through meiosis 1 errors. J Hum Genet 56 : 566-571, 2011.
PubMed
3) Holm VA, et al : Prader-Willi syndrome : consensus diagnostic criteria. Pediatrics 91 : 398-402, 1993.
PubMed
4) Gunay-Aygun M, et al : The changing purpose of Prader-Willi syndrome clinical diagnostic criteria and proposed revised criteria. Pediatrics 108 : E92, 2001.
PubMed
5) Nagai T, et al : Standard growth curves for Japanese patients with Prader-Willi syndrome. Am J Med Genet 95 : 130-134, 2000.
PubMed
6) Angulo M, et al : Growth hormone secretion and effects of growth hormone therapy on growth velocity and weight agin in children with Prader-Willi syndrome. J Pediatr Endocrinol Metab 9 : 393-400, 1996.
 
7) Grugni G, et al : Reduced growth hormone (GH) responsiveness to combined GH-releasing hormone and pyridostigmine administration in the Prader-Willi syndrome. Clin Endocrinol (Oxf) 48 : 769-775, 1998.
PubMed
8) Oto Y, et al : Grwoth hormone secretion and its effect on height in pediatric patients with different genotypes of Prader-Willi syndrome. Am J Med Genet A 158A : 1477-1480, 2012.
 
9) Eiholzer U, et al : Low insulin, IGF-I and IGFBP-3 levels in children with Prader-Labhart-Willi syndrome. Eur J Pediatr 157 : 890-893, 1998.
PubMed
10) Deal CL, et al : Growth Hormone Research Society workshop summary : consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome. J Clin Endocrinol Metab 98 : E1072-1087, 2013.
PubMed
P.456 掲載の参考文献
1) Silver HK, et al : Syndrome of congenital hemihypertrophy, shortness of stature, and elevatedurinary gonadotropins. Pediatrics 12 : 368-376, 1953.
PubMed
2) Russell A : A syndrome of intra-uterine dwarfism recognizable at birth with cranio-facial dysostosis, disproportionately short arms, and other anomalies (5 examples). Proc R Soc Med 47 : 1040-1044, 1954.
 
3) Brioude F, et al : CDKN1C mutation affecting the PCNA-binding domain as a cause of familial Russell Silver syndrome. J Med Genet 50 : 823-830, 2013.
PubMed
4) Begemann M, et al : Paternally Inherited IGF2 Mutation and Growth Restriction. N Engl J Med 373 : 349-356, 2015.
PubMed
5) Eggermann T, et al : Is maternal duplication of 11p15 associated with Silver-Russell syndrome? J Med Genet 42 : e26, 2005.
PubMed
6) Sch6nherr N, et al : The centromeric 11p15 imprinting centre is also involved in Silver-Russell syndrome. J Med Genet 44 : 59-63, 2007.
 
7) Monk D, et al : Duplication of 7p11.2-p13, including GRB10, in Silver-Russell syndrome. Am J Hum Genet 66 : 36-46, 2000.
PubMed
8) Eggermann T, et al : Deletion of the paternal allele of the imprinted MEST/PEG1 region in a patient with Silver-Russell syndrome features. Clin Genet 81 : 298-300, 2012.
 
9) Carrera IA, et al : Microdeletions of the 7q32.2 imprinted region are associated with Silver-Russell syndrome features. Am J Med Genet A 170 : 743-749, 2016.
PubMed
10) Wollmann HA, et al : Growth and symptoms in Silver-Russell syndrome : review on the basis of 386 patients. Eur J Pediatr 154 : 958-968, 1995.
PubMed
11) Lai KY, et al : Cognitive abilities associated with the Silver-Russell syndrome. Arch Dis Child 71 : 490-496, 1994.
PubMed
12) Wakeling EL, et al : Epigenotype-phenotype correlations in Silver-Russell syndrome. J Med Genet 47 : 760-768, 2010.
PubMed
13) Fuke T, et al : Molecular and clinical studies in l38 Japanese patients with Silver-Russell syndrome. PLoS One 8 : e60105, 2013.
 
14) Azzi S, et al : A prospective study validating a clinical scoring system and demonstrating phenotypical-genotypical correlations in Silver-Russell syndrome. J Med Genet 52 : 446-453, 2015.
PubMed
15) Wakeling EL, et al : Diagnosis and management of Silver-Russell syndrome : first international consensus statement. Nat Rev Endocrinol 13 : 105-124, 2017.
PubMed
P.461 掲載の参考文献
1) Mendez HM, Opitz JM : Noonan syndrome : a review. Am J Med Genet 21 : 493-506, 1985.
PubMed
2) Tartaglia M, et al : Mutations in PTPNI1, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet 29 : 465-468, 2001.
 
3) Ogata T, Yoshida R : PTPN11 mutations and genotype-phenotype correlations in Noonan and LEOPARD syndromes. Pediatr Endocrinol Rev 2 : 669-674, 2005.
PubMed
4) Stofega MR, et al : Mutation of the SHP-2 binding site in growth hormone (GH) receptor prolongs GH-promoted tyrosyl phosphorylation of GH receptor, JAK2, and STAT5B. Mol Endocrinol 14 : 1338-1350, 2000.
PubMed
5) Karkkainen MJ, et al : Molecular regulation of lymphangiogenesis and targets for tissue oedema. Trends Mol Med 7 : 18-22, 2001.
PubMed
6) Mariani S, et al : PDGF and the testis. Trends Endocrinol Metab 13 : 11-17, 2002.
PubMed
7) Niemeyer CM, Kratz C : Juvenile myelomonocytic leukemia. Curr Treat Options Oncol 4 : 203-210, 2003.
PubMed
8) Bader-Meunier B, et al : Occurrence of myeloproliferative disorder in patients with Noonan syndrome. J Pediatr 130 : 885-889, 1997.
PubMed
9) Tartaglia M, et al : Somatic mutations in PTPNII in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet 34 : 148-150, 2003.
 
10) Bentires-Alj M, et al : Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res 64 : 8816-8820, 2004.
PubMed
11) Aoki Y, et al : Recent advances in RASopathies. J Hum Genet 61 : 33-39, 2016.
PubMed
12) Romano AA, et al : Noonan syndrome : clinical features, diagnosis, and management guidelines. Pediatrics 126 : 746-759, 2010.
PubMed
13) Ferreira LV, et al : PTPN11 (protein tyrosine phosphatase, nonreceptor type 11) mutations and response to growth hormone therapy in children with Noonan syndrome. J Clin Endocrinol Metab 90 : 5156-5160, 2005.
PubMed
P.465 掲載の参考文献
1) Williams JC, et al : Supravalvular aortic stenosis. Circulation 24 : 1311-1318, 1961.
PubMed
2) Stromme P, et al : Prevalence estimation of Williams syndrome. J Child Neurol 17 : 269-271, 2002.
PubMed
3) Schubert C : The genomic basis of the Williams-Beuren syndrome. Cell Mol Life Sci 66 : 1178-1197, 2009.
PubMed
4) Morris CA : Williams Syndrome. GeneReviews(R) [Internet], University of Washington, Seattle, Initial Posting : April 9, 1999 ; Last Update : March 23, 2017. [https://www.ncbi.nlm.nih.gov/books/NBK1249/] (2019年2月閲覧)
 
5) 村島京子, ほか : ウィリアムス症候群における成長曲線の検討. 日本遺伝カウンセリング学会誌 29 : 39, 2008.
Medical*Online
6) Partsch CJ, et al : Central precocious puberty in girls with Williams syndrome. J Pediatr 141 : 441-444, 2002.
PubMed
7) Spielmann S, et al : Treatment of central precocious puberty and early puberty with GnRH analog in girls with Williams-Beuren syndrome. J Pediatr Endocrinol Metab 28 : 1363-1367, 2015.
PubMed
8) Kim YM, et al : Endocrine dysfunctions in children with Williams-Beuren syndrome. Ann Pediatr Endocrinol Metab 21 : 15-20, 2016.
PubMed
9) Jarvinen-Pasley A, et al : Defining the social phenotype in Williams syndrome : a model for linking gene, the brain, and behavior. Dev Psychopathol 20 : 1-35, 2008.
 
10) John AE, Mervis CB : Sensory modulation impairments in children with Wiiliams syndrome. Am J Med Genet C Semin Med Genet 154C : 266-276, 2010.
 
11) Morris CA, Mervis CB : Williams syndrome and related disorders. Annu Rev Genomics Hum Genet 1 : 461-484, 2000.
PubMed
12) 中村みほ : Williams症候群における学習のつまずきと支援の実際. 特異的発達障害診断・治療のための実践ガイドライン, p81-89, 診断と治療社, 2010.
 
13) Committee on Genetics : American Academy of Pediatrics : Health care supervision for children with Williams syndrome. Pediatrics 107 : 1192-1204, 2001.
 
P.469 掲載の参考文献
1) Cohen LE : Idiopathic short stature : a clinical review. JAMA 311 : 1787-1796, 2014,
PubMed
2) Visscher PM, et al : Assumption-free estimation of heritability from genome-wide identity-bydescent sharing between full siblings. PLoS Genet 2 : e41, 2006.
PubMed
3) Wood AR, et al : Defining the role of common variation in the genomic and biological architecture of adult human height. Nat Genet 46 : 1173-1186, 2014.
PubMed
4) Yang J, et al : Common SNPs explain a large proportion of the heritability for human height. Nat Genet 42 : 565-569, 2010.
PubMed
5) Dauber A, et al : Genome-wide association of copy-number variation reveals an association between short stature and the presence of low-frequency genomic deletions. Am J Hum Genet 89 : 751-759, 2011.
PubMed
6) Rappold G, et al : Genotypes and phenotypes in children with short stature : clinical indicators of SHOX haploinsufficiency. J Med Genet 44 : 306-313, 2007.
PubMed
7) Ranke MB, et al : Spontaneous adult height in idiopathic short stature. Horm Res 44 : 152-157, 1995.
PubMed
8) Rekers-Mombarg LT, et al : Spontaneous growth in idiopathic short stature. European Study Group. Arch Dis Child 75 : 175-180, 1996.
 
9) Ranke MB, et al : Age at growth hormone therapy start and first-year responsiveness to growth hormone are major determinants of height outcome in idiopathic short stature. Horm Res 68 : 53-62, 2007.
PubMed
10) Wit JM, et al : Benefit of postponing normal puberty for improving final height. Eur J Endocrinol 151 (Suppl 1) : S41-45, 2004.
 
11) van Gool SA, et al : Final height outcome after three years of growth hormone and gonadotropin-releasing hormone agonist treatment in short adolescents with relatively early puberty. J Clin Endocrinol Metab 92 : 1402-1408, 2007.
PubMed
12) Wickman S, et al : A specific aromatase inhibitor and potential increase in adult height in boys with delayed puberty : a randomised controlled trial. Lancet 357 : 1743-1748, 2001.
PubMed
13) Ranke MB : Treatment of children and adolescents with idiopathic short stature. Nat Rev Endocrinol 9 : 325-334, 2013.
PubMed
P.472 掲載の参考文献
1) Jones KL, Smith PW : Recognition of the fetal alcohol syndrome in early infancy. Lancet 302 : 999-1001, 1973.
 
2) Roozen S, et al : Worldwide Prevalence of Fetal Alcohol Spectrum Disorders : A Systematic Literature Review Including Meta-Analysis. Alcohol Clin Exp Res 40 : 18-32, 2016.
PubMed
3) Lange S, et al : Global Prevalence of Fetal Alcohol Spectrum Disorder Among Children and Youth : A Systematic Review and Meta-analysis. JAMA Pediatr 171 : 948-956, 2017.
PubMed
4) May PA, et al : Prevalence and characteristics of fetal alcohol spectrum disorders. Pediatrics 134 : 855-866, 2014.
PubMed
5) Centers for Disease Control and Prevention (CDC) : Alcohol use and binge drinking among women of childbearing age-United States, 2006-2010. MMWR Morb Mortal Wkly Rep 61 : 534-538, 2012.
PubMed
6) Jewett A, et al : Alcohol-Impaired Driving Among Adults-United States, 2012. MMWR Morb Mortal Wkly Rep 64 : 814-817, 2015.
PubMed
7) Michikawa T, et al : Baseline Profile of Participants in the Japan Environment and Children's Study (JECS). J Epidemiol 28 : 99-104, 2018.
 
8) Granato A, Dering B : Alcohol and the Developing Brain : Why Neurons Die and How Survivors Change. Int J Mol Sci 19 : 2992, 2018.
 
9) Lussier AA, et al : Prenatal Alcohol Exposure : Profiling Developmental DNA Methylation Patterns in Central and Peripheral Tissues. Front Genet 9 : 610, 2018.
PubMed
10) Caputo C, et al : Impact of fetal alcohol exposure on body systems : A systematic review. Birth Defects Res C Embryo Today 108 : 174-180, 2016.
PubMed
11) Hoyme HE, et al : Updated Clinical Guidelines for Diagnosing Fetal Alcohol Spectrum Disorders. Pediatrics 138 : 2016.
PubMed
12) Denny L, et al : Fetal Alcohol Syndrome and Fetal Alcohol Spectrum Disorders. Am Fam Physician 96 : 515-522, 2017.
PubMed
13) Lange S, et al : A comparison of the prevalence of prenatal alcohol exposure obtained via maternal self-reports versus meconium testing : a systematic literature review and meta-analysis. BMC Pregnancy Childbirth 14 : 127, 2014.
 
14) ACOG Committee Opinion No. 762 : Prepregnancy Counseling. Obstet Gynecol 133 : e78-e89, 2019.
PubMed

XII 性機能低下を伴う遺伝性 ( 先天性 ) 症候群

P.479 掲載の参考文献
1) Pagon RA, et al : Coloboma, congenital heart disease, and choanal atresia with multiple anomalies : CHARGE association. J Pediatr 99 : 223-227, 1981.
PubMed
2) Vissers LE, et al : Mutations in a new member of the chromodomain gene family cause CHARGE syndrome. Nat Genet 36 : 955-957, 2004.
 
3) Issekutz KA, et al : An epidemiological analysis of CHARGE syndrome : preliminary results from a Canadian study. Am J Med Genet A 133A : 309-317, 2005.
PubMed
4) Sanlaville D, et al : Phenotypic spectrum of CHARGE syndrome in fetuses with CHD7 truncating mutations correlates with expression during human development. J Med Genet 43 : 211-217, 2006.
PubMed
5) Janssen N, et al : Mutation update on the CHD7 gene involved in CHARGE syndrome. Hum Mutat 33 : 1149-1160, 2012.
PubMed
6) Blake KD, et al : CHARGE association : an update and review for the primary pediatrician. Clin Pediatr (Phila) 37 : 159-173, 1998.
PubMed
7) Jongmans MC, et al : CHARGE syndrome : the phenotypic spectrum of mutations in the CHD7 gene. J Med Genet 43 : 306-314, 2006.
 
8) Moccia A, et al : Genetic analysis of CHARGE syndrome identifies overlapping molecular biology. Genet Med 20 : 1022-1029, 2018.
PubMed
9) Lalani SR, et al : CHARGE Syndrome, GeneReviews(R) [Internet], University of Washington, Seattle, Initial Posting : October 2, 2006 ; Last Update : February 2, 2012. [https://www.ncbi.nlm.nih.gov/books/NBK1117/] (2019年2月閲覧)
 
10) Amiel J, et al : Temporal bone anomaly proposed as a major criteria for diagnosis of CHARGE syndrome. Am J Med Genet 99 : 124-127, 2001.
 
11) Verloes A : Updated diagnog. tic criteria for CHARGE syndrome : a proposal. Am J Med Genet A 133A : 306-308, 2005.
 
P.483 掲載の参考文献
1) Mueller RF : The Denys-Drash syndrome. J Med Genet 31 : 471-477, 1994.
PubMed
2) Hossain A, Saunders GF : The human sex-determining gene SRY is a direct target of WT1. J Biol Chem 276 : 16817-16823, 2001.
PubMed
3) Hastie ND : Dominant negative mutations in the Wilms tumour (WT1) gene cause Denys-Drash syndrome-proof that a tumour-suppressor gene plays a crucial role in normal genitourinary development. Hum Mol Genet 1 : 293-295, 1992.
 
4) Hutson JM, et al : Malformation syndromes associated with disorders of sex development. Nat Rev Endocrinol 10 : 476-487, 2014.
PubMed
5) Carter S, et al : Renal failure from birth-AKI or CKD? Answers. Pediatr Nephrol 31 : 2259-2262, 2016.
 
6) Lipska BS, et al : Genotype-phenotype associations in WTI glomerulopathy. Kidney Int 85 : 1169-1178, 2014.
 
7) Nso Roca AP, et al : Evolutive study of children with diffuse mesangial sclerosis. Pediatr Nephrol 24 : 1013-1019, 2009.
PubMed
8) Auber F, et al : Management of Wilms tumors in Drash and Frasier syndromes. Pediatr Blood Cancer 52 : 55-59, 2009.
PubMed
9) Aronson DC, et al : Long-term outcome of bilateral Wilms tumors (BWT). Pediatr Blood Cancer 56 : 1110-1113, 2011.
PubMed
10) Coppes MJ : Serum biological markers and paraneoplastic syndromes in Wilms tumor. Med Pediatr Oncol 21 : 213-221, 1993.
PubMed
11) 日本小児内分泌学会 性分化・副腎疾患委員会 : 性分化疾患の診断と治療, 2016.
 
12) Patek CE, et al : Effects on kidney disease, fertility and development in mice inheriting a protein-truncating Denys-Drash syndrome allele (WtltmT396). Transgenic Res 17 : 459-475, 2008.
PubMed
13) Jalanko H : Congenital nephrotic syndrome. Pediatr Nephrol 24 : 2121-2128, 2009.
PubMed
14) Kalish JM, et al : Surveillance Recommendations for Children with Overgrowth Syndromes and Predisposition to Wilms Tumors and Hepatoblastoma. Clin Cancer Res 23 : e115-e122, 2017.
PubMed
P.487 掲載の参考文献
1) Digilio MC, et al : Grouping of multiple-lentigines/LEOPARD and Noonan syndromes on the PTPN11 gene. Am J Hum Genet 71 : 389-394, 2002.
PubMed
2) Seishima M, et al : Malignant melanoma in a woman with LEOPARD syndrome : identification of a germline PTPN11 mutation and a somatic BRAF mutation. Br J Dermatol 157 : 1297-1299, 2007.
 
3) Cheng YP, et al : Scalp melanoma in a woman with LEOPARD syndrome : possible implication of PTPN11 signaling in melanoma pathogenesis. J Am Acad Dermatol 69 : e186-187, 2013.
 
4) Voron DA, et al : Multiple lentigines syndrome. Case report and review of the literature. Am J Med 60 : 447-456, 1976.
PubMed
5) 河内繁雄 : 汎発性黒子症候群 (LEOPARD症候群). 最新皮膚科学大系 8. 色素異常症 (玉置邦彦総編集), p53-54, 中山書店, 2002.
 
6) Motegi S, et al : Pathogenesis of multiple lentigines in LEOPARD syndrome with PTPN11 gene mutation. Acta Derm Venereol 95 : 978-984, 2015.
PubMed
P.491 掲載の参考文献
1) Bokenkamp A, Ludwig M : The oculocerebrorenal syndrome of Lowe : an update. Pediatr Nephrol 31 : 2201-2212, 2016.
PubMed
2) Lowe CU, et al : Organic-aciduria, decreased renal ammonia production, hydrophthalmos, and mental retardation ; a clinical entity. AMA Am J Dis Child 83 : 164-184, 1952.
PubMed
3) Attree O, et al : The Lowe's oculocerebrorenal syndrome gene encodes a protein highly homologous to inositol polyphosphate-5-phosphatase. Nature 358 : 239-242, 1992.
 
4) Hoopes RR, et al : Dent Disease with mutations in OCRL1. Am J Hum Genet 76 : 260-267, 2005.
PubMed
5) Hichri H, et al : From Lowe syndrome to Dent disease : correlations between mutations of the OCRL1 gene and clinical and biochemical phenotypes. Hum Mutat 32 : 379-388, 2011.
PubMed
6) Bokenkamp A, et al : Dent-2 disease : a mild variant of Lowe syndrome. J Pediatr 155 : 94-99, 2009.
PubMed
7) Mehta ZB, et al : The cellular and physiological functions of the Lowe syndrome protein OCRL1. Traffic 15 : 471-487, 2014.
PubMed
8) Mukherjee D, et al : RhoGTPase-binding proteins, the exocyst complex and polarized vesicle trafficking. Small GTPases 5 : e28453, 2014.
PubMed
9) Vicinanza M, et al : OCRL controls trafficking through early endosomes via PtdIns4,5P2- dependent regulation of endosomal actin. EMBO J 30 : 4970-4985, 2011.
PubMed
10) Kruger SJ, et al : Cataracts and glaucoma in patients with oculocerebrorenal syndrome. Arch Ophthalmol 121 : 1234-1237, 2003.
PubMed
11) Kenworthy L, et al : Cognitive and behavioral profile of the oculocerebrorenal syndrome of Lowe. Am J Med Genet 46 : 297-303, 1993.
PubMed
12) Bockenhauer D, et al : Renal phenotype in Lowe Syndrome : a selective proximal tubular dysfunction. Clin J Am Soc Nephrol 3 : 1430-1436, 2008.
PubMed
13) GUnther W, et al : The ClC-5 chloride channel knock-out mouse-an animal model for Dent's disease. Pflugers Arch 445 : 456-462, 2003.
PubMed
14) Zaniew M, et al : Long-term renal outcome in children with OCRL mutations : retrospective analysis of a large international cohort. Nephrol Dial Transplant 33 : 85-94, 2018.
PubMed
15) 三浦健一郎 : 尿細管性蛋白尿を呈する遺伝性疾患の全国調査. 厚生労働科学研究費補助全難治性疾患政策研究事業, 平成28年度総括・分担研究報告書, 2016.
 
16) Ruellas AC, et al : Orthodontic treatment of a patient with Lowe syndrome. Am J Orthod Dentofacial Orthop 140 : 562-568, 2011.
PubMed
P.495 掲載の参考文献
1) Handley MT, et al : Mutation spectrum in RAB3GAP1, RAB3GAP2, and RAB18 and genotype-phenotype correlations in warburg micro syndrome and Martsolf syndrome. Hum Mutat 34 : 686-696, 2013.
PubMed
2) Martsolf JT, et al : Severe mental retardation, cataracts, short stature, and primary hypogonadism in two brothers. Am J Med Genet 1 : 291-299, 1978.
 
3) Handley M, Sheridan E : RABI8 Deficiency. GeneReviews(R) [Internet], University of Washingtont Seattle, Initial Posting : January 4, 2018. [https://www.ncbi.nlm.nih.gov/books/NBK475670/] (2019年2月閲覧)
 
4) Martsolf syndrome. MedGen UID : 208658・Concept ID : C0796037 [https://www.ncbi.nlm.nih.gov/medgen/C0796037] (2019年2月閲覧)
 
5) Sanchez JM, et al : Two brothers with Martsolfs syndrome. J Med Genet 22 : 308-310, 1985.
PubMed
6) Strisciuglio P, et al : Martsolfs syndrome in a non-Jewish boy. J Med Genet 25 : 267-269, 1988.
 
7) Hennekam RC, et al : Martsolf syndrome in a brother and sister : clinical features and pattern of inheritance. Eur J Pediatr 147 : 539-543, 1988.
 
8) Harbord MG, et al : Microcephaly, mental retardation, cataracts, and hypogonadism in sibs : Martsolfs syndrome. J Med Genet 26 : 397-400, 1989.
PubMed
9) Aligianis IA, et al : Mutation in Rab3 GTPase-activating protein (RAB3GAP) noncatalytic subunit in a kindred with Martsolf syndrome. Am J Hum Genet 78 : 702-707, 2006.
 
10) Ehara H, et al : Martsolf syndrome in Japanese siblings. Am J Med Genet A 143A : 973-978, 2007.
PubMed
11) Bora E, et al : A new case of Martsolf syndrome. Genet Couns 18 : 71-75, 2007.
PubMed
12) 福田光則 : Rabファミリーと細胞内小胞輸送. 生体の科学 59 : 360-361, 2008.
 
13) Gumus E : Case report of four siblings in southeast Turkey with a novel RAB3GAP2 splice site mutation : Warburg micro syndrome or Martsolf syndrome? Ophthalmic Genet 39 : 391-395, 2018.
PubMed
14) 琉球大学遺伝性疾患データベース. [http://becomerich.lab.u-ryukyu.ac.jp/] (2019年2月閲覧)
 
P.499 掲載の参考文献
1) Larizza L, et al : Rothmund-Thomson syndrome. Orphanet J Rare Dis 5 : 2, 2010.
PubMed
2) Wang LL, Plon SE : Rothmund-Thomson syndrome. GeneReviews(R) [Internet], Initial Posting : October 6, 1999 ; Last Update : January 3, 2019. [https://www.ncbi.nlm.nih.gov/books/NBK1237/] (2019年2月閲覧)
 
3) 早老症の実態把握と予後改善を目指す集学的研究班 : ロスムンド・トムソン症候群 (指定難病 186). [http://www.nanbyou.or.jp/entry/4472] (2019年2月閲覧)
 
4) Rothmund A : Uber Cataracte in Verbindung mit einer eigenthuemlichen Hautdegeneration. Albrecht von Graefes Arch Klin Exp Ophthal 14 : 159-182, 1868.
 
5) Thomson MS : Poikiloderma congenitale. Br J Dermatol 48 : 221-234, 1936.
 
6) Taylor WB : Rothmund's syndrome ; Thomson's syndrome ; congenital poikiloderma with or without juvenile cataracts. AMA Arch Derm 75 : 236-244, 1957.
PubMed
7) 関政幸, ほか : BLM (RECQ2), WRN (RECQ3), RTS (RECQ4). 日本臨牀 73 (増刊 : 家族性腫瘍学) : 276-280, 2015.
 
8) Mann MB, et al : Defective sister-chromatid cohesion, aneuploidy and cancer predisposition in a mouse model of type II Rothmund-Thomson syndrome. Hum Mol Genet 14 : 813-825, 2005.
 
9) Kitao S, et al : Mutations in RECQL4 cause a subset of cases of Rothmund-Thomson syndrome. Nat Genet 22 : 82-84, 1999.
 
P.503 掲載の参考文献
1) Rud E : Et Tilfaelde af Infantilisme med Tetani. Epilepsi, Polyneuritis, Ichthyosis og Anaemi of pernicios Type. Hospitalstidende 70 : 525-538, 1927.
 
2) Rud E : Et tilfaelde af hypogenitalisme (eunuchoidismus feminus) med pertiel gigantisme og ichthyosis. Hospitalstidende 72 : 426-433, 1929.
 
3) Van Bogaert L : Les dysplasies neuroectodermiques congenitales. Rev Neurol 63 : 353-398, 1935.
 
4) Stewart RM : Congenital ichthyosis, idiocy, infantilism and epilepsy : the syndrome of Rud. J Ment Sci 85 : 256-263, 1939.
 
5) Munke M, et al : Genetic heterogeneity of the ichthyosis, hypogonadism, mental retardation, and epilepsy syndrome. Clinical and biochemical investigations on two patients with Rud syndrome and review of the literature. Eur J Pediatr 141 : 8-13, 1983.
PubMed
6) Fraser N, et al : Identification of incomplete coding sequences for steroid sulphatase on the human Y chromosome : evidence for an ancestral pseudoautosomal gene? Development 101 (Suppl) : 127-132, 1987.
 
7) Traupe H, et al : Steroid sulfatase (STS) testing in the Rud syndrome reveals two different types. J Invest Dermatol 76 : 429, 1981.
 
8) Marxmiller J, et al : Rud syndrome revisited : ichthyosis, mental retardation, epilepsy and hypogonadism. Dev Med Child Neurol 27 : 335-343, 1985.
PubMed
9) York-Moore ME, Rundle AT : Rud's syndrome. J Ment Defic Res 6 : 108-118, 1962.
 
10) Traupe H : Ichthyosis and hypogonadism : reflections on the so-called Rud's syndrome. In : The Ichthyoses : AGuide to Clinical Diagnosis, Genetic Counseling, and Therapy (ed by Traupe H, Melnik B), p91-97, Springer-Verlag, Berlin, 1989.
 
11) Kaufman LM : Asyndrome of retinitis pigmentosa, congenital ichthyosis, hypergonadotropic hypogonadism, small stature, mental retardation, cranial dysmorphism, and abnormal electroencephalogram. Ophthalmic Genet 19 : 69-79, 1998.
 
12) Oji V, et al : Revised nomenclature and classification of inherited ichthyoses : Results of the First Ichthyosis Consensus Conference in Soreze 2009. J Am Acad Dermatol 63 : 607-641, 2010.
PubMed
13) Happle R : Rud syndrome does not exist. Eur J Dermatol 22 : 7, 2012.
 
14) Marconi S, et al : Rud syndrome with focal cortical dysplasia : a case report. Brain Dev 33 : 683-686, 2011.
PubMed
15) Pavani K, et al : Rud's syndrome. Indian Dermatol Online J 5 : 173-175, 2014.
PubMed
P.507 掲載の参考文献
1) Smith DW, et al : A Newly Recognized Syndrome of Multiple Congenital Anomalies. J Pediatr 64 : 210-217, 1964.
PubMed
2) Kelley RI, Hennekamb RC : The Smith-Lemli-Opitz syndrome. J Med Genet 37 : 321-335, 2000.
 
3) Moebius FF, et al : Molecular cloning and expression of the human delta7-sterol reductase. Proc Natl Acad Sci USA 95 : 1899-1902, 1998.
PubMed
4) Nanni L, et al : The mutational spectrum of the sonic hedgehog gene in holoprosencephaly : SHH mutations cause a significant proportion of autosomal dominant holoprosencephaly. Hum Mol Genet 8 : 2479-2488, 1999.
 
5) Waterham HR, Hennekamb RC : Mutational spectrum of Smith-Lemli-Opitz syndrome. Am J Med Genet C Semin Med Genet 160C : 263-284, 2012.
 
6) Matsumoto Y, et al : R352Q mutation of the DHCR7 gene is common among Japanese Smith-Lemli-Opitz syndrome patients. J Hum Genet 50 : 353-356, 2005.
PubMed
7) 松崎秀夫 : 自閉症の脂質代謝. 分子精神医学 14 : 99-103, 2014.
Medical*Online
8) Jayamanne C, et al : Smith-Lemli-Opitz syndrome presenting as acute adrenal crisis in a child : a case report. J Med Case Rep 12 : 217, 2018.
 
9) 松本浩, ほか : Smith-Lemli-Opitz症候群 ; 性機能低下を伴う遺伝性 (先天性) 症候群. 別冊日本臨牀新領域別症候群シリーズ No. 3 内分泌症候群 (第2版) III, p488-491, 日本臨牀社, 2006.
 
10) Porter FD : Smith-Lemli-Opitz syndrome : pathogenesis, diagnosis and management. Eur J Hum Genet 16 : 535-541, 2008.
PubMed
11) Nittono H, et al : Diagnostic determination system for high-risk screening for inborn errors of bile acid metabolism based on an analysis of urinary bile acids using gas chromatography-mass spectrometry : results for 10 years in Japan. Pediatr Int 51 : 535-543, 2009.
 
12) 積田綾子, ほか : 乳児期・早期より卵黄レシチン投与を行ったSmith-Lemli-Opitz症候群の1例. 日本小児栄養消化器肝臓学会雑誌 28 : 17-21, 2014.
Medical*Online
13) Irons M, et al : Treatment of Smith-Lemli-Opitz syndrome : results of a multicenter trial. Am J Med Genet 68 : 311-314, 1997.
PubMed
14) Svoboda MD, et al : Treatment of Smith-Lemli-Opitz syndrome and other sterol disorders. Am J Med Genet C Semin Med Genet 160C : 285-294, 2012.
PubMed
15) DeBarber AE, et al : Smith-Lemli-Opitz syndrome. Expert Rev Mol Med 13 : e24, 2011.
PubMed
P.509 掲載の参考文献
1) Sohval AR, Soffer LJ : Congenital familial testicular deficiency. Am J Med 14 : 328-348, 1953.
PubMed
2) 菅野潤子, ほか : Sohval-Soffer症候群 ; 性機能低下を伴う遺伝性 (先天性) 症候群. 別冊日本臨牀新領域別症候群シリーズ No. 3 内分泌症候群 (第2版) III, p492-493, 日本臨牀社, 2006.
 
P.512 掲載の参考文献
1) France JT, Liggins GC : Placental sulfatase deficiency. J Clin Endocrinol Metab 29 : 138-141, 1969.
PubMed
2) Webster D, et al : X-linked ichthyosis due to steroid-sulphatase deficiency. Lancet i : 70-72, 1978.
PubMed
3) Taylor NF : Review : placental sulphatase deficiency. J Inherit Metab Dis 5 : 164-176, 1982.
PubMed
4) Hernandez-Martin A, et al : X-linked ichthyosis : an update. Br J Dermatol 141 : 617-627, 1999.
PubMed
5) Fernandes NF, et al : X-linked ichthyosis : an oculocutaneous genodermatosis. J Am Acad Dermatol 62 : 480-485, 2010.
PubMed
6) Craig WY, et al : Prevalence of steroid sulfatase deficiency in California according to race and ethnicity. Prenat Diagn 30 : 893-898, 2010.
PubMed
7) Kashork CD, et al : Low or absent unconjugated estriol in pregnancy : an indicator for steroid sulfatase deficiency detectable by fluorescence in situ hybridization and biochemical analysis. Prenat Diagn 22 : 1028-1032, 2002.
 
8) Reed MJ, et al : Steroid sulfatase : molecular biology, regulation, and inhibition. Endocr Rev 26 : 171-202, 2005.
PubMed
9) Marcos J, et al : Maternal urine and serum steroid measurements to identify steroid sulfatase deficiency (STSD) in second trimester pregnancies. Prenat Diagn 29 : 771-780, 2009.
PubMed
10) Diociaiuti A, et al : X-linked ichthyosis : Clinical and molecular findings in 35 Italian patients. Exp Dermatol, 2018. [Epub ahead of print] (doi : 10.1111/exd.13667)
 
11) Idkowiak J, et al : Steroid Sulfatase Deficiency and Androgen Activation Before and After Puberty. J Clin Endocrinol Metab 101 : 2545-2553, 2016.
PubMed
12) Kent L, et al : X-linked ichthyosis (steroid sulfatase deficiency) is associated with increased risk of attention deficit hyperactivity disorder, autism and social communication deficits. J Med Genet 45 : 519-524, 2008.
PubMed
P.516 掲載の参考文献
1) Narumi S, et al : SAMD9 mutations cause a novel multisystem disorder, MIRAGE syndrome, and are associated with loss of chromosome 7. Nat Genet 48 : 792-797, 2016.
 
2) Buonocore F, et al : Somatic mutations and progressive monosomy modify SAMD9-related phenotypes in humans. J Clin Invest 127 : 1700-1713, 2017.
PubMed
3) Bluteau O, et al : A landscape of germ line mutations in a cohort of inherited bone marrow failure patients. Blood 131 : 717-732, 2018.
 
4) Jeffries L, et al : A novel SAMD9 mutation causing MIRAGE syndrome : An expansion and review of phenotype, dysmorphology, and natural history. Am J Med Genet A 176 : 415-420, 2018.
 
5) Kim YM, et al : A case of an infant suspected as IMAGE syndrome who were finally diagnosed with MIRAGE syndrome by targeted Mendelian exome sequencing. BMC Med Genet 19 : 35, 2018.
 
6) Wilson DB, et al : Comment on : Acquired monosomy 7 myelodysplastic syndrome in a child with clinical features of dyskeratosis congenita and IMAGe association. Pediatr Blood Cancer 65, 2018. (doi : 10.1002/pbc.26747)
 
7) Shima H, et al : Two patients with MIRAGE syndrome lacking haematological features : role of somatic second-site reversion SAMD9 mutations. J Med Genet 55 : 81-85, 2018.
PubMed
8) Shima H, et al : MIRAGE syndrome is a rare cause of 46, XY DSD born SGA without adrenal insufficiency. PLoS One : 13 : e0206184, 2018.
PubMed
9) Csillag B, et al : Somatic mosaic monosomy 7 and UPD7q in a child with MIRAGE syndrome caused by a novel SAMD9 mutation. Pediatr Blood Cancer, e27589, 2018. [Epub ahead of print]
 
10) 鳴海覚志, 長谷川奉延 : MIRAGE症候群. 周産期医学 48 : 1526-1530, 2018. [Epub ahead of print]
 

XIII 内分泌性高血圧

P.523 掲載の参考文献
1) Lenders JW, et al : Phaeochromocytoma. Lancet 366 : 665-675, 2005.
PubMed
2) 名和田新, ほか : 副腎ホルモン産生異常症. 厚生省特定疾患ホルモン受容機構異常分科会総括研究事業報告書, p11-55, 1999.
 
3) Colao A, et al : Systemic complications of acromegaly : epidemiology, pathogenesis, and management. Endocr Rev 25 : 102-152, 2004.
PubMed
4) Saito I, et al : The effect of age on blood pressure in hyperthyroidism. J Am Geriatr Soc 33 : 19-22, 1985.
 
5) Fletcher AK, et al : Hypertension and hypothyroidism. J Hum Hypertens 12 : 79-82, 1998.
PubMed
6) Saito I, et al : Hypothyroidism as a cause of hypertension. Hypertension 5 : 112-115, 1983.
PubMed
7) Diamond TW, et al : Parathyroid hypertension. A reversible disorder. Arch Intern Med 146 : 1709-1712, 1986.
PubMed
8) Pepe J, et al : Cardiovascular manifestations of primary hyperparathyroidism : a narrative review. Eur J Endocrinol 177 : R297-R308, 2017.
PubMed
9) Sato A, et al : Glucocorticoid increases angiotensin II type 1 receptor and its gene expression. Hypertension 23 : 25-30, 1994.
PubMed
10) Stewart PM, et al : 11 beta-Hydroxysteroid dehydrogenase activity in Cushing's syndrome : explaining the mineralocorticoid excess state of the ectopic adrenocorticotropin syndrome. J Clin Endocrinol Metab 80 : 3617-3620, 1995.
PubMed
11) Ojamaa K, et al : Acute effects of thyroid hormone on vascular smooth muscle. Thyroid 6 : 505-512, 1996.
PubMed
12) Ellison DH, et al : Effects of calcium infusion on blood pressure in hypertensive and normotensive humans. Hypertension 8 : 497-505, 1986.
PubMed
13) Wetzel J, et al : Plasma parathyroid hormone and cardiovascular disease in treatment-naive patients with primary hyperparathyroidism : The EPATH trial. J Clin Hypertens (Greenwich) 19 : 1173-1180, 2017.
 
14) Hulter HN, et al : Chronic continuous PTH infusion results in hypertension in normal subjects. J Clin Hypertens 2 : 360-370, 1986.
PubMed
15) Benham JL, et al : Proportion of patients with hypertension resolution following adrenalectomy for primary aldosteronism : a systematic review and meta-analysis. J Clin Hypertens (Greenwich) 18 : 1205-1212, 2016.
PubMed
P.528 掲載の参考文献
1) Crane MG : Iatrogenic Hypertension. In : Hypertension : Pathophysiology, Diagnosis, and Management (ed by Laragh JH, Brenner BM), p976-988, Raven Press, New York, 1990.
 
2) Woods JW : Oral contraceptives and hypertension. Lancet 2 : 653, 1967.
PubMed
3) Nabulsi AA, et al : Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities Study Investigators. N Engl J Med 328 : 1069-1075, 1993.
 
4) Stampfer MJ, et al : Past use of oral contraceptives and cardiovascular disease : a meta-analysis in the context of the Nurses' Health Study. Am J Obstet Gynecol 163 : 285-291, 1990.
PubMed
5) Chasan-Taber L, et al : Prospective study of oral contraceptives and hypertension among women in the United States. Circulation 94 : 483-489, 1996.
PubMed
6) Du Y, et al : Use of oral contraceptives in Germany : prevalence, determinants and useassociated health correlates. Results of National Health Surveys from 1984 to 1999. Eur J Obstet Gynecol Reprod Biol 134 : 57-66, 2007.
PubMed
7) Johnson JA, et al : Effects of estradiol on sodium and potassium balances in adrenalectomized dogs. Am J Physiol 223 : 194-197, 1972.
PubMed
8) Kaplan's Clinical Hypertension, 9th ed (ed by Kaplan NM), p424, Lippincott Williams and Wilkins, Philadelphia, 2005.
 
9) Woods JW : Oral contraceptives and hypertension. Hypertension 11 (3 Pt 2) : II11-5, 1988.
 
10) Tanis BC, et al : Oral contraceptives and the risk of myocardial infarction. N Engl J Med 345 : 1787-1793, 2001.
PubMed
11) 日本産科婦人科学会 (編) : 低用量経口避妊薬の使用に関するガイドライン (改訂版). 日本産科婦人科学会雑誌 58 : 894-962, 2006.
 
12) 日本産科婦人科学会 (編) : 低用量経口避妊薬, 低用量エストロゲン・プロゲストーゲン配合剤ガイドライン (案), 2015.
 
13) Grant EC, Robinson J : The R. C. G. P. oral contraception study. Lancet 1 : 1206-1207, 1981.
 
P.534 掲載の参考文献
1) 斉藤滋 : 妊娠高血圧症候群の定義分類変更. 第70回日本産科婦人科学会学術講演会, p433-434, 2018.
 
2) Redman CW, Sargent IL : Latest advances in understanding preeclampsia. Science 308 : 1592-1594, 2005.
PubMed
3) Chapman AB, et al : Temporal relationships between hormonal and hemodynamic changes in early human pregnancy. Kidney Int 54 : 2056-2063, 1998.
PubMed
4) Zeeman GG, et al : The magnitude of hemoconcentration with eclampsia. Hypertens Pregnancy 28 : 127-137, 2009.
PubMed
5) Maynard SE, et al : Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 111 : 649-658, 2003.
PubMed
6) Venkatesha S, et al : Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 12 : 642-649, 2006.
 
7) Weir RJ, et al : Plasma renin, renin substrate, angiotensin II, and aldosterone in hypertensive disease of pregnancy. Lancet 1 : 291-294, 1973.
PubMed
8) Karlberg BE, et al : Changes in the renin-angiotensin-aldosterone and kallikrein-kinin systems during normal and hypertensive pregnancy. Acta Obstet Gynecol Scand Suppl 118 : 17-24, 1984.
PubMed
9) Malha L, et al : Renin-Angiotensin-Aldosterone Profiles in Pregnant Women With Chronic Hypertension. Hypertension 72 : 417-424, 2018.
PubMed
10) Walsh SW : Preeclampsia : an imbalance in placental prostacyclin and thromboxane production. Am J Obstet Gynecol 152 : 335-340, 1985.
PubMed
11) Carreras LO, et al : Prostacyclin and pre-eclampsia. Lancet 1 : 442, 1981.
PubMed
12) Kamoi K, et al : Plasma endothelin-1 levels in patients with pregnancy-induced hypertension. N Engl J Med 323 : 1486-1487, 1990.
PubMed
13) Borghi C, et al : Relationship of systemic hemodynamics, left ventricular structure and function, and plasma natriuretic peptide concentrations during pregnancy complicated by preeclampsia. Am J Obstet Gynecol 183 : 140-147, 2000.
PubMed
14) Narita T, et al : Placental (pro) renin receptor expression and plasma soluble (pro) renin receptor levels in preeclampsia. Placenta 37 : 72-78, 2016.
PubMed
15) Tatemoto K, et al : Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun 251 : 471-476, 1998.
PubMed
16) Kalkunte SS, et al : Transthyretin is dysregulated in preeclampsia, and its native form prevents the onset of disease in a preclinical mouse model. Am J Pathol 183 : 1425-1436, 2013.
 
17) Xia Y, et al : Potential roles of angiotensin receptor-activating autoantibody in the pathophysiology of preeclampsia. Hypertension 50 : 269-275, 2007.
PubMed
18) 日本妊娠高血圧学会 (編) : 管理の基礎妊娠高血圧症候群 (PIH) 管理ガイドライン 2009, p44, メジカルビュー社, 2009.
 
P.538 掲載の参考文献
1) Maschio G : "Erythropoietin and systemic hypertension, Nephrol Dial Transplant 10 (Suppl 2) : 74-79, 1995.
 
2) Novak BL, et al : Erythropoietin-induced hypertensive urgency in a patient with chronic renal insufficiency : case report and review of the literature. Pharmacotherapy 23 : 265-269, 2003.
 
3) Eschbach JW, et al : Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med 111 : 992-1000, 1989.
PubMed
4) 草野英二, 秋元哲 : エリスロポエチン使用と高血圧透析療法における血液学的問題点. 臨牀透析 14 : 1139-1148, 1998.
 
5) 医薬品インタビューフォーム 持続型赤血球造血刺激因子製剤 ネスプ(R) 注射薬, キリンファーマ株式会社, 2018.
 
6) 医薬品インタビューフォーム 持続型赤血球造血刺激因子製剤 ミルセラ(R) 注シリンジ, 中外製薬株式会社, 2018.
 
7) Agarwal R : Mechanisms and mediators of hypertension induced by erythropoietin and related molecules. Nephrol Dial Transplant 33 : 1690-1698, 2018.
PubMed
8) Boyle SM, Berns JS : Erythropoietin and resistant hypertension in CKD. Semin Nephrol 34 : 540-549, 2014.
PubMed
9) Vaziri ND : Cardiovascular effects of erythropoietin and anemia correction. Curr Opin Nephrol Hypertens 10 : 633-637, 2001.
PubMed
10) KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney International Supplements, Vol 2, Issue 4, p288-335, 2012.
 
11) Phrommintikul A, et al : Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin : a meta-analysis. Lancet 369 : 381-388, 2007.
PubMed
12) Flamme I, et al : Mimicking Hypoxia to Treat Anemia : HIF-Stabilizer BAY 85-3934 (Molidustat) Stimulates Erythropoietin Production without Hypertensive Effects. PLoS One 9 : e111838, 2014.
PubMed
13) Chen N, et al : Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG4592 for treatment of anemia in China. Nephrol Dial Transplant 32 : 1373-1386, 2017.
PubMed
P.541 掲載の参考文献
1) Robertson PW, et al : Hypertension due to a renin-secreting renal tumour. Am J Med 43 : 963-976, 1967.
PubMed
2) Steffens J, et al : Renin-producing renal cell carcinomas-clinical and experimental investigations on a special form of renal hypertension. Urol Res 20 : 111-115, 1992.
PubMed
3) Kurt B, et al : Deletion of von Hippel-Lindau protein converts renin-producing cells into erythropoietin-producing cells. J Am Soc Nephrol 24 : 433-444, 2013.
 
4) Martini AG, et al : Transcriptome Analysis of Human Reninomas as an Approach to Understanding Juxtaglomerular Cell Biology. Hypertension 69 : 1145-1155, 2017.
PubMed
5) Oei L. et al : Reninoma : A Rare Cause of Curable Hypertension and Hypokalemia. Am J Med 129 : e131-132, 2016.
PubMed
6) Chao CT, Wu VC : Aliskiren for reninoma. Nephrology (Carlton) 17 : 308-309, 2012.
PubMed
7) Diker-Cohen T, et al : Reninoma presenting in pregnancy. J Clin Endocrinol Metab 99 : 2625-2626, 2014.
PubMed
8) Paragliola RM, et al : A rare case of juvenile hypertension : coexistence of type 2 multiple endocrine neoplasia-related bilateral pheochromocytoma and reninoma in a young patient with ACE gene polymorphism. BMC Endocr Disord 15 : 30, 2015.
 
9) Wong L, et al : Reninoma : case report and literature review. J Hypertens 26 : 368-373, 2008.
PubMed
10) Wolley M, et al : Reninoma : the importance of renal vein renin ratios for lateralisation and diagnosis. Am J Nephrol 39 : 16-19, 2014.
PubMed
11) Torricelli FC, et al : Nephron-sparing surgery for treatment of reninoma : a rare renin secreting tumor causing secondary hypertension. Int Braz J Urol 41 : 172-176. 2015.
PubMed
12) Kim MJ, et al : Reninoma Masked by the Use of an Angiotensin Receptor Blocker. Iran J Kidney Dis 10 : 413-415, 2016.
PubMed
13) Maiolino G, et al : Cure With Cryoablation of Arterial Hypertension Due to a Renin-Producing Tumor. Am J Hypertens 31 : 537-540, 2018.
PubMed
14) Gil NS, et al : Anesthetic management for percutaneous computed tomography-guided radiofrequency ablation of reninoma : a case report. Korean J Anesthesiol 68 : 78-82, 2015.
PubMed
15) Shera AH, et al : Recurrent malignant juxtaglomerular cell tumor : Arare cause of malignant hypertension in a child. J Indian Assoc Pediatr Surg 16 : 152-154, 2011.
 
P.546 掲載の参考文献
1) 日本内分泌学会 (編) : わが国の原発性アルドステロン症の診療に関するコンセンサス・ステートメント, 診断と治療社, 2016.
 
2) Korah HE, Scholl UI : An Update on Familial Hyperaldosteronism. Horm Metab Res 47 : 941-946, 2015.
PubMed
3) Ferrari P : The role of 11β-hydroxysteroid dehydrogenase type 2 in human hypertension. Biochim Biophys Acta 1802 : 1178-1187, 2010.
 
4) 柳瀬敏彦 : 内科学書 [改訂第8版] (小川聡, ほか編), p176-185, 中山書店, 2013.
 
5) Yanase T, et al : 17 alpha-hydroxylase/17, 20-lyase deficiency : from clinical investigation to molecular definition. Endocr Rev 12 : 91-108, 1991.
PubMed
6) Taniyama M, et al : Subtle 17alpha-hydroxylase/17, 20-lyase deficiency with homozygous Y201N mutation in an infertile woman. J Clin Endocrinol Metab 90 : 2508-2511, 2005.
 
7) Wilkins L, et al : Treatment of congenital adrenal hyperplasia with cortisone. J Clin Endocrinol Metab 11 : 1-25, 1951.
PubMed
8) 柴田洋孝 : コルチコステロン産生腫瘍 ; 副腎. アルドステロン異常症. 原発性アルドステロン症および類縁疾患. 別冊日本臨牀新領域別症候群シリーズ No. 1 内分泌症候群 (第2版) I, p638-640, 日本臨牀社, 2006.
 
9) 柴田洋孝 : デオキシコルチコステロン産生腫瘍 ; 副腎. アルドステロン, 異常症. 原発性アルドステロン症および類縁疾患. 別冊日本臨牀新領域別症候群シリーズ No. 1 内分泌症候群 (第2版) I, p641-644, 日本臨牀社, 2006.
 
10) Charmandari E, et al : Primary generalized familial and sporadic glucocorticoid resistance (Chrousos syndrome) and hypersensitivity. Endocr Dev 24 : 67-85, 2013.
PubMed
11) Snyder PM, et al : Mechanism by which Liddle's syndrome mutations increase activity of a human epithelial Na+channel. Cell 83 : 969-978, 1995.
PubMed
12) Boyden LM, et al : Mutations in kelch-like 3 and cullin 3 cause hypertension and electrolyte abnormalities. Nature 482 : 98-102, 2012.
PubMed

XIV 電解質異常を伴う内分泌疾患

P.556 掲載の参考文献
1) Kardalas E, et al : Hypokalemia : a clinical update. Endocr Connect 7 : R35-R146, 2018.
 
2) 柴垣有吾 : より理解を深める! 体液電解質異常と輸液 (改訂3版), p88-93, 中外医学社, 2007.
 
3) 木村秀樹 : 電解質, 酸塩基平衡検査を苦手にしない カリウムの読み方. 臨床検査 58 : 793-800, 2014.
 
4) 戸田晶子, 山門実 : 電解質異常の診断の進め方-Na, K, Cl. Mebio 28 : 20-26, 2011.
Medical*Online
5) Calhoun DA : Hyperaldosteronism as a common cause of resistant hypertension. Annu Rev Med 64 : 233-247, 2013.
PubMed
P.562 掲載の参考文献
1) Ishikawa S : Is exaggerated release of arginine vasopressin an endocrine disorder? Pathophysiology and treatment. J Clin Med 6. pii : E102, 2017.
 
2) Saito T, et al : Role of aquaporin-2 gene expression in hyponatremic rats with chronic vasopressin-induced antidiuresis. Kidney Int 60 : 1266-1276, 2001.
PubMed
3) Saito T, et al : Hypotonicity reduces the activity of murine aquaporin-2 promoter induced by dibutyryl cAMP. Exp Physiol 93 : 1147-1156, 2008.
PubMed
4) Feldman BJ, et al : Nephrogenic syndrome of inappropriate antidiuresis. N Engl J Med 352 : 1884-1890, 2005.
PubMed
5) Asano T, et al : Hyponatremia is the valuable manifestation for initiating diagnosis of hypopituitarism in elderly. Endocr J 59 : 1015-1020, 2012.
PubMed
6) Saito T, et al : Vasopressin-dependent upregulation of aquaporin-2 gene expression in glucocorticoid-deficient rats. Am J Physiol Renal Physiol 279 : F502-F508, 2000.
PubMed
7) Ishikawa S, et al : Close association of urinary excretion of aquaporin-2 with appropriate and inappropriate arginine vasopressin-dependent antidiuresis in hyponatremia in elderly subjects. J Clin Endocrinol Metab 86 : 1665-1671, 2001.
 
8) Avioli LV, et al : Chronic and sustained hypernatremia, absence of thirst, diabetes insipidus, and adrenocorticotrophin insufficiency resulting from widespread destruction of the hypothalamus. Ann Intern Med 56 : 131-140, 1962.
PubMed
9) Hayashi T, et al : Pathogenesis of chronic hypernatremia with dehydrated and non-dehydrated states in hypothalamic space-occupying lesions. Endocr J 55 : 651-655, 2008.
PubMed
10) Fujiwara TM, Bichet BG : Molecular biology of hereditary diabetes insipidus. J Am Soc Nephrol 16 : 2836-2846, 2005.
 
P.569 掲載の参考文献
1) Ward LM, et al : Disorders of calcium, phosphate, and bone metabolism. In : Pediatric Endocrinology and Inborn Errors of Metabolism, 2nd ed (ed by Sarafoglou K, et al), p799-874, McGraw Hill, New York, 2017.
 
2) Shoback DM, et al : Metabolic Bone Disease. In : Greenspan's Basic & Clinical Endocrinology 10th ed (ed by Gardner DG, Shoback DM), p239-297, McGraw Hill, New York, NY, 2018.
 
3) Bilezikian JP : Approach to Parathyroid Disorders. In : Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 9th ed (ed by Bilezikian JP), p613-618, Wiley-Blackwell, Hoboken, 2019.
 
4) Shoback DM, et al : Presentation of Hypoparathyroidism : Etiologies and Clinical Features. J Clin Endocrinol Metab 101 : 2300-2312, 2016.
PubMed
5) Schafer AL, Shoback DM : Hypocalcemia : Definition, Etiology, Pathogenesis, Diagnosis, and Management. In : Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 9th ed (ed by Bilezikian JP), p646-653, Wiley-Blackwell, Hoboken, 2019.
 
6) Clarke BL, et al : Epidemiology and Diagnosis of Hypoparathyroidism. J Clin Endocrinol Metab 101 : 2284-2299, 2016.
PubMed
7) Mantovani G, et al : Diagnosis and management of pseudohypoparathyroidism and related disorders : first international Consensus Statement. Nat Rev Endocrinol 14 : 476-500, 2018.
PubMed
8) Endo Y, et al : Dominant mutations in ORAI1 cause tubular aggregate myopathy with hypocalcemia via constitutive activation of store-operated Ca2+ channels. Hum Mol Genet 24 : 637-648, 2015.
PubMed
9) Randall V, et al : Great vessel development requires biallelic expression of Chd7 and Tbx1 in pharyngeal ectoderm in mice. J Clin Invest 119 : 3301-3310, 2009.
PubMed
10) Roizen JD, et al : CYP3A4 mutation causes vitamin D-dependent rickets type 3. J Clin Invest 128 : 1913-1918, 2018.
 
11) Brandi ML, et al : Management of Hypoparathyroidism : Summary Statement and Guidelines. J Clin Endocrinol Metab 101 : 2273-2283, 2016.
PubMed
12) Stokes VJ, et al : Hypercalcemic Disorders in Children. J Bone Miner Res 32 : 2157-2170, 2017.
 
13) Silverberg SJ, et al : Primary Hyperparathyroidism. In : Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 9th ed (ed by Bilezikian JP), p619-628, Wiley-Blackwell, Hoboken, 2019.
 
14) Arnold A, et al : Familial States of Primary Hyperparathyroidism. In : Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 9th ed (ed by Bilezikian JP), p629-638, Wiley-Blackwell, Hoboken, 2019.
 
15) Horwitz MJ : Non-Parathyroid Hypercalcemia. In : Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 9th ed (ed by Bilezikian JP), p639-645, Wiley-Blackwell, Hoboken, 2019.
 
P.574 掲載の参考文献
1) Kinoshita Y, Fukumoto S : X-linked hypophosphatemia and FGF23-related hypophosphatemic diseases : Prospect for new treatment. Endocr Rev 39 : 274-291, 2018.
PubMed
2) Urakawa I, et al : Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444 : 770-774, 2006.
PubMed
3) Shimada T, et al : FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19 : 429-435, 2004.
 
4) Okazaki R, et al : Assessment criteria for vitamin D deficiency/insufficiency in Japan : proposal by an expert panel supported by the Research Program of Intractable Diseases, Ministry of Health, Labour and Welfare, Japan, the Japanese Society for Bone and Mineral Research and the Japan Endocrine Society. J Bone Miner Metab 35 : 1-5, 2017.
 
5) Adams JS, et al : Regulation of the extrarenal CYP27B1-hydroxylase. J Steroid Biochem Mol Biol 144 (Pt A) : 22-27, 2014.
 
6) Cheng JB, et al : Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. Proc Natl Acad Sci USA 101 : 7711-7715, 2004.
PubMed
7) Roizen JD, et al : CYP3A4 mutation causes vitamin D-dependent rickets type 3. J Clin Invest 128 : 1913-1918, 2018,
 
8) The HYP Consortium : A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. Nat Genet 11 : 130-136, 1995.
 
9) Topaz O, et al : Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. Nat Genet 36 : 579-581, 2004.
 
10) Araya K, et al : A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis. J Clin Endocrinol Metab 90 : 5523-5527, 2005.
 
11) Ichikawa S, et al : A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. J Clin Invest 117 : 2684-2691, 2007.
PubMed
12) Frishberg Y, et al : Hyperostosis-hyperphosphatemia syndrome : a congenital disorder of O-glycosylation associated with augmented processing of fibroblast growth factor 23. J Bone Miner Res 22 : 235-242, 2007.
 
13) Roberts MS, et al : Autoimmune hyperphosphatemic tumoral calcinosis in a patient with FGF23 autoantibodies. J Clin Invest 128 : 5368-5373, 2018.
 
P.579 掲載の参考文献
1) de Baaij JH, et al : Magnesium in man : implications for health and disease. Physiol Rev 95 : 1-46, 2015.
PubMed
2) Wong ET, et al : A high prevalence of hypomagnesemia and hypermagnesemia in hospitalized patients. Am J Clin Pathol 79 : 348-352, 1983.
PubMed
3) Schimatschek HF, Rempis R : Prevalence of hypomagnesemia in an unselected German population of 16,000 individuals. Magnes Res 14 : 283-290, 2001.
 
4) Pham PC, et al : Hypomagnesemia in patients with type 2 diabetes. Clin J Am Soc Nephrol 2 : 366-373, 2007.
PubMed
5) Song Y, et al : Effects of oral magnesium supplementation on glycaemic control in Type 2 diabetes : a meta-analysis of randomized double-blind controlled trials. Diabet Med 23 : 1050-1056, 2006.
PubMed
6) Verma H, Garg R : Effect of magnesium supplementation on type 2 diabetes associated cardiovascular risk factors : a systematic review and meta-analysis. J Hum Nutr Diet 30 : 621-633, 2017.
PubMed
7) Quamme GA : Renal magnesium handling : new insights in understanding old problems. Kidney Int 52 : 1180-1195, 1997.
PubMed
8) Shibutani Y, et al : Plasma and erythrocyte magnesium concentrations in thyroid disease : relation to thyroid function and the duration of illness. Jpn J Med 28 : 496-502, 1989.
PubMed
9) Disashi T, et al : Magnesium metabolism in hyperthyroidism. Endocr J 43 : 397-402, 1996.
PubMed
10) Gonzalez-Campoy JM, et al : Escape from the sodium-retaining effects of mineralocorticoids : role of ANF and intrarenal hormone systems, Kidney Int 35 : 767-777, 1989.
PubMed
11) Kolloch RE, et al : Role of epinephrine-induced hypokalemia in the regulation of renin and aldosterone in humans. J Lab Clin Med 127 : 50-56, 1996.
PubMed
12) Dai LJ, et al : Cellular mechanisms of chlorothiazide and cellular potassium depletion on Mg2+ uptake in mouse distal convoluted tubule cells. Kidney Int 51 : 1008-1017, 1997.
PubMed
13) Rizos E, et al : Multiple metabolic abnormalities in a patient with the syndrome of inappropriate antidiuresis. Nephron 91 : 339-340, 2002.
 
14) Viering DHHM, et al : Genetic causes of hypomagnesemia, a clinicai overview. Pediatr Nephrol 32 : 1123-1135, 2017.
 
15) Freitag JJ, et al : Evidence for skeletal resistance to parathyroid hormone in magnesium deficiency. Studies in isolated perfused bone. J Clin Invest 64 : 1238-1244, 1979.
 
16) Rude RK, et al : Low serum concentrations of 1, 25-dihydroxyvitamin D in human magnesium deficiency. J Clin Endocrinol Metab 61 : 933-940, 1985.
PubMed
17) Uwitonze AM, Razzaque MS : Role of Magnesium in Vitamin D Activation and Function. J Am Osteopath Assoc 118 : 181-189, 2018.
PubMed

XV その他

P.587 掲載の参考文献
1) 加齢男性性腺機能低下症候群-LOH症候群-診療の手引き (日本泌尿器科学会, 日本Men's Health医学会, 「LOH症候群診療ガイドライン」検討ワーキング委員会編), じほう, 2007.
 
2) Heinemann LAJ, et al : A new 'aging males' symptoms' rating scale. Aging Male 2 : 105-114, 1999.
 
3) Nieschlag E, et al : Investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male 8 : 56-58, 2005.
PubMed
4) 岩本晃明, ほか : 日本人成人男子の総テストステロン, 遊離テストステロンの基準値の設定. 日本泌尿器科学会雑誌 95 : 751-760, 2004.
 
P.591 掲載の参考文献
1) Kobori H, et al : The intrarenal renin-angiotensin system : from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev 59 : 251-287, 2007.
 
2) Ruggenenti P, et al : Mechanisms and treatment of CKD. J Am Soc Nephrol 23 : 1917-1928, 2012.
PubMed
3) 菅原照 : 慢性腎不全・ネフローゼ症候群・血液透析. 日本臨牀 62 (増刊 : 臨床分子内分泌学 1-心血管内分泌代謝系 (上)) : 107-109, 2004.
 
4) Hamano T : Vitamin D and renal outcome : the fourth outcome of CKD-MBD? Oshima Award Address 2015. Clin Exp Nephrol 22 : 249-256, 2018.
PubMed
5) ADHR Consortium : Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 26 : 345-348, 2000,
PubMed
6) Hu MC, et al : Fibroblast growth factor 23 and Klotho : physiology and pathophysiology of an endocrine network of mineral metabolism. Annu Rev Physiol 75 : 503-533, 2013.
PubMed
7) Hasegawa H, et al : Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int 78 : 975-980, 2010.
PubMed
8) Ben-Dov IZ, et al : The parathyroid is a target organ for FGF23 in rats. J Clin Invest 117 : 4003-4008, 2007.
PubMed
9) Kuro-o M, et al : Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390 : 45-51, 1997.
PubMed
10) Matsumura Y, et al : Identification of the human klotho gene and its two transcripts encoding membrane and secreted klotho protein. Biochem Biophys Res Commun 242 : 626-630, 1998.
PubMed
11) Faul C, et al : FGF23 induces left ventricular hypertrophy. J Clin Invest 121 : 4393-4408, 2011.
PubMed
12) Yamashita T, et al : Elongation of the epiphyseal trabecular bone in transgenic mice carrying a klotho gene locus mutation that leads to a syndrome resembling aging. J Endocrinol 159 : 1-8, 1998.
PubMed
13) Asada N, et al : Dysfunction of fibroblasts of extrarenal origin underlies renal fibrosis and renal anemia in mice. J Clin Invest 121 : 3981-3990, 2011.
PubMed
14) Al-Ahmad A, et al : Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 38 : 955-962, 2001.
PubMed
15) Carrero JJ, et al : Endocrine aspects of chronic kidney disease. In : Brenner and Rector's The Kidney, 9th ed (ed by Taal MW, et al), p2122-2137, Saunders, Philadelphia, 2012.
 
P.595 掲載の参考文献
1) Peters LJ : Radiation therapy tolerance limits. For one or for all? -Janeway Lecture. Cancer 77 : 2379-2385, 1996.
 
2) Hong JH, et al : Induction of acute phase gene expression by brain irradiation. Int J Radiat Oncol Biol Phys 33 : 619-626, 1995.
PubMed
3) Larkins RG, Martin FIR : Hypopituitarism after extracranial irradiation : evidence for hypothalamic origin. Br Med J 1 : 152-153, 1973.
 
4) Samaan NA, et al : Hypopituitarism after external irradiation. Evidence for both hypothalamic and pituitary origin. Ann Intern Med 83 : 771-777, 1975.
PubMed
5) Tan BC, Kunaratum N : Hypopituitary dwarfism following radiotherapy for nasopharyngeal carcinoma. Clin Radiol 17 : 302-304, 1966.
 
6) Shalet SM, et al : The effect of varying doses of cerebral irradiation on growth hormone production in childhood. Clin Endocrinol (Oxf) 5 : 287-290, 1976.
PubMed
7) Wara WM, et al : Hypopituitarism after irradiation in children. Int J Radiat Oncol Biol Phys 2 : 549-552, 1977.
PubMed
8) Storr HL et al : Clinical and endocrine responses to pituitary radiotherapy in pediatric Cushing's disease : an effective second-line treatment. J Clin Endocrinol Metab 88 : 34-37, 2003.
PubMed
9) Duffner PK, et al : Long-term effects of cranial irradiation on endocrine function in children with brain tumors. A prospective study. Cancer 56 : 2189-2193, 1985.
PubMed
10) Constine LS, et al : Hypothalamic-pituitary dysfunction after radiation for brain tumors. N Engl J Med 328 : 87-94, 1993.
PubMed
11) Arlt W, et al : Frequent and frequently overlooked : treatment-induced endocrine dysfunction in adult long-term survivors of primary brain tumors. Neurology 49 : 498-506, 1997.
PubMed
12) Pai HH, et al : Hypothalamic/pituitary function following high-dose conformal radiotherapy to the base of skull : demonstration of a dose-effect relationship using dose-volume histogram analysis. Int J Radiat Oncol Biol Phys 49 : 1079-1092, 2001.
 
13) Spoudeas HA, et al : Hypothalamo-pituitary-adrenal axis integrity after cranial irradiation for childhood posterior fossa tumours. Med Pediatr Oncol 40 : 224-229, 2003.
PubMed
14) Rappaport R, Brauner R : Growth and endocrine disorders secondary to cranial irradiation. Pediatr Res 25 : 561-567, 1989.
PubMed
15) Kyriakakis N, et al : Pituitary dysfunction following cranial radiotherapy for adult-onset nonpituitary brain tumours. Clin Endocrinol (Oxf) 84 : 372-379, 2016.
PubMed
16) Merchant TE, et al : Preirradiation endocrinopathies in pediatric brain tumor patients determined by dynamic tests of endocrine function. Int J Radiat Oncol Biol Phys 54 : 45-50, 2002.
PubMed
17) Taku N, et al : Time dependence of radiation-induced hypothalamic-pituitary axis dysfunction in adults treated for non-pituitary, intracranial neoplasms. Clin Oncol (R Coll Radiol) 29 : 34-41, 2017.
PubMed
P.600 掲載の参考文献
1) 衞藤義勝 (編) : ライソゾーム病-最新の病態, 診断, 治療の進歩-. 診断と治療社, 2011.
 
2) Faggiano A, et al : Endocrine dysfunction in patients with Fabry disease. J. Clin Endocrinol Metab. 91 : 4319-4325, 2006.
PubMed
P.603 掲載の参考文献
1) Backeljauw PF, et al : Disorders of growth hormone/insulin like growth factor secretion and action. In : Pediatric Endocrinology, 4th ed (ed by Sperling M), p378-384, Elsevier, Philadelphia, 2014.
 
2) Joss EE, et al : Adult height in constitutionally tall stature : accuracy of five different height prediction methods. Arch Dis Child 67 : 1357-1362, 1992.
PubMed
3) Sotos JF, et al : Overgrowth disorders associated with tall stature. Adv Pediatr 55 : 213-254, 2008.
PubMed
4) Sorgo W, et al : Critical analysis of height reduction in oestrogen-treated tall girls. Eur J Pediatr 142 : 260-265, 1984.
PubMed
5) Reinehr T, et al : Treatment of tall stature in boys : comparison of two different treatment regimens. Horm Res Paediatr 76 : 343-347, 2011.
PubMed
P.607 掲載の参考文献
1) Soejima H, Higashimoto K : Epigenetic and genetic alterations of the imprinting disorder Beckwith-Wiedemann syndrome and related disorders. J Hum Genet 58 : 402-409, 2013.
PubMed
2) Shuman C, et al : Beckwith-Wiedemann Syndrome. GeneReviews(R) [Internet], University of Washington, Seattle, Initial Posting : 2000 March 3, Last Update : 2016 August 11. [https://www.ncbi.nlm.nih.gov/books/NBK1394/] (2019年1月閲覧)
 
3) Brioude F, et al : Expert consensus document : Clinical and molecular diagnosis, screening and management of Beckwith-Wiedemann syndrome : an international consensus statement. Nat Rev Endocrinol 14 : 229-249, 2018.
PubMed
4) Mussa A, et al : Prevalence of Beckwith-Wiedemann syndrome in North West of Italy. Am J Med Genet A 161A : 2481-2486, 2013.
PubMed
5) Uyar A, Seli E : The impact of assisted reproductive technologies on genomic imprinting and imprinting disorders. Curr Opin Obstet Gynecol 26 : 210-221, 2014.
PubMed
6) Lazaraviciute G, et al : A systematic review and meta-analysis of DNA methylation levels and imprinting disorders in children conceived by IVF/ICSI compared with children conceived spontaneously. Hum Reprod Update 21 : 555-557, 2015.
PubMed
7) Mussa A, et al : Assisted Reproductive Techniques and Risk of Beckwith-Wiedemann Syndrome. Pediatrics 140. pii : e20164311, 2017.
 
8) Higashimoto K, et al : A novel de novo point mutation of the OCT-binding site in the IGF2/H19-imprinting control region in a Beckwith-Wiedemann syndrome patient. Clin Genet 86 : 539-544, 2014.
 
9) Murakami K, et al : Suggestive evidence for chromosomal localization of non-coding RNA from imprinted LIT1. J Hum Genet 52 : 926-933, 2007.
PubMed
10) Ohtsuka Y, et al : Identification of consensus motifs associated with mitotic recombination and clinical characteristics in patients with paternal uniparental isodisomy of chromosome 11. Hum Mol Genet 25 : 1406-1419, 2016.
PubMed
11) Mussa A, et al : (Epi) genotype-phenotype correlations in Beckwith-Wiedemann syndrome. Eur J Hum Genet 24 : 183-190, 2016.
PubMed
12) Maas SM, et al : Phenotype, cancer risk, and surveillance in Beckwith-Wiedemann syndrome depending on molecular genetic subgroups. Am J Med Genet A 170 : 2248-2260, 2016.
PubMed
13) Mussa A, et al : Cancer Risk in Beckwith-Wiedemann Syndrome : A Systematic Review and Meta-Analysis Outlining a Novel (Epi) Genotype Specific Histotype Targeted Screening Protocol. J Pediatr 176 : 142-149.e1, 2016.
 
P.611 掲載の参考文献
1) Biesecker LG : Pallister-Hall Syndrome. GeneReviews(R) [Internet], University of Washington, Seattle, Initial Posting : 2000 May 25, Last Update : 2017 May 18. [http://www.genetests.org] (2019年2月閲覧)
 
2) Ruiz i Altaba A : Gli proteins encode context-dependent positive and negative functions : implications for development and disease. Development 126 : 3205-3216, 1999.
PubMed
3) Johnston JJ, et al : Molecular and clinical analyses of Greig cephalopolysyndactyly and Pallister-Hall syndromes : robust phenotype prediction from the type and position of GLI3 mutations. Am J Hum Genet 76 : 609-622, 2005.
PubMed
4) Johnston JJ, et al : Molecular analysis expands the spectrum of phenotypes associated with GLI3 mutations. Hum Mutat 31 : 1142-1154, 2010.
PubMed
5) Demurger F, et al : New insights into genotype-phenotype correlation for GLI3 mutations. Eur J Hum Genet 23 : 92-102, 2015.
PubMed
6) 齋藤伸治 : Pallister-Hall症候群. 小児科診療 79 (Suppl) : 53, 2016.
 
7) 琉球大学遺伝性疾患データベース. [http://becomerich.lab.u-ryukyu.ac.jp/top.html] (2019年2月閲覧)
 
P.615 掲載の参考文献
1) Hutchinson J : Congenital Absence of Hair and Mammary Glands with Atrophic Condition of the Skin and its Appendages, in a Boy whose Mother had been almost wholly Bald from Alopecia Areata from the age of Six. Med Chir Trans 69 : 473-477, 1886.
 
2) Gilford H : Progeria : a form of senilism, Practitioner 73 : 188-217, 1904.
 
3) Gordon LB, et al : Hutchinson-Gilford Progeria Syndrome. In : GeneReviews(R) [Internet] (ed by Adam MP, et al), University of Washington, Seattle, 2003. [updated 2015 Jan 8]
 
4) Hennekam RC : Hutchinson-Gilford progeria syndrome : review of the phenotype. Am J Med Genet A 140 : 2603-2624, 2006.
PubMed
5) Merideth MA, et al : Phenotype and course of Hutchinson-Gilford progeria syndrome. N Engl J Med 358 : 592-604, 2008.
PubMed
6) Eriksson M, et al : Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature 423 : 293-298, 2003.
PubMed
7) De Sandre-Giovannoli A, et al : Lamin a truncation in Hutchinson-Gilford progeria. Science 300 : 2055, 2003.
PubMed
8) Moulson CL, et al : Increased progerin expression associated with unusual LMNA mutations causes severe progeroid syndromes. Hum Mutat 28 : 882-889, 2007.
PubMed
9) Burke B, Stewart CL : Life at the edge : the nuclear envelope and human disease. Nat Rev Mol Cell Biol 3 : 575-585, 2002.
PubMed
10) Sato-Kawano N, et al : The clinical characteristics of Asian patients with classical-type Hutchinson-Gilford progeria syndrome. J Hum Genet 62 : 1031-1035, 2017.
PubMed
11) Gordon LB, et al : Clinical Trial of the Protein Farnesylation Inhibitors Lonafarnib, Pravastatin, and Zoledronic Acid in Children With Hutchinson-Gilford Progeria Syndrome. Circulation 134 : 114-125, 2016.
PubMed
12) Gordon LB, et al : Association of lonafarnib treatment vs no treatment with mortality rate in patients with Hutchinson-Gilford progeria syndrome. JAMA 319 : 1687-1695, 2018.
PubMed
P.619 掲載の参考文献
1) Kearns TP, Sayre GP : Retinitis pigmentosa, external ophthalmophegia, and complete heart block : unusual syndrome with histologic study in one of two cases. AMA Arch Ophthalmol 60 : 280-289, 1958.
PubMed
2) Rowland LP : Molecular genetics, pseudogenetics, and clinical neurology. The Robert Wartenberg Lecture. Neurology 33 : 1179-1195, 1983.
 
3) DiMauro S, Hirano M. Mitochondrial DNA deletion syndromes. GeneReviews(R). 2011. (PMID : 20301382)
 
4) Schaefer AM, et al : Prevalence of mitochondrial DNA disease in adults. Ann Neurol 63 : 35-39, 2008.
PubMed
5) 後藤雄一 : 慢性進行性外眼筋麻痺症候群, Kearns-Sayre症候群 ; ミトコンドリア病. ミトコンドリア病の臨床的表現型による分類. 別冊日本臨牀新領域別症候群シリーズ No. 33 骨格筋症候群 (第2版) (下), p198-201, 日本臨牀社, 2015.
 
6) Chinnery PF, et al : Risk of developing a mitochondrial DNA deletion disorder. Lancet 364 : 592-596, 2004.
PubMed
7) Broomfield A, et al : Paediatric single mitochondrial DNA deletion disorders : an overlapping spectrum of disease. J Inherit Metab Dis 38 : 445-457, 2015.
 
8) Quade A, et al : Endocrine abnormalities in mitochondrial myopathy with external ophthalmoplegia. Clin Investig 70 : 396-402, 1992.
PubMed
9) Chow J, et al : Mitochondrial disease and endocrine dysfunction. Nat Rev Endocrinol 13 : 92-104, 2017.
PubMed
10) Whittaker RG, et al : Prevalence and progression of diabetes in mitochondrial disease. Diabetologia 50 : 2085-2089, 2007.
PubMed
11) Harvey JN, Barnett D : Endocrine dysfunction in Kearns-Sayre syndrome. Clin Endocrinol (Oxf) 37 : 97-103, 1992.
PubMed
12) Wilichowski E, et al : Hypoparathyroidism and deafness associated with pleioplasmic large scale rearrangements of the mitochondrial DNA : a clinical and molecular genetic study of four children with Kearns-Sayre syndrome. Pediatr Res 41 : 193-200, 1997.
PubMed
13) Berenberg RA, et al : Lumping or splitting? "Ophthalmoplegia-plus" or Kearns-Sayre syndrome? Ann Neurol 1 : 37-54, 1977.
 
14) Artuch R, et al : Multiple endocrine involvement in two pediatric patients with Kearns-Sayre syndrome. Horm Res 50 : 99-104, 1998.
PubMed
15) Boles RG, et al : Mitochondrial DNA deletion with Kearns Sayre syndrome in a child with Addison disease. Eur J Pediatr 157 : 643-647, 1998.
 
P.623 掲載の参考文献
1) Misawa S, Kuwabara S : Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes (Crow-Fukase) syndrome : Diagnostic criteria and treatment perspectives. Clin Exp Neuroimmunol 4 : 318-325, 2013.
 
2) Arimura K, Hashiguchi T : Crow-Fukase syndrome : clinical features, pathogenesis and treatment in Japan. In : Current Topics in Neuroimmunology (ed by Yamamura T, et al), p241-245, Medimond, Bologna, 2007.
 
3) Watanabe O, et al : Greatly raised vascular endothelial growth factor (VEGF) in POEMS syndrome. Lancet 347 : 702, 1996.
PubMed
4) Kanai K, et al : Markedly upregulated serum interleukin-12 as a novel biomarker in POEMS syndrome. Neurology 79 : 575-582, 2012.
PubMed
5) Suichi T, et al : Proposal of new clinical diagnostic criteria for POEMS syndrome. J Neurol Neurosurg Psychiatry 90 : 133-137, 2019.
PubMed
6) Gandhi GY, et al : Endocrinopathy in POEMS syndrome : the Mayo Clinic experience. Mayo Clin Proc 82 : 836-842, 2007.
 
7) Nakanishi T, et al : The Crow-Fukase syndrome : a study of 102 cases in Japan. Neurology 34 : 712-720, 1984.
PubMed
8) Kourelis TV, et al : Long-term outcome of patients with POEMS syndrome : An update of the Mayo Clinic experience. Am J Hematol 91 : 585-589, 2016.
 
9) Misawa S, et al : Vascular endothelial growth factor as a predictive marker for POEMS syndrome treatment response : retrospective cohort study, BMJ Open 5 : e009157, 2015.
PubMed
10) Humeniuk MS, et al : Outcomes of patients with POEMS syndrome treated initially with radiation. Blood 122 : 68-73, 2013.
PubMed
11) D'Souza A, et al : Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma) : a single-center experience. Blood 120 : 56-62, 2012.
PubMed
12) Ohwada C, et al : Long-term evaluation of physical improvement and survival of autologous stem cell transplantation in POEMS syndrome. Blood 131 : 2173-2176, 2018.
PubMed
13) Misawa S, et al : Safety and efficacy of thalidomide in patients with POEMS syndrome : a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 15 : 1129-1137, 2016.
PubMed
14) Nozza A, et al : Lenalidomide and dexamethasone in patients with POEMS syndrome : results of a prospective, open-label trial. Br J Haematol 179 : 748-755, 2017.
PubMed
15) He H, et al : Successful treatment of newly diagnosed POEMS syndrome with reduced-dose bortezomib based regimen. Br J Haematol 181 : 126-128, 2018.
PubMed
P.629 掲載の参考文献
1) Miller RW, et al : Association of Wilms's Tumor with Aniridia, Hemihypertrophy and Other Congenital Malformations. N Engl J Med 270 : 922-927, 1964.
 
2) Fischbach BV, et al : WAGR syndrome : a clinical review of 54 cases. Pediatrics 116 : 984-988, 2005.
PubMed
3) Takada Y, et al : Sustained endocrine profiles of a girl with WAGR syndrome. BMC Med Genet 18 : 117, 2017.
PubMed
4) Yamamoto T, et al : Narrowing of the responsible region for severe developmental delay and autistic behaviors in WAGR syndrome down to 1.6Mb including PAX6, WT1, and PRRG4. Am J Med Genet A 164A : 634-638, 2014.
 
5) Balay L, et al : A familial pericentric inversion of chromosome 11 associated with a microdeletion of 163 kb and microduplication of 288 kb at 11p13 and 11q22.3 without aniridia or eye anomalies. Am J Med Genet A 170A : 202-209, 2016.
PubMed
6) Han JC, et al : Association of brain-derived neurotrophic factor (BDNF) haploinsufficiency with lower adaptive behaviour and reduced cognitive functioning in WAGR/11p13 deletion syndrome. Cortex 49 : 2700-2710, 2013.
PubMed
7) Xu S, et al : Characterization of 11p14-p12 deletion in WAGR syndrome by array CGH for identifying genes contributing to mental retardation and autism. Cytogenet Genome Res 122 : 181-187, 2008.
PubMed
8) Justice ED, et al : The WAGR syndrome gene PRRG4 is a functional homologue of the commissureless axon guidance gene. PLoS Genet 13 : e1006865, 2017.
PubMed
9) Niaudet P, Gubler MC : WTI and glomerular diseases. Pediatr Nephrol 21 : 1653-1660, 2006.
 
10) Breslow NE, et al : End stage renal disease in patients with Wilms tumor : results from the National Wilms Tumor Study Group and the United States Renal Data System. J Urol 174 : 1972-1975, 2005.
 
11) Ahn YH, et al : Genotype-phenotype analysis of pediatric patients with WTI glomerulopathy. Pediatr Nephrol 32 : 81-89, 2017.
 
12) Dahan K, et al : Small glomeruli in WAGR (Wilms Tumor, Aniridia, Genitourinary Anomalies and Mental Retardation) syndrome. Am J Kidney Dis 49 : 793-800, 2007.
PubMed
13) Franzoni A, et al : ACGH array procedure to detect PAX6 gene structural defects. Mol Cell Probes 32 : 65-68, 2017.
 
14) Wawrocka A, et al : 11p13 deletions can be more frequent than the PAX6 gene point mutations in Polish patients with aniridia. J Appl Genet 54 : 345-351, 2013.
 

XVI トピックス

P.636 掲載の参考文献
1) Wing K, et al : CTLA-4 control over Foxp3+ regulatory T cell function. Science 322 : 271-275, 2008.
PubMed
2) Keir ME, et al : PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26 : 677-704, 2008.
PubMed
3) Tivol EA, et al : Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3 : 541-547, 1995.
PubMed
4) Okazaki T, Honjo T : The PD-1-PD-L pathway in immunological tolerance. Trends Immunol 27 : 195-201, 2006.
PubMed
5) Ansari MJ, et al : The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 198 : 63-69, 2003.
PubMed
6) Wang J, et al : Establishment of NOD-Pdcd1-/- mice as an efficient animal model of type I diabetes. Proc Natl Acad Sci USA 102 : 11823-11828, 2005.
PubMed
7) Colli ML, et al : PDL1 is expressed in the islets of people with type 1 diabetes and is up-regulated by interferons-α and -γ via IRF1 induction. EBioMedicine 36 : 367-375, 2018.
 
8) Hiromine Y, et al : Trinucleotide repeats of programmed cell death-1 gene are associated with susceptibility to type 1 diabetes mellitus. Metab Clin Exp 56 : 905-909, 2007.
PubMed
9) Fujisawa R, et al : Low programmed cell death-1 (PD-1) expression in peripheral CD4 (+) T cells in Japanese patients with autoimmune type 1 diabetes. Clin Exp Immunol 180 : 452-457, 2015.
PubMed
10) Baden MY, et al : Characteristics and clinical course of type 1 diabetes mellitus related to anti programmed cell death 1 therapy. Diabetology International, 2018. (DOI : 10.1007/s13340-018-0362-2).
 
11) Stamatouli AM, et al : Collateral Damage : Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors. Diabetes 67 : 1471-1480, 2018.
PubMed
12) 花房俊昭, ほか : 劇症1型糖尿病調査研究委員会報告 (追補) -発症時のウイルス抗体価について. 糖尿病 51 : 531-536, 2008.
 
13) 日本糖尿病学会ホームページ : 免疫チェックポイント阻害薬使用患者における1型糖尿病の発症に関するRecommendation, 2016. [http://www.fakyorin.co.jp/jds/uploads/recommendation_nivolumab.pdf] (2019年2月閲覧)
 
P.641 掲載の参考文献
1) El Osta B, et al : Not all immune-checkpoint inhibitors are created equal : Meta-analysis and systematic review of immune-related adverse events in cancer trials. Crit Rev Oncol Hematol 119 : 1-12, 2017.
PubMed
2) 佐藤哲郎, ほか : 免疫チェックポイント阻害薬の関連. 日本甲状腺学会雑誌9 : 16-21, 2018.
 
3) Borodic G, et al : Drug-induced graves disease from CTLA-4 receptor suppression. Ophthalmic Plast Reconstr Surg 27 : e87-88, 2011.
PubMed
4) McElnea E, et al : Thyroid-like ophthalmopathy in a euthyroid patient receiving Ipilimumab. Orbit 33 : 424-427, 2014.
 
5) Umeguchi H, et al : Autoimmune-Related Primary Hypoparathyroidism Possibly Induced by the Administration of Pembrolizumab : A Case Report. J Oncol Pract 14 : 449-451, 2018.
PubMed
6) Win MA, et al : Acute symptomatic hypocalcemia from immune checkpoint therapy-induced hypoparathyroidism. Am J Emerg Med 35 : 1039.e5-1039.e7, 2017.
 
7) Buchbinder E, et al : Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade. J Clin Invest 125 : 3377-3383, 2015.
PubMed
8) Faje A : Immunotherapy and hypophysitis : clinical presentation, treatment, and biologic insights. Pituitary 19 : 82-92, 2016.
 
9) Morganstein DL, et al : Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma. Clin Endocrinol (Oxf) 86 : 614-620, 2017.
PubMed
10) Osorio JC, et al : Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol 28 : 583-589, 2017.
 
11) 日本内分泌学会 : 免疫チェックポイント阻害薬による内分泌障害の診療ガイドライン. 日本内分泌学会雑誌 94 (Suppl) : 1-11, 2018.
 
12) がん免疫療法ガイドライン (日本臨床腫瘍学会編), 金原出版, 2016.
 
13) JCOG (日本臨床腫瘍研究グループ) ホームページ. [http://www.jcog.jp/]
 

書評

最近チェックした商品履歴

Loading...